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Abstract 
This study aimed to engineer a collagen membrane scaffold for the delivery of 
platelet rich plasma (PRP) and bone marrow derived mesenchymal stem cells (BM-
MSCs) for complex fracture repair. The design of the guided bone regeneration 
device was based on the microarchitecture of the induced membrane which was 
found to be rich in high organised collagen fibres and have less distinct bi-layer 
organisation than expected. This contributed towards the design, optimisation and 
manufacturing of a working prototype made of 70% collagen and 30% 
polycaprolactone (PCL) using novel needleless-electrospinning technology. The 
scaffolds produced had substantial mechanical properties and were found to be 
biocompatible. The scaffold was also found to be made up of nano-scale fibres and 
sub-micron pores which acted as a barrier. The scaffold can be tailored using laser 
cutting to incorporate pores as well as folding and heat-treating the scaffold to 
increase the construct’s thickness. PRP was also optimised as a biological 
signalling product to maximise BM-MSC migration and proliferation at the site of 
injury. Removal of leukocytes was not found to improve cell migration or 
proliferation as expected and all platelet products tested induced significantly more 
cell migration than fetal calf serum (FCS). Most promising was the experiments that 
combined the platelet products, BM-MSCs and scaffolds, which found that the 
loaded scaffolds were effectively able to support rare BM-MSC colony formation 
from bone marrow aspirate. These promising findings indicate that this scaffold 
could be effectively translated in future treatment of bone reconstruction alongside 
clinical standard PRP. 
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1 Introduction 
The designing and engineering of a collagen membrane scaffold for the delivery of 
platelet rich plasma (PRP) and bone marrow derived mesenchymal stem cells (BM-
MSCs) for fracture repair is an interdisciplinary project that encompasses various 
fields of research including, engineering, materials and textiles, anatomy and 
biology. To bring these research areas together for this project, this introductory 
review provides an outline of the current understanding of bone fractures and the 
factors involved in their repair.  
1.1 Bone physiology: 
The human skeleton constantly remodels itself to maintain a homeostasis between 
its main functions; providing strong mechanical support to the body and supplying 
the body with calcium via resorption of old bone and laying down new bone. This 
process is carried out by three main cells types; osteoclasts, osteoblasts and 
osteocytes. Detection of increased hormone and cytokine levels activate pre-
osteoclast cells to differentiate into osteoclasts [2] and attach to the bone. Once 
attached, osteoclasts break down the bone matrix via acidification and enzymatic 
breakdown to re-release the ions. Osteoblasts are similarly activated to differentiate 
from osteoblast precursor cells, also termed mesenchymal stem cells (MSCs), by 
stimulants such as in full bone morphogenic protein-2 (BMP-2) to form new bone [2]. 
Osteoblasts deposit bone by secreting type 1 collagen and osteocalcin, the building 
blocks essential for mineral deposition [3]. The deposited bone accumulates around 
the osteoblast trapping it whilst it differentiates into an osteocyte. The embedded 
osteocyte forms long processes along the canaliculi network of the osteons which 
help it to detect and communicate mechanical and chemical signals [4] as well as 
release its own signals to stimulate and inhibit bone growth [5]. These cells interact 
constantly to create tissue, which in turn supports the cell attachment, proliferation 
and differentiation necessary for bone remodelling.  
With regards to the anatomy of bone, they are usually composed of three main 
regions; the periosteum, cortical bone, and trabecular bone. Firstly, surrounding the 
bone is the periosteum tissue with its superficial fibrous layer and inner cellular 
layer [6] this tissue is highly vascularised and a rich source of osteogenic progenitor 
cells required for regeneration [7].  Periosteum also has a specialised 
mechanosensory role and is able to activate osteogenic differentiation of local 
- 2 - 
 
MSCs when under strain, for example when damaged during fracture [8]. Cortical 
bone is made up of the hydroxyapatite bone matrix secreted by osteoblasts which 
accumulate to form densely packed concentric mineralised osteons interspersed 
with lacunae and haversian canals. It is the cortical bone’s solid structure which 
allows bone to function as a mechanical support system to the body. Trabecular (or 
cancellous) bone is found toward the centre of long bones such as the femur and 
flat bones like the skull and iliac crest of the pelvis. It consists of mineralised 
trabeculae that align in the direction of stress into the bone marrow, it is less dense 
than cortical bone and its porous structure provides a high-surface area for cell 
attachment and proliferation [9] Because of their porous structure and large surface 
area, trabecular bones (the iliac crest in particular) are a rich source of bone 
marrow derived MSCs (BM-MSCs) for clinical and research applications [10, 11]. 
1.2 Fracture Repair: 
Despite bone’s strong structure, it is still susceptible to damage and fracture. Most 
fractures are small in size and the body is able to repair them via two mechanisms: 
intramembranous ossification (IMO) and endochondral ossification (ECO). IMO 
occurs in mechanically stable fractures and is characterised by MSCs migrating 
from the periosteum or the bone marrow to the fracture [12] and differentiating into 
osteoblasts [13] to develop new bone. ECO occurs in non-stabilised sites and sees 
MSCs initially differentiate into chondrocytes which lay down a hyaline cartilage 
template around the defect forming a protective callus [14]. After an initial loss of 
blood flow to the injury, vascularisation to the callus increases due to the 
hypertrophic chondrocytes secreting the angiogenic growth factors; vascular 
endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) which 
stimulates angiogenesis and allows the infiltration of osteogenic committed MSCs. 
These progenitor cells differentiate into osteoblasts and secrete the extracellular 
matrix to first form an immature poorly-mineralised bone which is later remodelled 
into mechanically competent bone tissue [12].  
Immature bone is first rapidly secreted in a coarse, woven structure with a non-
uniform collagen arrangement to partially restore the bone’s functional properties 
and is later resorbed and restructured into highly organised lamellar bone. Once the 
cartilage callus has completely ossified, osteoclasts resorb the excess bone, 
returning the defect to its original shape. However, some fractures are too large or 
the patient has co-morbidities that prevent the defect from healing, known as 
complex fractures and require clinical intervention. 
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1.3 Clinical need:  
Arising from injury and age-related diseases, fractures are highly prevalent in all 
societies and are a particular burden on public health services, costing an 
estimated £726 million in the UK in 2000 alone [15]. Furthermore, despite the 
significant improvements in treatment and fracture healing techniques, it has been 
estimated that 5–10% of all patients with long bone fractures will develop impaired 
fracture healing processes, such as delayed healing and non-union [15] [16, 17]. A 
range of techniques currently exist to minimise complications and increase bone 
healing, examples include internal fixation using metal plates and screws, and 
external fixation using the Ilizarov technique (extending an external frame to distract 
the fracture ends) [18, 19] for critical sized defects (CSD). A CSD is defined as bone 
loss greater than 2.5cm [20] or as a defect that will not heal unaided. In conjunction 
with these fixation devices, cancellous bone autografts are often used to fill the 
defect site and provide a scaffold for regeneration. Commercial scaffolds such as 
decellurised allogeneic, xenogeneic bone chips and synthetic materials are also 
used for larger defects but autografts are considered the gold standard  because of 
their efficacy and safety [11].  
If the fracture site is infected an antibiotic loaded bone cement is first used to 
stabilise the bone whilst the infection is treated. It was observed that by using this 
technique, a naturally induced membrane (IM) forms around the fracture. By 
carefully removing the cement and retaining the IM, the defect gap can be filled with 
autograft bone and a commercial scaffold material loaded with autologous bone 
marrow (BM) aspirates, this two-step process is known as the Masquelet technique 
[21]. It has been shown that the IM which forms around the cement spacer can be 
used as a protective membrane to retain the grafted material and act as a guided 
bone regeneration device. However, this technique is limited not only by the need of 
a cement spacer, and therefore two surgeries, but also by the rarity of MSCs in the 
grafted material which is poorly controlled and also varies significantly between 
patients.  All these techniques described aim to manage and repair bone defects by 
incorporating basic tissue engineering principles that utilise stem cells, growth 
factors (GFs), scaffolds and mechanical stability as outlined in the diamond concept 
[1] shown in figure 1. 
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Figure 1: Adapted from Giannoudis et al. The diamond concept [1] which outlines 
the fundamental principles of bone regeneration. 
 
Specifically for bone healing, the presence of stem cells with osteogenic potential, 
osteo-inductive GFs, osteo-conductive scaffolds and sufficient mechanical stability 
around the defect site initiates a range of complex pathways which facilitate bone 
healing. However, despite the wide range of products and techniques available, 
there is still significant room for optimisation of the bone regeneration process. This 
review will cover each principle of the diamond concept to outline our current 
understanding and identify key areas of further research.  
1.4 Adult Stem cells and MSCs: 
Stem cells are defined as undifferentiated cells which are able to remain 
unspecialised and self-renew indefinitely during the organism’s lifetime. Once 
activated, they can differentiate into a range of cell lineages depending on their 
classification. Totipotency is a rare characteristic only found in zygotes and allows 
these cells to differentiate into any and every cell in the human body. Pluripotency 
is limited to embryonic stem cells and enables them to differentiate into any somatic 
cell type except cells forming extra-embryonic tissues [22]. Multipotent cells have the 
most limited differentiation abilities of the stem cell classes as they can only 
differentiate down the cell lineage they are a progenitor for, for example, bone 
resident mesenchymal stem cells (BM-MSC) can only differentiate into 
chondrogenic, osteogenic and adipogenic cells [23, 24]. BM-MSCs, although a rare 
population of cells making up just ~0.001–0.01% cells in the bone marrow aspirates 
[25], their trilineage potential and role in laying down new bone has made them the 
focus of bone tissue engineering and regeneration research.  
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1.4.1 Mesenchymal Stem Cells: 
Mesenchymal stem cells (MSCs), which are also sometimes referred to as ‘stromal 
cells’ are characterised by their ability to adhere to plastic [25], differentiate into 
osteoblasts, adipocytes and chondroblasts in vitro [26], express  CD73, CD90 and 
CD105 and lack the expression of CD45, CD34, CD14 or HLA-DR surface markers 
[27]. They were first identified as a result of experiments throughout the 1960’s and 
1970’s by Alexander Friedenstein who extracted them from bone marrow aspirate 
(BMA) and discovered their ability to differentiate down multiple lineages depending 
on experimental in vitro influences [28]. Since their initial discovery and 
characterisation, MSC-like cells have been found in essentially all post-natal human 
tissues [29] although their differentiation potentials differ depending on the host 
tissue’s location. The cell’s differences in differentiation potential has been 
demonstrated by Kellner et al. who used a calcium deposition stain (alizarin red) 
and found that although the cells are morphologically similar they vary in 
functionality [30]. This work has more recently been superseded by, and enhanced, 
by numerous in vivo studies that support MSCs unique differentiation potential and 
demonstrate their self-renewal capabilities [31, 32]. 
 
However, the current understanding of MSCs and their differences is inadequate 
because of a majority of the evidence is based on experiments using cultured-
expanded MSCs which is known to alter their gene expression [33, 34], cell surface 
markers [35], morphology [36], and functionality [34, 37] as they adapt to the in vitro 
environment. This is not only a misleading representation of the in vivo 
environment, but also almost impossible to replicate in the clinic because of current 
health and safety regulations of the Medicines and Healthcare Products Regulatory 
Agency’s (MHRA). Once a patient’s bone marrow or blood sample leaves the 
theatre and enters the lab for culture expansion of MSCs it becomes an advanced 
therapeutic medicinal product (ATMP) and its use is highly restricted. To overcome 
these restrictions, current research is focusing on using uncultured bone marrow 
which has been aspirated from a patient’s iliac crest during surgery and can be 
concentrated to enrich BM-MSC s for delivery to the fracture site. 
 
1.4.2 BM-MSC variability: 
BM-MSCs make up between 0.001- 0.01% of aspirated mononuclear cells in adult 
humans [25, 38] and it is thought there are even less in donors whose health is 
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compromised, particularly those with systemic bone diseases such as osteoporosis. 
This is based on animal data from osteoporotic mice which suggests that bone 
diseases causes a change in the BM-MSCs’ morphology and slows their growth 
and proliferation rate [39], but no significant difference has been found in humans in 
other diseases such as leukemia [40] or neurodegenerative disorders such as 
amyotrophic lateral sclerosis [41].  Another factor which can cause variation in BM-
MSCs between patients is age. A recent review by Ganguly et al. describe how not 
only the quantity, but also the quality of BM-MSCs declines with age having knock-
on effects linked to osteoarthritis and osteoporosis [42]number and “fitness” of 
mesenchymal stromal cells (MSCs) in the bone marrow (BM) niche has been 
suggested as one of the factors contributing to bone abnormalities in OP and OA. 
Their work summarised that for older donors, their cells could be ‘rejuvenated’ 
following exposure to a younger donor’s blood serum. 
The quality of the sample is also cause of variation as it can be prone to dilution 
with peripheral blood (haemodilution) as bleeding into the extraction site is 
unavoidable [40].  To minimize contamination with blood, it is recommended that 
small volumes (<5 ml) are aspirated, ideally only 1 ml as this has been found to be 
the most MSC abundant volume [43, 44]. Because of this variability in an already rare 
cell population, bone regeneration therapies have historically focused on providing 
more autogenous BM-MSCs directly from aspirates by concentrating MSCs using 
various volume reduction techniques. Recently however, there has been a shift in 
attention to attracting neighbouring MSCs to the site of repair through the use of 
chemokines and GFs most notably released from platelets.  
1.5 Growth Factors and Chemokines: 
GFs are proteins which are manufactured and secreted by nucleated cells and 
platelets which can bind to specific transmembrane receptors on target cells. Once 
bound, they initiate a range of cell signalling pathways activating target genes such 
as the osteogenic transcription factor Runx2 which are responsible for cell fate 
changes including proliferation, migration and differentiation. Specific GFs which 
have already been linked to bone regeneration include insulin-like growth factor 1 
(IGF-1), platelet-derived GFs (PDGFs), vascular endothelial growth factor (VEGF), 
bone morphogenic protein 2 (BMP-2) and transforming growth factor-beta 1 (TGF-
β1) to name a few.  
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1.5.1 Main GFs and chemokines involved in bone fracture repair: 
IGF-1 is a small ‘growth-promoting’ peptide which regulates signalling pathways 
resulting in the production of insulin receptor substrate one and two (IRS2) [45] which 
knockout studies in mice found reduced overall bone mass suggesting their role in 
bone maintenance [46]. PDGF is a family of dimeric proteins which include the 
isoforms: AA/AB/BB/CC and are released in high concentrations from platelets at 
the site of trauma [47]. PDGF’s role in bone repair is to activate MSC proliferation [48] 
as well as act as a chemoattractant to recruit other cells to the site of fracture [49]. 
VEGF regulates vascularisation and angiogenesis during bone formation to provide 
nutrients and transport for the migrating cells [50]. BMP-2 is a key growth factor 
which regulates osteoblast differentiation and bone repair and disruption of its 
expression is an underlying contributor to many adult bone pathologies such as 
osteopenia, osteoarthritis and calcification of the vasculature [51]. TGF-β1 protein 
has also been closely linked to bone repair since several studies in human patients 
have found significantly elevated TGF-β1 concentrations circulating in the 
peripheral blood following injury and have stayed elevated for months after [52]. 
Knock-out studies of these GFs have found that not only are all these GFs involved 
in bone remodelling and repair, but that they also work in combination and enhance 
each other’s function. Single knock-outs results in some decrease in function but 
rarely function is completely lost [53].  
These GFs also act alongside chemokines, a sub-set of a cytokines whose role it is 
to induce chemotaxis in nearby cells and include interleukin-8 (IL8), chemokine 
ligand 5 (CCL5/RANTES), tumor necrosis factor alpha (TNFa), soluble intracellular 
adhesion molecule (sICAM) and stromal cell-derived factor 1 (SDF-1). SDF-1, 
sometimes referred to as CXCL12, is particularly important in recruiting MSCs by 
binding to the CXCR4 receptor [54] . As a whole, these molecules also work by 
exacerbating inflammation to the site of injury by additionally attracting innate and 
adaptive immune cells as well as aiding migration and MSC adhesion to the trauma 
site. Immune cell response at the fracture site is necessary to remove necrotic cells 
and debris as well as to activate osteoclasts to remove dead bone, however, 
excessive production of immune cell-produced cytokines such as TNFα and 
interferon gamma (IFg) is also known to inhibit MSC osteogenesis.  
The majority of these GFs and chemokines are readily distributed where needed by 
platelets, but due to the down regulation of chemokine receptors in culture 
expanded BM-MSCs their exact mechanisms of action is difficult to study in vitro [55]. 
For example, a study in rats found that expression levels of the chemokine 
- 8 - 
 
receptors CCR1, CCR2, and CXCR4 in BM-MSCs was four times lower after four 
passages than in freshly cultured BM-MSCs [56]. Because of this down regulation, 
some research groups are focusing on first over-expressing chemokine receptors 
before culturing as a novel way to increase MSC sensitivity to chemotactic signals. 
This method involves first isolating the BM-MSCs and then increasing gene 
expression of their chemokine receptors using either recombinant protein or viral 
vectors. However, despite findings of improved MSC migration and accelerated 
wound-healing [57], this technique is extremely costly, time-consuming and labour 
intensive so is yet to be perfected as a treatment strategy. 
 
1.6 Platelets and platelet-rich plasma (PRP): 
Platelets are small fragments of megakaryocytes found in abundance (150–
400×109 platelets/L) in the peripheral blood. These annucleate cells are the smallest 
in the blood, 0.5 – 3 µm in size and discoid in shape [58]. Their major function is to 
generate and release proteins by means of their secretory granules when 
chemically activated via their numerous and highly sensitive membrane receptors. 
One of the most common activators following trauma is thrombin which acts on the 
platelets’ PAR1 and PAR4 receptors prompting them to change shape and release 
GFs [59].  Platelets’ capacity to produce a range of proteins, their significant 
concentration in the peripheral blood and ease of collection makes them an ideal 
source of GFs and chemokines alongside other fracture repair techniques.  
Platelets can be utilised as an orthopaedic therapy in the form of autologous 
platelet rich plasma (PRP) which can be generated in the laboratory and in surgery 
from a patient’s whole peripheral blood. In the clinical setting, whole blood is 
collected using the BioCUE device and centrifuged at 1100g for 15 min. Following 
centrifugation, supernatant is removed and the platelet containing fraction can be 
extracted using a syringe resulting in reported increases in platelet concentrations 
up to 4-fold greater than baseline [60, 61]. 
DeLong et al. classified PRP into four groups depending on their fold increase and 
end platelet concentration whereby; low PRP was anything below a two fold 
increase, moderate PRP was between a one to four fold increase, high PRP was 
between four to six fold and very high was anything greater than a six fold increase 
[62]. However this system is limited by the lack of a definitive ‘optimum’ platelet 
concentration and therefore assumes that the more platelets, the better despite 
some papers finding that osteoblast proliferation plateaus after 2.5 fold increase 
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and diminishes at greater concentrations indicating potentially biologically adverse 
effects [63]. The DeLong study also developed the PAW system (platelets, activation, 
and white blood cells (WBCs)) which categorises PRP based on platelet quantity, 
mechanism of activation and the presence of leukocytes. This is an improved 
system because despite the absence of an optimal platelet quantity, it includes the 
fixed activation and leukocyte parameters and so considers the ongoing debate 
about the presence of WBCs.  
Whether or not WBCs should be totally depleted to produce ‘pure’ PRP (pPRP) or 
concentrated as leukocyte-rich-PRP (L-PRP) is still not clear. The argument for 
purifying PRP is based on findings that high leukocyte concentrations induce 
necrotic and inflammatory effects at the site of application [64] however some 
findings are contradictory to this and have found that pPRP’s significant anabolic 
effects increases the formation of scar tissue [65] as well as evidence that culture of 
BM-MSCs in L-PRP increases proliferation compared to in pPRP and PPP [66].  The 
differences in opinion stem from the unclear characterisation of all large cells found 
in PRP as ‘leukocytes’ despite the wide range of cells that come under that 
category. Some of these cells can be beneficial for bone regeneration whereas 
others can have more harmful effects, so to simply include or exclude all WBCs 
limits PRP’s effectiveness. Polymorphonuclear cells (PMN) for example have 
catabolic effects on various tissues whereas macrophages have been found to 
promote MSC’s osteoblastic differentiation and fracture repair [67]. It may therefore 
be beneficial to concentrate macrophages in the PRP whilst removing all PMNs. 
This is just one example of how further research and standardisation is needed to 
better define each cell type and its role in fracture regeneration. 
The lack of understanding comes partly from the lack of standardisation between 
researchers generating PRP. There is variation in the number and length of 
centrifugation steps, in platelet extraction techniques, in inclusion or exclusion of 
WBCs and in their activating methods. The lack of standardisation makes PRP’s 
clinical efficacy unpredictable and in vitro findings less translatable to patients.  
Activation of the PRP is important to maximise the release of GFs from the platelets 
which can either be released quickly using high concentrations of thrombin, sodium 
citrate (SC) or calcium chloride, or slowly with just the intrinsic mechanical and 
biochemical stimuli of environment. Both release techniques have their advantages 
and disadvantages. Fast release for example, may only induce a short lived but 
potent response which has been found in vitro to improve osteoblast viability [68]  
and neovascularization [69], whereas a slow release brings about a more sustainable 
but less active response due to clots suppressing growth factor release.  
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There is still a lot of debate about how to best optimise PRP but it clearly has 
significant potential to even replace autologous bone marrow in improving bone 
regeneration in patients by creating an optimal niche for cell proliferation as well as 
an effective attractant for endogenous MSCs. However, platelets aren’t entirely 
responsible for generating all the proteins necessary for bone repair since they lack 
factors such as BMP-2 and parathyroid hormone (PTH) which knock-out studies 
have found to be upregulated in the osteogenic processes of fracture healing [70, 71].  
These proteins will have to come from another cellular source and could be a 
limiting factor in the efficiency of platelets if used unaccompanied with another 
treatment.  
1.7 Induced Membrane and Biomimetic Scaffolds: 
A limiting factor of both PRP and autologous BM-MSCs is their tendency to diffuse 
away from the site of application which has led to attempts to retaining as much of 
the GFs and stem cells as possible to the defect site. The natural formation of the 
induced membrane (IM) as a result of the masquelet technique lends itself perfectly 
for this use. The IM has a bilayer structure similar to that of periosteum with a deep 
cellular layer which a study by Cuthbert et al. found to stain positive for BM-MSCs 
[72]. Superficially to the cellular layer is fibrous-collagen layer which seems to act as 
protection from soft tissue infiltration into the defect site. Both layers are well 
vascularised and stain well for important GFs and chemokines such as VEGF and 
SDF-1 [72]. The IM’s structure, together with the added PRP and osteogenic cells, 
which has been shown to induce regeneration [72], creates an enriched environment 
for guided bone regeneration. This forms the basis of a novel treatment option for 
fractures using biocompatible scaffolds. 
 
1.7.1 Biomimetic Scaffolds: 
For bone, several types of scaffold have been developed; with hard scaffolds being 
designed to mimic the properties of cancellous bone, and soft scaffolds, which are 
more flexible and can adhere to or wrap around bone, emulating the environment of 
the extracellular matrix found in periosteum [6, 73, 74]. Hard scaffolds are usually made 
up from hydroxyapatite or decellurised xenogenic or allogenic bone which can be 
mixed with autologous MSCs and PRP and packed into fracture sites to allow new 
bone growth. Products such as Orthoss (derived from decellurised bovine bone) are 
already widely available commercially and used regularly in orthopaedic surgery. 
Soft scaffolds, which usually exist as membranes, are relatively new and only 
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currently used in dentistry because of their small size and weak mechanical 
properties. However; since the discovery of the IM, larger stronger membranes are 
now being developed for fractures. They can be generated from a range of material 
sources including synthetic polymers such as polyester, natural polymers such as 
alginate and proteins such as collagen. Because of its biocompatibility, abundance 
in bone and extracellular matrix [75], collagen is the favoured choice for membrane 
scaffolds. Collagen also has a unique structure hierarchy of triple helices which 
combine to form fibrils which further combine to form fibres which allows for better 
control over its final arrangement and degradation rate. Another benefit of collagen 
is that when it does degrade, its by-products are also biocompatible unlike synthetic 
polymers which can breakdown into acids and cause oxidative stress [76, 77]. 
Collagen is not without its drawbacks; so far, existing scaffolds of pure collagen lack 
mechanical strength needed for large orthopaedic applications and the 
strengthening methods available often involve toxic chemicals and can make the 
scaffold brittle [78]. Due to its protein structure, collagen is also relatively sensitive to 
temperature and chemical exposure which can cause microscopic alterations and 
denaturation to its fibres, weakening the final construct. This limits the sterilisation 
options available by excluding all heat treatments (autoclaving and steam), most 
chemical treatments (ethylene oxide) and physical treatments (low dose γ-radiation) 
[79] and so as of yet, no perfect option exists. However, despite these 
disadvantages, the benefits of using collagen are still thought to outweigh the risks, 
making it the optimal material to manufacture a biomimetic scaffold from. 
 
1.8 Electrospinning a collagen scaffold: 
Whilst many methods exist to manufacture scaffolds including additive 
manufacturing, tissue decellurisation and injection moulding, none offer such fine 
control over the final micro-architecture of the scaffold as electrospinning (ES). ES 
is a nano- and micro- fibre forming method from a range of natural and synthetic 
polymers dissolved in a solvent system [80]. As shown in figure 2, the technology 
involves charging a polymer solution through a needle at high voltage (typically 
between 20-60kV) until the electrostatic forces cause the polymer solution droplet 
at the needle tip to deform into a cone shape (taylor cone). From the taylor cone, 
the charged solution forms a jet and is attracted towards the earthed collector. 
During this process, the solvent evaporates from the polymer solution leaving a dry 
mesh of fibres on the collector. This technique enables the production of sub-
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micron fibres which are known to possess enhanced mechanical properties 
compared to the bulk material from which they were processed due to their being 
stretched in the charged jet [81]. Constructs made using this process offer 
remarkably high surface-area to volume ratios, interconnected pores and a 
tuneable porosity of up to 90% [82]. These properties render a scaffold with vast 
biomedical applications due to their mechanical properties and resemblance to the 
extra cellular matrix. Because of this, ES as a manufacturing process has become a 
vibrant research area in the last decade, particularly in the areas of tissue 
engineering and regenerative medicine. However, despite its low cost and 
simplicity, ES’s notoriously low fibre production rate is well documented in the 
literature [83], restricting sufficient industrial scale production, as well as the 
translation of research into ‘real world’ products and its commercial exploitation. 
The traditional set-up of a syringe solution container connected to a single needle 
spinneret are thought responsible for holding back the out-put of this technology as 
the incorporation of multiple jets isn’t possible due to repulsion of the charged jets. 
A recent advancement in the technology overcomes its limited output by replacing 
the needle-based setup with an open bath setup – allowing multiple jets to form [84]. 
Furthermore, using needle-less ES (or free-surface ES) increases not only the rate 
of output through the increased number of jets, but also the volume produced as 
the volume is no-longer restricted to the volume of a syringe. Free-surface ES has 
successfully been demonstrated as a practical approach to the mass production of 
sub-micron fibre containing constructs. 
 
 
Figure 2: Demonstrating the formation of a taylor cone from the syringe which 
separates into multiple jets towards the grounded collector. As the jets 
evaporate mid-air, a mesh of nano- and micro fibres form. Figure of needle-
based ES adapted from a paper by Yalcinkaya and Callioglu [85]. 
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Figure 3: Demonstration of needleless ES using a bath set-up to charge the 
polymer solution which is attracted towards a grounded collector. This method 
forms multiple taylor cones and jets increasing the fibre output. Image 
adapted from Niu et al [86] 
 
Due to the relatively recent development in this technology, its application in tissue 
engineering is still in its infancy and, as of yet, its potential for manufacturing 
biomaterials, particularly collagen-based biomaterials has still been largely 
unexplored. Optimising the process and parameters is one of the key aims of this 
work. 
1.9 Mechanical Stability:  
For optimal regeneration of bone, as well as supplementary stem cells, GFs and 
scaffolds, the fracture site also needs to be mechanically stable. Stability is vital to 
facilitate callus formation by ECO in the correct alignment, as well as prevent 
excessive movement and reduce further tissue damage [87]. There are several 
options of providing stability to a fracture including intramedullary nailing, external 
fixation devices and plates, each with their advantages and disadvantages. The 
choice of fixation device used depends on the location of injury, mechanical 
stresses and strains carried by the bone and the degree of bone loss. The first 
option, intramedullary nailing, uses a metal rod inserted into the intramedullary 
cavity of bone to bridge defects with significant diaphyseal bone loss.  This 
technique preserves the bone’s length and allows some micromotions, stresses and 
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strains which have been found to improve bone regeneration [88]. Nailing cannot be 
used for epiphyseal or metaphyseal fractures or for fractures of the forearm, nor 
can it be used when the fracture site requires distraction. However an advantage to 
their use is their application alongside external fixation methods like the Ilizarov 
technique.  
External fixation devices involve frames to distract, lengthen or shorten the bone. It 
is thought to be a more versatile technique than intramedullary nailing, however the 
pins used to attach the frame to the bone are prone to infection and require regular, 
thorough cleaning. These factors, as well as the frame’s size and external 
placement, make it an obtrusive treatment option with poor patient acceptance only 
used for more extreme cases. An alternative to external fixation is internal plates, a 
more common choice of treatment for surgeons which uses metal screws to attach 
metal plates to bones. These plates stabilise the defect site in cases where most of 
the bone has been preserved. It is also used to prevent and treat non-union and 
malunion fractures but is less adaptable than the other techniques as it doesn’t 
accommodate any lengthening or shortening.  
Ensuring mechanical support of the fracture site is the fourth aspect of the diamond 
concept; however other factors also play a role in the success of bone healing.  
 
1.10  Other factors affecting bone regeneration: 
So far, the main contributors to bone healing have been described; as long as there 
are cells and GFs available, a scaffold for them to adhere to and a mechanically 
stable environment, the bone should repair itself. However, the rate at which the 
bone heals, and the quality of the end result can vary greatly on a range of factors 
which aren’t covered by the diamond concept.  
Vascularisation of the tissue plays a key role in determining the success of bone 
regeneration as it not only provides nutrients and removes waste but also acts as a 
transport conduit for osteoprogenitors, GFs and importantly, inhibitors of osteoclast 
activity such as osteoprotegerin [65].  
Immediately after a fracture, the intraosseous blood supply to the bone is disrupted 
and pro-inflammatory cascades stimulate the blood vessels in the soft tissue to 
vasodilate. This increased blood supply to the fracture site not only increases red 
blood cell delivery of oxygen and nutrients to prevent tissue necrosis, but also 
initiates the deposition of fibrin and collagen in the formation of a haematoma to 
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provide mechanical stability and a natural scaffold for cells to adhere and new blood 
vessels to form [89, 90]. Angiogenesis after fracture is vital in the recruitment of 
macrophages and other white blood cells in aiding the removal of bone debris, as 
well as MSCs to form the initial callus and red blood cells to ensure cell and tissue 
survival. Its importance in bone regeneration is such that, supporting new blood 
vessel growth is a key characteristic in designing scaffolds that can aid 
angiogenesis and support the new blood vessels [50, 91]. 
Other factors to take into account are the patient’s health profile and includes their 
age, physical fitness, health and co-morbidities e.g diabetes or osteoporosis and 
whether or not the patient smokes. The age of the patient is well understood to 
impact bone healing. A study in ‘juvenile’, ‘middle-aged’ and ‘old’ mice found that 
the older mice’s tibial fractures expressed fewer angiogenic factors (indicative of 
diminished vascularisation) and healed slower than the younger mice [92]. Reduced 
healing is mostly thought to be due to the ageing of MSCs and changes in their 
morphology and functioning, supported by findings that younger donor’s MSCs had 
better differentiation capacities and are a better source of MSCs than older donors 
[93]. However, another study also found that the decrease in bone repair in elderly 
patients may not be due to the decreased functioning of MSCs and osteoblasts, but 
instead due to the lack of environmental cues for them to differentiate and begin 
laying down new bone[94]. Elderly patients are also more likely to have co-
morbidities which may affect bone regeneration, the most common and detrimental 
being type 2 diabetes, obesity and osteoporosis [95]. Osteoporosis is a disease that 
modulates osteoblast activity causing inadequate bone formation and excessive 
bone resorption resulting in brittle and weak bones. This makes stabilising the injury 
difficult as well as finding enough autologous graft material to fill the defect. 
Diabetes mellitus is even more problematic as is also causes brittle bones as well 
as weaker calluses and delayed healing post-fracture which have been related to 
reduced expression of TGF-β1 and BMP-2 [96].  
It is clear then that, when thinking about bone trauma, vascularisation and patient 
characteristics are as significant as the use of osteogenic cells, GFs, scaffolds and 
mechanical stability in treating fractures and must be carefully considered. 
1.11 Hypothesis and aims: 
The hypothesis for this study is to develop and test a biomimetic collagen-based 
membrane to act as a guided bone regeneration device in the treatment of long 
bone fracture repair when loaded with BMA and PRP. 
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To address the hypothesis, this project aims to fully characterise the naturally-
formed IM (chapter 3), specifically its collagen orientation and architecture; to 
design and engineer a collagen-based membrane scaffold which mimics the IM 
(chapter 4); to optimise PRP for supporting BM-MSC survival and migration 
(chapter 5), and finally to test the interaction and functionality between the cells, 
PRP and scaffold (chapter 6).  
Collectively, the aim of this work is to further the treatment of complex bone 
fractures and lead to the translation of a clinically relevant medical device. 
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2 Materials and Methods 
Details of the brands and manufacturers used for the reagents, consumables, 
equipment and software can be found in the appendices 1, 2, 3 and 4 respectively. 
2.1 Sample collection: 
Patients undergoing elective orthopaedic surgery with no underlying disease were 
recruited and gave informed written consent in compliance with the Helsinki 
Declaration. Ethics committee approval was obtained from the local National Health 
Service Research & Development Department, National Research Ethics Service, 
Leeds East Research Ethics Committee for the harvesting of these samples under 
the NHS Leeds east ethics code: 06/Q1206/127. 
2.2 Bone marrow aspirate (BMA) sample collection  
BMA was collected from recruited patients (n=11, 5 females and 6 males, median 
age 40, range 17-63) as outlined in table 1. 4mL of bone marrow were aspirated 
from the anterior iliac crest using an 11-gauge, bevel-tipped trocar and 10 ml 
syringe flushed with 1000 U/mL sodium heparin solution. The samples were 
collected in EDTA vacuettes and inverted to prevent clot formation. Once collected, 
samples were kept at 4°C and processed within 24 hours before being used in 
CFU-F assays, proliferation assays, and migration assays. 
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Table 1: BMA donors 
Bone marrow aspirate 
Patient Number Gender Age (years) 
1 M 63 
2 F 54 
3 F 39 
4 F 69 
5 F 23 
6 M 19 
7 M 49 
8 F 45 
9 M 26 
10 M 17 
11 M 31 
2.3 Whole blood sample collection: 
Whole blood was also collected from patients (n=12, 4 females and 8 males, 
median age 49, range 19-80) as outlined in table 2. 20-30 mL of blood in 10% ACD-
A was drawn in an ACD-A flushed 30 mL syringe and inverted to prevent clotting. 
The syringe was sealed and stored at 4°C before processing within two hours of 
collection. The whole blood samples were used to generate ‘in-house’ PRP and PL 
in proliferations assays, migration assays and for loading the scaffold.  
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Table 2: Whole blood donors 
Sample ID Age Sex Used to generate 
A 30 M PRP, C-PRP 
B 22 M PRP, C-PRP 
C 23 F PRP, C-PRP 
D 34 F PRP, C-PRP 
E 40 M PRP 
F 24 F PRP, fPRP 
G 28 F PRP 
H 28 M PRP, fPRP 
I 44 M PRP, fPRP 
J 33 M PRP 
K 30 M PRP 
L 36 M PRP 
*Platelet rich plasma (PRP, fPRP (filtered PRP), C-PRP (commercial PRP) 
 
2.4 C-PRP sample collection: 
C-PRP was also collected from patients (n=4, 2 females and 2 males, median age 
27, range 22-34) as outlined in table 2. C-PRP was made in theatre by first drawing 
60 mL of whole blood into two 30mL syringes, each containing  3 mL ACD-A to give 
a final anticoagulant concentration of 10%. The anticoagulated blood was then 
transferred to the platelet concentration system and centrifuged at 1100 xg for 15 
minutes spin step in a specialised in-theatre centrifuge.  
Following centrifugation, the PPP fraction is first removed by inverting the device 
and extracting 25 mL using a syringe at the outlet, then the C-PRP fraction is 
removed by agitating the device and extracting the remaining 5 mL of C-PRP from 
the outlet. A 1 mL sample of the C-PRP fraction was collected from each donor in 
EDTA vacuettes, as well as 1mL of donor-matched whole blood, for analysis using 
the Hematology-Analyzer. The C-PRP samples were used in BM-MSC proliferation 
and migration assays as well as for loading onto the scaffolds (chapters 5 and 6). 
Three patients also donated 20mL of whole blood for the production of ‘in-house’ 
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PRP as outlined in section 5.2.1 to enable donor matched comparisons between 
the two platelet products.  
2.5 Induced membrane and periosteum samples 
Induced membrane and periosteal biopsies were collected from patients 
undergoing second stage masquelet surgery specifically with no underlying disease 
(n=7, 4 females and 3 males, median age 43yrs, range 32-58yrs from the ulna=1, 
femur=3 and tibia=3) outlined in table 4. The surgical procedure involves 
debridement of the polymethyl methacrylate cement spacer that was placed during 
the first surgery from the defect site to expose the IM tissue. An area of 1 cm2 IM 
tissue was carefully harvested adjacent from the muscle followed by careful 
dissection of 1 cm2 periosteal tissue harvested at least 10 cm from the area of the 
bone defect. Tissues were placed in 5 mL sterile PBS and stored at 4°C until 
processing up to 4 hours later. Samples were processed for histological analysis, 
SEM imaging, and polarised light imaging. 
Table 3: IM and periosteum donors: 
Sample ID Age Gender Location of defect Weeks in situ 
Donor 1 32 M Femur 14 
Donor 2 40 F Ulna 7 
Donor 3 34 F Tibia 8 
Donor 4 44 M Femur 3 
Donor 5 58 M Femur 17 
Donor 6 47 F Tibia 7  
Donor 7 45 F Tibia 11 
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2.6 Processing bone marrow nucleated cells (NCs) for 
storage: 
BMA samples were first filtered through a 70 μm filter to remove large debris before 
being diluted in a 4:1 ratio of ammonium chloride solution to bone marrow. The 
suspension was mixed until homogenous thoroughly and cooled on ice for 10 
minutes to lyse contaminating red blood cells. The cell suspension was then 
centrifuged (500 xg, 5 min), before washing in 10 mL DMEM and being 
resuspended in 10 mL DMEM and counted using a haemocytometer. To count the 
cells, 10 μL of cell suspension was mixed with 10 μL of Trypan blue and 10 μL of 
the stained cell solution was pipetted onto the haemocytometer. Live cells in the 
peripheral 4x4 squares were counted. To calculate the number of NCs/mL and in 
total, the following equation was used:  
 
𝑁𝐶 𝑐𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑚𝐿 = 𝑇𝑜𝑡𝑎𝑙 𝑛𝑜 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 10,000 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (2) 
𝑇𝑜𝑡𝑎𝑙 𝑁𝐶 𝑐𝑜𝑢𝑛𝑡 = 𝑁𝐶 𝑐𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑚𝑙 × 𝑣𝑜𝑙𝑢𝑚𝑒 
Equation 1: Calculating number of nucleated cells in bone marrow aspirate 
 
 
Freezing mix (10%DMSO, 45% FCS, 45% DMEM) was then added to the cells 
(approximately 1 mL of freezing mix per 20x106 cells) and frozen in cryovials using 
a freezing container at -80°C. After 24 hrs at -80°C vials were moved to liquid 
nitrogen tanks for long term storage at -175°C. 
2.7 Processing BM nucleated cells for culture: 
Cells purified from the lysed bone marrow aspirate were seeded into T-25 tissue 
culture grade flasks at a density of 2.5 × 104 cells/mL in 8 mL Stem Macs media 
containing 100µg/mL of Penicillin/Streptomycin. Unless stated otherwise, all cell 
incubations were carried out at 37°C in humidified 5% CO2/air. Following a PBS 
wash after 48 hrs to remove unattached cells, the media was replenished. Adherent 
cells were expanded with half media changes twice a week and trypsinised when 
they reached 80% confluence. For expansion, the trypsinised cells were re-plated 
at a density of 1 x 104cells/mL up to passage four. Expanded BM-MSCs were used 
in chapter 5 to assay the proliferative and migratory effects of PRP, and to assess 
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the quality of BMA of the target population based on BM-MSC number. Expanded 
BM-MSCs were also used in chapter 6 to investigate the cytotoxic potential of the 
scaffolds as well as test the scaffold’s functionality based on how they support BM-
MSC proliferation. 
2.8 Colony-forming unit-fibroblast (CFU-F) assay: 
To enumerate BM-MSCs, the samples that were collected in up to 4 vacuettes 
(depending on volume aspirated) were pooled into a single falcon tube and filtered 
using a 70 µm cell strainer to remove clots. 80 µL of each sample was plated onto 
duplicate 60 mm x 15 mm dishes with 5 mL of Stem Macs media and kept in an 
incubator at 37°C. After 48 hours, dishes were washed with 10 mL PBS to remove 
red blood cells other unattached BM cells and replaced with 5mL Stem Macs media 
followed by a bi-weekly half media change. After two weeks, the dishes were 
washed with PBS and fixed in 3 ml of 3.7% formaldehyde for 15 minutes at RT. 
After fixing, the dishes were covered in 8 mL 1% (w/v) methylene blue solution for 
30 minutes at RT, washed with distilled water and left to air dry. Visible colonies 
made up of at least 50 cells were counted, averaged and multiplied by 12.5 to get 
the number of colonies/mL. 
2.9 XTT assay: 
The XTT assay was used to quantify BM-MSC proliferation in the presence of 
different platelet lysate (PL) products (chapter five) as well as to assay the potential 
cytotoxicity of the scaffolds (chapter six) whereby a decrease in the number of living 
cells results in a decrease in the total activity of mitochondrial dehydrogenases in 
the sample. This decrease directly correlates to the amount of orange formazan 
formed, as monitored by the optical density at 450nm. In general, cells were seeded 
in triplicate in a 96 well plate (densities varied depending on specific assay) in 
200µL stem macs media and incubated to allow cell attachment. After 24 hours 
incubation, the stem macs media was removed, the wells gentle rinsed in PBS, and 
the cells were treated with 200µL of the treatment media (either PL based for 
chapter 5 or containing scaffold eluate for chapter 6). Following exposure to the 
treatment medias (exposure duration depends on whether proliferation or 
cytotoxicity are being assessed) the wells are replaced with 100 μL of DMEM with 
10% FCS and 50 µL of the XTT solution and incubated for 4hrs at 37°C. An aliquot 
of 100 µl is transferred from each well into the corresponding well of a new plate 
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which is read on a microplate reader at 450nm and 630nm (reference wavelength). 
The value for the reference wave at 630nm is deducted from the 450nm reading to 
give the final optical density (OD).  
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3 Characterising the naturally induced membrane 
 
3.1  Introduction:  
Fracture non-union (sometimes referred to as “delayed union”) is a common 
complication of a  fracture affecting 2-12% of all fracture patients [1, 2]; characterised 
by the absence of fracture healing after 6 months [3]. As previously described, for 
severe non-unions of a critical sized defect the current ‘gold-standard’ treatment 
involves a two-stage surgical procedure known as the Masquelet technique. In the 
first surgery, all loose and nonviable tissue is removed and the fracture void is filled 
with a polymethylmethacrylate (PMMA) cement. Exposure to the cement induces a 
response from the surrounding tissues which leads to the formation of a bioactive 
IM. After 4-12 weeks, in a second surgery, the surgeon incises the IM to remove the 
PMMA cement, the defect void is then filled with osteogenic graft material and 
internally fixed with metalwork. While this technique has been found to have 
widespread clinical success, it still requires at least two separate surgeries – which 
is costly in time and finance and does not always guarantee the induction of a 
robust membrane [10, 13]. One solution to address these limitations would be to 
engineer a synthetic biomimetic membrane based on the tissue which is thought to 
be the key player in the Masquelet techniques’ success; the IM. The IM was chosen 
as the foundation for the biomimetic scaffold based on its unique structure and role 
in 1) acting as a guided bone regeneration device, 2) retaining the grafted material 
to the defect site and 3) acting as a protective layer. Some of its characteristics 
have already been determined through the study of animal models and human 
samples, the key findings of which have been outlined in table 6, but there has 
been little examination carried out on human samples due to the precious nature of 
the tissue [4-6]. Fundamental differences between animal and human tissues such as 
their size, composition and healing pathways necessitate the need for further 
analysis of human samples to better understand what its key characteristics are 
that contribute to its role as a guided bone regeneration tissue. Collectively, the 
studies describe the IM’s bilayer structure as composed of a thin, densely 
populated cell layer as well as a larger fibrous layer synonymous to that seen in 
periosteum tissue which is highly vascular initially but this, and its overall thickness, 
decrease over time [7, 8]. However, as it stands, there is still uncertainty surrounding 
the development of the tissue, better understanding how it develops will help 
identify the key features to its success.  
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Table 4: Induced membrane literature review 
 
Study Species IM 
exposure to 
PMMA 
Main findings 
Henrich et al . 
2016 
Rat 6 weeks - IM vascularity decreases after 1 month 
- IM has a bilayer similar to the 
periosteum, only thicker 
Wang et al . 
2015 
Rabbit 8 weeks - IM has a bilayer similar to the 
periosteum, only thicker 
- Thickness and vascularity of the IM 
decreases over time 
Liu et al . 2014 Rabbit 8 weeks - IM has a bilayer 
- Thickness and vascularity decreased 
after 1 month 
Aho et al . 
2013 
Human 22 months - Optimal time for performing second-
stage surgery is 1 month after PMMA 
implantation 
- Tissue vascularity decreased over time 
Cuthbert et al . 
2013 
Human 8 weeks - IM is a thick, vascularised bilayered 
structure that resembles periosteum 
Viateau et al . 
2006 
Sheep 6 months - IM is a highly vascularised collagenous 
tissue positive for type I collagen 
Pelissier et al . 
2004 
Rabbit 8 weeks - IM has a distinct bilayer which is highly 
vascular 
- IM reaches ‘peak’ maturity with regard to 
growth factor release at 1 month 
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The recent focus on biomimetics in tissue engineering stems from the theory that 
each tissue’s distinctive microarchitecture are critical to their specific functions and 
therefore need to be fully understood [9, 10]. In non-union fractures especially, 
there is a need to create an IM surrogate that acts as a focal point for BM-MSC 
proliferation and migration to the site of injury.  
The purpose of this chapter is to characterise the human IM samples (alongside 
periosteum from the same anatomical location as a comparison), particularly its 
collagen structure and composition, the findings of which will contribute to the 
design of a novel biomimetic membrane. When combined with appropriate internal 
fixation and autologous osteogenic stem cells and growth factors, the simulated 
biological tissue has the potential to negate the need for the second surgery, and 
streamline the current two-step reconstructive process. As well as reducing the 
number of surgeries required, use of a synthetic IM could also reduce the risk of 
complications as well as accelerate bone healing.  
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3.2 Chapter specific methods: 
3.2.1 Tissue processing for histology: 
To characterise the structure and microarchitecture of the natural IM and periosteal 
tissues, the biopsied samples (figure 4) were fixed in paraformaldehyde, before 
being dehydrated and embedded in paraffin wax as outlined in 3.2.2 . The 
embedded samples were sectioned in 5 µm thin slices and mounted onto glass 
slides before staining with haematoxylin and eosin, masons trichrome, picro sirius 
red (PSR) and verhoeff van gieson stain. Seven IM samples were fixed and stained 
for imaging as well as two periosteal samples. 
 
 
Figure 4: An example IM tissue biopsy harvested from the femur before fixing and 
processing for histology. Figure shows tissue in a 15 cm petri dish. 
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3.2.2 Fixing: 
After harvesting, the IM and periosteum samples were transferred to 3.7% 
formaldehyde for 7 days at room temperature. The fixed samples were then placed 
into individual cases and processed overnight using an automated vacuum tissue 
processor the solutions and durations of each step are outlined in table 5. 
Table 5: Tissue processing protocol 
 
 
 
3.2.3 Embedding and sectioning: 
The samples were orientated in a cassette to allow a full cross-section of the tissue 
and covered in paraffin wax at 70°C. Once hardened the tissues could be sectioned 
using a microtome set to 5 µm thickness. Sections were floated in a water bath set 
at 40°C and mounted on glass slides before heat-treating on a hot plate at 60°C for 
2 hours prior to staining. 
Step Solution and reagents Time (hr:min) Temperature (°C) 
1 70% ethanol 0:30 37 
2 80% ethanol 0:30 37 
3 90% ethanol 0:30 37 
4 95% ethanol 0:30 37 
5 100% ethanol 1:00 37 
6 100% ethanol 1:00 37 
7 100% ethanol 1:30 37 
8 Xylene 1:00 37 
9 Xylene 1:30 37 
10 Xylene 1:30 37 
11 Paraffin wax 1:00 65 
12 Paraffin wax 1:00 65 
13 Paraffin wax 1:00 65 
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3.2.4 Tissue staining: 
To gain an accurate understanding of the IM’s microarchitecture, a range of 
histology stains were utilised to identify the various structures. Haematoxylin and 
eosin was used to give a general overview of the tissues’ morphology by staining 
nuclei blue and extracellular proteins, such as collagen, varying degrees of pink. To 
gain better definition of the individual collagen fibres, picro sirius red stain was used 
which stains collagen fibres red, extracellular matrix pale yellow and nuclei black. 
Picro Sirius red stain was also used to image the tissue sections under polarised 
light to gain insight into the collagen fibrils maturity based on their structure, 
thickness, and orientation. Finally, verhoeff van giesons stain was used to identify 
the presence of elastin fibres by staining elastin and cell nuclei black, collagen 
fibres red and cytoplasm yellow. 
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3.2.5 Haematoxylin and eosin stain 
Table 6: Haematoxylin and eosin stain 
 
Process Step Solutions and reagents Time (min:s) 
Dewaxing 1 Xylene 3:00 
2 Xylene 3:00 
3 Xylene 3:00 
4 Xylene 3:00 
Rehydration 5 100% ethanol 3:00 
6 100% ethanol 3:00 
7 100% ethanol 3:00 
8 100% ethanol 3:00 
9 75% ethanol 3:00 
10 50% ethanol 3:00 
11 25% ethanol 3:00 
12 Running tap water 1:00 
Staining 13 Mayer’s haematoxylin 2:00 
14 Running tap water 1:00 
15 Scott’s tap water 2:00 
16 Running tap water 1:00 
17 Eosin 2:00 
18 Running tap water 1:00 
Dehydration 19 100% ethanol 0:15 
20 100% ethanol 1:00 
21 100% ethanol 5:00 
22 100% ethanol 5:00 
Clearing 23 Xylene 3:00 
24 Xylene 3:00 
25 Xylene 3:00 
Coverslip 26 DPX (to adhere coverslip to slide) N/a 
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3.2.6 Picro sirius red stain 
Table 7: Picro sirius red stain 
Process Step Solutions and reagents Time (min:s) 
Dewaxing 1 Xylene 3:00 
2 Xylene 3:00 
3 Xylene 3:00 
4 Xylene 3:00 
Rehydration 5 100% ethanol 3:00 
6 100% ethanol 3:00 
7 100% ethanol 3:00 
8 100% ethanol 3:00 
9 75% ethanol 3:00 
10 50% ethanol 3:00 
11 25% ethanol 3:00 
12 Running tap water 1:00 
Staining 13 Weigerts solution A & B 8:00 
14 Running tap water 10:00 
15 Picro sirius red 60:00 
16 Acidified water 0:15 
17 Acidified water 0:15 
Dehydration 18 100% ethanol 0:15 
19 100% ethanol 1:00 
20 100% ethanol 5:00 
21 100% ethanol 5:00 
Clearing 22 Xylene 3:00 
23 Xylene 3:0 
24 Xylene 3:00 
Coverslip 25 DPX (to adhere coverslip to slide) N/a 
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3.2.7 Verhoeff van gieson stain 
Table 8: Verhoeff van gieson stain 
Process Step Solutions and reagents Time (min:s) 
Dewaxing 1 Xylene 3:00 
2 Xylene 3:00 
3 Xylene 3:00 
4 Xylene 3:00 
Rehydration 5 100% ethanol 3:00 
6 100% ethanol 3:00 
7 100% ethanol 3:00 
8 100% ethanol 3:00 
9 75% ethanol 3:00 
10 50% ethanol 3:00 
11 25% ethanol 3:00 
12 Running tap water 1:00 
Staining 13 Acid potassium permanganate 5:00 
14 Running tap water 0:15 
15 1% oxalic acid 2:00 
16 Running tap water 1:00 
17 95% ethanol 0:15 
18 Running tap water 1:00 
19 Weigert’s haematoxylin 10:00 
20 Running tap water 1:00 
21 Picro Sirius red 10:00 
22 Running tap water 1:00 
Dehydration 23 100% ethanol 0:15 
24 100% ethanol 1:00 
Clearing 25 Xylene 3:00 
26 Xylene 3:00 
Coverslip 27 DPX (to adhere coverslip to slide) N/a 
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3.2.8 Microscopy and imaging: 
Stained tissue sections were examined by bright field microscopy using an inverted 
microscope and captured using the camera function. The images were then 
processed using the image acquisition software Imagescope (see appendix 2, 
section 9.2) to measure the different sections of the tissues which was calibrated 
using a haemocytometer with known dimensions. 
3.2.9 Histology measurements: 
To measure the lumen diameter of blood vessels, H&E stained IM samples were 
imaged. Once imaged, blood vessels perpendicular to the vessel path were 
measured using a 10 x objective. The mean lumen diameter from a minimum of 20 
characteristic blood vessels, which were selected randomly using three observation 
grids, was calculated. The mean lumen diameter was plotted against the duration of 
exposure of the IM to the PMMA cement (referred to as ‘age of IM’) to identify any 
trend of changing lumen size. It has already been described in previous literature 
that the IM is made up of two layers [7], the thicknesses of these layers were 
measured using a 10x objective at three depths of the tissue block (superficial, 
intermediate, and deep – each region was approximately 30 sections apart) and at 
a minimum 20 points across the length of each section (figure 5) . The mean 
thickness for each sample’s cellular and fibrous layer was also plotted against the 
age of the IM to identify any trend in size change.  
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Figure 5: An example of how the IM bilayers were measured along the length of 
each cross section using ImageScope software before exporting the data into 
a GraphPad document for analysis. Scale bar indicates 400μm 
. 
 
3.2.10 Polarized light microscopy: 
Tissue sections were cut 5µm thick and stained with picro sirius red according to 
section 3.2.6. Collagen molecules are known to be rich in basic amino acids, which 
strongly interact with the six sulfonate groups in sirius red [11]. Binding between the 
amino acids and sulfonates enhances the birefringence of the collagen fibrils that 
can be viewed under light waves from a single plane: polarized light. Due to 
differences in density between mature and newly formed collagen fibrils, mature 
collagen appears red-yellow under polarised light, whilst thinner, newly formed 
collagen appears green. Following staining, a Zeiss Axioplan microscope with 
circularly polarized microscopy filters aligned to 0° so that the background in the 
field of view was as dark as possible. Images were captured under an exposure 
time of 130 ms using a light path of 5V. 
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3.2.11 Statistics 
All statistical analyses were carried out using GraphPad Prism software (GraphPad 
software). Data is expressed as mean ± standard deviation for each parameter, the 
non-parametric Mann-Whitney U test was used to examine differences in cellular 
and fibrous IM layer thickness at different time points. A P-value of < 0.05 was 
considered signiﬁcant.  
3.3 Results  
Gaining insight into the structure and morphology of the IM and how they contribute 
to its success as a guided bone regeneration device is a crucial step towards 
designing a novel biomimetic membrane. Histological techniques were primarily 
used as the principal technique to visualise and characterise the bilayer (figure 6 
and 7), collagen content (figure 8), elastin content (figure 9) as well as analysis of 
the lumen diameter (figure 10) and bilayer thickness (figure 11). 
3.3.1 Characterisation of the bilayer membrane structure: 
Whilst the IM in animal models has been well characterised as sharing some 
morphological characteristics with periosteum [4-6] such as the presence of a 
bilayer structure, there is less known about human IM due to scarcity of samples. 
The human IM and periosteum samples collected from patients undergoing second 
stage masquelet surgery and were characterised using haematoxylin and eosin 
(figure 6) to elucidate their structure. Haematoxylin stains basophilic structures, 
primarily found in nuclei and is used to identify cell distribution. Eosinophilic 
structures, such as cytoplasm and extracellular matrix stain with different degrees 
of intensity – keratin fibres in muscle will stain a dark pink whilst collagen fibres will 
appear a much fainter pink [12].  
- 40 - 
 
 
Figure 6: Basic features of periosteum and IM tissues stained with H&E. Left 
column 4 x magnification, scale bar represents 200μm. Right column 10 x 
magnification, scale bar represents 100 μm. The blue line indicates where the 
cement resided, whilst arrows indicate muscle fibres (purple arrows), regions 
of damaged cambium (blue arrow), and blood vessels (red arrows). The 
cambium (c) and fibrous (f) layer of the periosteum are also identified 
separately. 
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Looking first at the control periosteum sample, the stain revealed a loose outer 
fibrous layer and a more cellular cambium layer at the bone interface indicated in 
the figure by the blue line. The cambium layer was not found to be completely intact 
due to connective sharpeys fibres attaching the tissue to the bone, a phenomenon 
which has also been described in the literature [13, 14]. Severing these fibres 
during sample collection caused the observable damage to the cambium layer (blue 
arrows, figure 6). The tissue also appears to be highly vascular (red arrows), 
contributing to its role in supplying nutrients to the bone and the surrounding muscle 
layer is also visible (purple arrows).  
Of the 7 IM samples stained for H&E, all showed some degree of variation in 
morphology, due to either age of IM or anatomical location, therefore 5 samples 
representative of the range will be discussed. IM from donor 1, which was exposed 
to PMMA for 14 weeks, had distinct collagen staining throughout the tissue as well 
as an equal distribution of cells that infiltrated the whole tissue rather than being 
localised as a cellular layer adjacent to where the cement spacer resided (blue 
line). IM from donors 2 and 3, which were both exposed to PMMA for 7 weeks, had 
a cellular organisation that correlated the most to what has been described in the 
literature with an intact cellular layer beside a much larger fibrous layer. 
Interestingly, IM from donor 4, which was exposed to the PMMA for only 3 weeks 
has the starkest contrast in morphology. Whereas donors 1-3 had some 
resemblance of cellular and fibrous organisation, the more immature IM from donor 
4 has no observable structural arrangement. The lack of organisation is likely due to 
the initial inflammatory reaction to the PMMA spacer with MSC, and fibroblast cell 
infiltration contributing to the IM formation. The unusual morphology of donor 4’s 
tissue supports findings in the literature that the second stage of the masquelet 
procedure should be carried out after a minimum of 4 weeks to ensure full IM 
development before grafting [15, 16].  
As expected, all the IM samples were distinctly thicker and denser than the 
periosteum and were mostly made up of fibrous matrix. Interestingly, with regard to 
the IM’s bilayer, the different donors all displayed varying degrees of distinction 
between the layers and some samples lacked any observable bilayer at all (IM from 
donor 4). This absence of an obvious cellular layer which is described as putative  
in the literature [4, 7] is likely to stem from either differences in age of the IM (with 
regards to its exposure to PMMA), or its anatomical location, as the different 
mechanical forces on the tissue could bring about different morphological 
characteristics. Furthermore, as is often seen in periosteum histology where the 
cambium layer is lost due to its attachment to the bone and subsequent damage 
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during collection, the IM could be exposed to similar damage following dissection 
from the PMMA. Injuries in different anatomical locations may result in cement 
spacers that are more or less difficult to remove resulting in varying degrees of cell 
layer preservation. Damage to the IM’s innermost layer in-contact with the PMMA 
could explain its varying presence across donors. This variation isn’t seen in animal 
IM studies whereby the whole IM capsule is extracted and dissection from the 
cement spacer can be carried out more carefully. This is a limitation of using human 
tissues that is difficult to overcome due to the need to preserve as much of the 
tissue for the patients treatment as possible. It is also of note that the images taken 
at 10 x magnification lacked white balance, a technical issue that would be 
addressed in future work. 
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Figure 7: Detailed imaging of donor 5’s IM tissue histoarchitecture using H&E stain, 
highlighted in A and B are two regions of the bilayer at x 20 magnification, 
scale bars indicate 1mm (top) and 100μm (bottom). Green arrows indicate 
region of acute inflammation and blue arrows indicate elongated fibroblast 
cells. 
 
The IM from donor 5 was exposed to PMMA the longest of all the samples (17 
weeks) and had the most intact bilayer. This sample was imaged separately (figure 
7) under 20 x magnification to allow better characterisation. It can be seen that the 
innermost component adjacent to the PMMA is made up of densely packed 
elongated fibroblast-like cells orientated parallel to the PMMA (figure 4A and B, blue 
arrows). Deeper into the tissue, and further from the cement interface, the cells 
generally become more dispersed. And exception to this reduction in cells is a 
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region of acute inflammation (figure 7B, green arrows) which appears to be made 
up of multinucleated giant cells consistent with foreign body reactions and IM’s role 
as an inflammatory response tissue [17].  
 
3.3.2 Polarised light microscopy: 
Whilst haematoxylin and eosin is capable of staining collagen, it isn’t able to 
differentiate between the fibrous proteins of the extracellular matrix such as 
collagen, elastin, laminin and reticulin, therefore, to enable more accurate 
characterisation of the IM’s structure, samples were fixed and stained with picro 
sirius red (figure 8). Under bright field microscopy, picro sirius red stains collagen 
red and muscle and cytoplasm yellow [18, 19]. To get more definition, the slides 
can also be viewed under polarised light whereby closely compacted and thick 
collagen fibres appear strongly birefringent (red-yellow) whilst thinner, loosely 
connected thinner collagen fibres appear faintly birefringent (green). 
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Figure 8: Picro sirius red staining of periosteum and IM biopsies under brightfield 
microscopy (left column) and polarised light (right column) both at 20x 
magnification. Scale bars indicates 50μm and arrows identify blood vessels 
(red arrows) and red blood cells (black arrows).Under bright field microscopy 
collagen fibres appear dark pink and under polarised light they appear green, 
yellow and red depending on their thickness and maturity. 
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Looking first at the collagen structure of periosteum, under bright field microscopy 
the picro sirius red stain has stained positively for collagen fibres (red) and it is clear 
that the fibres are not densely arranged. Furthermore, the stain highlights a region 
rich in red blood cells in yellow (black arrows), which is seen commonly in the 
literature due to periosteum’s highly vascular nature. Under polarised light, the 
network of collagen fibres can be seen more clearly, and their sparsity as seen 
under bright field is confirmed by a majority of green birefringence. Although an 
occasional thick fibre is seen at the cambium layer, no overall gradient or change in 
collagen thickness was seen along the periosteum’s cross-section, this indicates a 
generally homogenous tissue.  
Demonstrated in previous stains, all four of the IM samples stained with picro Sirius 
red showed a degree of donor variation so were analysed individually. Donor 5, 
which was exposed to PMMA the longest of all the IM samples stained much more 
intensely for collagen than periosteum when viewed under bright field microscopy 
indicating denser and thicker collagen fibres. This was confirmed under polarised 
light which showed the IM was evidently more birefringent proximal to PMMA with a 
trend of decreasing density away from the cement spacer suggestive of a reduction 
in the secretion of fibrous, protective collagen. This further supports the notion that 
the IM is formed as a reactive response to the PMMA. The collagen fibres were 
clearly highly organised as bundles that were aligned parallel to the where PMMA 
resided. Analysis of donor 1, under both bright field and polarised light showed 
intensely dark collagen staining of fibres that also found to be highly stratified along 
where initially was the open defect. Unusually, no distinct gradient of birefringence 
was observed across the tissue as the whole tissue appeared to be made up of 
dense, thick fibres, with the only non-birefringent regions being blood vessels (red 
arrows). Donor 3 also stained more intensely for PSR than periosteum under bright 
field. Under polarised light donor 3 presented consistently intense birefringence 
(red) with no clear gradient, the weaker birefringence bisecting the sample is due to 
large blood vessels and adjacent to the PMMA is likely due to damage following 
harvesting. Despite this damage, the fibres’ parallel alignment in bundles is still 
clearly visible. Finally, donor 4, which had the shortest exposure to the PMMA (3 
weeks) demonstrated the most disordered collagen alignment supporting the H&E 
staining results. This tissue in particular was of interest as it appeared to grow 
perpendicular to the PMMA demonstrating the chaotic production of collagen 
following the initial response to the injury and cement spacer.  
Overall, although there is some degree of donor variation, all samples to some 
extent showed significantly darker collagen staining and birefringence than 
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periosteum. In addition, all samples demonstrated the IM’s organisation of collagen 
fibres into crimped bundles, and with the exception of the underdeveloped IM tissue 
from donor 4, all appeared to lay down collagen parallel to the PMMA spacer. The 
absence of this uniformity in IM from donor 4 suggests that during weeks 0-3 the IM 
is composed of randomly orientated collagen bundles which begin to align some 
point after week 3. This change in orientation is likely caused by both an increase in 
density (as more cell migrate to the site and more collagen is produced over time), 
as well as external musculoskeletal forces compressing the tissue into alignment.  
 
3.3.3 Elastin content of IM: 
The verhoeff-van gieson stain was used to elucidate the presence of elastic fibres 
which are involved in providing flexibility and elasticity to tissues such as skin and 
ligaments as well as to high-volume blood vessels (figure 9). High volume blood 
vessels are demonstrative of ‘mature’ blood vessels and can be used to identify 
tissue maturation. As expected, there was very little positive staining for elastic 
fibres (black staining) throughout the tissues indicating a general lack of elasticity 
and flexibility. The little staining that was observed was concentrated around larger 
blood vessels and was found in almost all IM donors. Interestingly, the only IM 
sample where elastin staining was completely absent was donor 4, which had the 
shortest exposure to the PMMA. Elastin’s absence in this tissue supports the 
findings that IM tissues take at least 4 weeks to fully develop [4, 20].  
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Figure 9: Elastin staining of periosteum and IM biopsies under brightfield 
microscopy at 10x magnification (left column) with scale bars indicating 
200μm, and 20x magnification (right column) with scale bars indicating 
100μm. Verhoeff-van gieson stain identifies collagen fibres (red), elastin fibres 
(black), muscle and cytoplasm (yellow). 
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3.3.4 Characterisation of IM’s maturity: 
After characterising the IM’s histoarchitecture, it appeared that the lumen diameter 
varied between donors, and the overall size of the IM varied between donors. It was 
hypothesised that both these characteristics had a correlation to duration of 
exposure to PMMA (‘age of IM’), whereby lumen diameter and IM thickness would 
be higher in mature IMs. To investigate whether these changes were related to the 
age of IM or donor variation seven samples were processed, stained and measured 
throughout the sample block to identify any correlation in donor age and IM maturity 
(figure 10). 
 
Figure 10: Mean lumen diameter of samples stained with H&E before imaging on 
Imagescope for analysis. Lines indicate standard deviation. 
 
Analysis of the lumen diameter results indicate some degree of interrelationship 
between the age of the IM and increased lumen diameter with linear regression 
analysis of the data points revealing an R2 value of 0.73 and the greatest increase 
occurring between 3 and 7 weeks. By 8 weeks, the average lumen diameter 
appears to plateau between 200 – 250 µm with the only observable change being 
an increase in diversification of blood vessel size demonstrated by an increased 
standard deviation at 17 weeks.  
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Figure 11: Membrane thickness for IM biopsies collected from patients 3-17 weeks 
after the initial surgery. Were present, both the cellular and fibrous layers 
were measured. The dotted line indicates the measurement of the 
periosteum. 
 
Another key characteristic of the IM tissue is the thickness of the layers which were 
measured and plotted against their respective IM’s age (figure 11). For samples 
that lacked a distinct cellular layer, only their fibrous layer was measured. This data 
effectively demonstrated the regularity in the IM’s total thickness and how there was 
no significant time point at which thickness peaked, nor was there any significant 
degradation in size over time. Despite collecting samples from different IM ages (3-
17 weeks) and anatomical locations (femur, ulna and tibia), the individual bilayers 
and total thickness were found to be generally consistent between donors. The 
cellular layer on average was found to measure 95 ± 23 µm and the fibrous layer 
was found to be measure 1861 ± 227 µm. The overall thickness was 1942 ± 220 
µm on average (range: 1706-2286 µm). Consistently, every IM sample, at every 
time point was found to be thicker than periosteum which measured 516 µm (dotted 
line figure 11). These measurements correlate to previous work by Cuthbert et al on 
human samples who found periosteal samples to measure 860 µm [7]. Interestingly, 
there was little change in IM thickness from 3 weeks onwards, indicating that it has 
reached maximal thickness by this time point and can be considered a ‘mature’ 
tissue. This supports findings in rat femurs whereby, once fully formed, the IM’s size 
remained static for up to 6 weeks [21]. However, longer studies in rabbits observed 
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degradation in size from 8 – 16 weeks [6]. As was seen in lumen measurements, 
more samples from more time points, particularly at the extremities, are necessary 
to identify any reliable trend of changing IM thickness.  
3.4 Discussion: 
The aim of this chapter was to address the lack of human IM tissue characterisation 
in the literature and to better understand its key structural characteristics in order to 
design a novel biomimetic GBR device. Previous work on characterising the IM has 
used animal tissues and generally focused on identifying the cells and growth 
factors present rather than the microarchitecture of the tissue [22]. This study 
enhanced the clinical characterisation of the IM in the literature by investigating the 
structure, collagen distribution and organisation, elastin content, lumen diameter 
and tissue thickness.   
Analysis of the structure found that all the donor IMs were noticeably thicker and 
denser than periosteum confirming published research by Cuthbert et al and 
Pelissier et al on human [7] and animal studies [21] respectively that describe the 
IM as a reactive protective tissue [17]. Interestingly, although the presence of the 
IM’s bilayer (analogous to the periosteum’s fibrous and cambium layers) is 
described in the literature as putative [23], the samples stained for this chapter 
demonstrated varying degrees of distinction between the layers. Furthermore, the 
IM’s bilayer, when present, seems to possess a more gradual transition between 
the layers. The absence of an obvious cellular layer which is described in the 
literature [4, 7] could be caused by damage during tissue harvesting as is often 
seen in periosteum histology where the cambium layer is lost due to its attachment 
to the bone.  The IM’s innermost layer in-contact with the PMMA could be exposed 
to similar damage following dissection especially when considering that injuries in 
different anatomical locations may also result in IM biopsies that are more or less 
difficult to extract, resulting in varying degrees of cell layer preservation. This 
variation isn’t seen in animal IM studies whereby the whole IM capsule is extracted 
and dissection from the cement spacer can be carried out more carefully. This is a 
limitation of using human tissues that is difficult to overcome due to the need to 
preserve as much of the tissue for the patients treatment as possible. It is also of 
note that due to the precious nature of the tissue, the biopsies collected for 
histological analysis were small in size and often taken from the edges of the tissue 
that were surplus for the masquelet technique. Biopsies 1cm2 in size taken from the 
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edge of the tissue are useful for giving an insight into the tissue’s histoarchitecture 
but may not reflect the whole tissue.  
Analysis of the collagen structure identified the IM tissue supports previous 
literature on the IM possessing some similar characteristics to periosteum, such as 
the presence of a bilayer [24], as well highlights their differences, such as the IM 
being made up of dense organised collagen bundles than periosteum. Although 
both tissues are predominantly collagen-based, their organisation and composition 
distinguishes them as two distinct tissues demonstrating the importance of using a 
range of histological techniques. Periosteum was found to be composed of thin, 
loosely connected collagen fibres whilst the IM samples were composed of thicker 
fibres that are tightly connected. Despite being found in very similar anatomical 
locations it is clear from this stain that they’re biologically very different, suggestive 
of their different roles. Collagen’s relatively high tensile strength and inextensible 
properties [25] suggest that the IM is mechanically stronger than periosteum.  
With regards to elastin content of the tissue, as expected very little positive staining 
was observed across all samples indicating a general lack of elasticity in the tissue. 
The presence of elastin was appeared to be localised exclusively around large 
blood vessels, the only sample that lacked any elastin staining was donor 4, which 
had the shortest exposure to the PMMA. Elastin’s absence in this tissue supports 
findings in the literature that the IM tissues take at least 4 weeks to fully develop [4, 
20]. Despite the lack of positive staining from this data, it is still useful to inform the 
clinical understanding of the tissue. 
Analysis of the lumen diameter discovered a plateau in lumen diameter around 200 
– 250 µm by 8 weeks which opposes the reported decrease in vascularity described 
in animal studies after 1 month [4, 20, 21, 26, 27]. Although the results were not 
found to be significant, they suggest some disparity between human and animal 
tissues and highlights the need for additional characterisation of the former. Due to 
the nature of the masquelet surgery, most tissue harvesting is carried out between 
weeks 4 to 12; therefore it is rare to get samples outside or even at the extremities 
of this range which is likely to be the cause of the disparity between this study’s 
findings and previously published data. Aho et al who described the strongest trend 
of decreasing vascularity did so in human biopsies up to 22 months, a time point 
which is considerably anomalous to the ordinary treatment window and would be 
difficult to reproduce in future human studies [20].  
Analysis of the 7 IM samples’ thickness found them to measure 1942 ± 220 µm on 
average which supports previous work on human by Cuthbert et al who found total 
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median thickness of IM to measure 1422 μm and which were also distinctly thicker 
than periosteum samples [7]. Interestingly, there was little change in total IM 
thickness from 3 weeks onwards, indicating that it reaches maximal thickness by 
this time point  supporting findings whereby, once fully formed from 2 weeks, the 
IM’s size remained static for up to 6 weeks in rat models [21] and 8 weeks in rabbit 
models [4]. Longer studies in rabbits did eventually observe a reduction in size from 
8 – 16 weeks [6] but this could be due to the smaller size of the original defect 
(compared to human studies) and the basic anatomical and physiological 
differences between humans and rabbits.  
Whether or not the human IM’s structure changed over time was not clear based on 
the literature, and so, to create a biomimetic tissue based on the IM there was a 
demand for more certainty that the structural features observed in the histological 
‘snapshots’ were representative of the tissue. To address this, samples were often 
discussed in relation to their duration of exposure to PMMA or ‘age of IM’. However, 
often there were other significant variations between the samples other than ‘age of 
IM’, for example age of donor (24 to 61 years), anatomical location (femur, tibia and 
ulna) as well as the severity and size of defect. These factors undoubtedly 
influenced important features such as vascularisation since the vascularity and 
healing potential in a younger subject is presumed to be greater than that of an 
older subject. Further age- and site-controlled studies would increase the power of 
this data. The precious nature of the IM also limited the biopsy size available for 
analysis and was often harvested from the extremities of the defect which may not 
be representative of the whole tissue. To better understand the tissue as a whole, a 
much larger sample size would be necessary as well as multiple biopsies from the 
same tissue. Despite its limitations, the variability in this study reflects the clinical 
population and range of trauma patients with severe bone defects who would be the 
target population for this guided bone regeneration (GBR) device. 
As the aim of this work was to further characterise the structure of the human IM 
and use the findings to mimic its role in bone repair, how these factors will inform 
the manufacturing process need to be considered. Based on the literature, it is 
understood that the key functions behind the IM’s success as a GBR device is its 
ability to contain grafted material to the defect site and to provide GF to non-
autologous bone grafts [22]. Therefore when considering the biomimetic 
membrane’s size there may need to be compromise between thickness, 
mechanical strength and plasticity (with regards to it being capable of being molded 
into a desired form). A membrane that is too thick will act more like a sponge and 
be less moldable, whilst a membrane that is too thin won’t absorb as much BMA 
- 54 - 
 
and GF (discussed in chapter 5) and may not be mechanically strong enough for 
function. Our data and the literature also collectively point to the inclusion of regular 
pores around 200-250 μm to allow blood vessel ingrowth, nutrient transport and 
MSC infiltration. Furthermore the bilayer was not found to be so distinct in the 
samples assayed in this chapter and will not play an integral part in the design 
process, instead the membrane will be populated with autologous bone marrow 
aspirate and growth factors which will serve as an interim tissue.  
Overall these findings contribute towards a better understanding of the IM’s unique 
structure and properties to aid the design and manufacture of a biomimetic guided 
bone regeneration device in chapter 4.  
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4 Manufacture and process-structure relationships of the 
collagen-poly(ε-caprolactone) membrane  
 
4.1 Introduction: 
In the clinical setting, the gold-standard masquelet treatment for fracture non-union 
results in the formation of an induced membrane (IM) around the defect. This 
membrane-like tissue is believed to actively contribute towards guided bone 
regeneration through its protective role, preventing soft tissue ingrowth, and acting 
as an osteogenic niche. However, the current gold-standard clinical treatment for 
non-union requires two separate surgeries, whereby the formation of the IM is not 
always guaranteed. The debilitating pain associated with non-union, the extended 
recovery time for patients and the increasing medical and socioeconomic costs is 
making the development of a new membrane-based bone regeneration strategy a 
global priority. In order to address this, the design of multifunctional systems for 
orthopaedics and scalable manufacturing routes has received growing attention, 
whereby either synthetic or natural polymers have been employed [1] [2]. 
The membrane-forming multifunctional system should induce bone regeneration 
and accelerated healing in non-union fractures. As described by Giannoudis et al 
[3], the membrane building block must; 1) support osteogenic cell proliferation, 2) 
be compatible with growth factors and act as a vehicle for their localised delivery, 3) 
enable osteoconductivity, and 4) be mechanically stable to provide support and 
protect the defect site from soft-tissue ingrowth. Additionally, the specific design 
criteria for a successful cell-homing membrane architecture has been described by 
Matassi et al to include; 1) high porosity to provide space for cell adhesion and 
appropriate pore distribution to minimise diffusion constraints and facilitate 
homogenous tissue formation, 2) a controllable degradation profile, 3) cyto and 
immune compatibility of both the bulk material and its degradation by-products, and 
finally, 4) manufacturability and reproducibility at industrial scale [4]. 
 
 
- 57 - 
 
 
Figure 12: Schematic outlining the key characteristics and properties to aim for as 
part of the biomaterial design strategy. 
 
These 8 design criteria informed the choice of material and the methods used to 
make the biomimetic membrane. The most common synthetic materials used are 
polyesters such as polylactide (PLA), polyglycolide (PGA), copolymers of PLA and 
PGA (PLGA), and poly(ε-caprolactone) (PCL). For engineering bone specifically, 
PCL is the most common choice as not only has it been found to be biocompatible, 
biodegradable, and with enhanced mechanical properties such as high mechanical 
strength and low rigidity [1, 5]; but also because PCL degradation, whilst breaking 
down into ε-hydroxycaproic acid  [5], does not produce as much of an acidic local 
environment as PLA and PGA do [6, 7]. Furthermore, it is a comparatively low-cost 
material and can be processed easily using a wide range of industrial 
manufacturing methods. Despite its processability and appropriate mechanical 
properties, it is a highly hydrophobic material which limits its ability to absorb and 
deliver growth factors [1], it isn’t  known for its ability to induce osteogenesis and 
osteogenic cell proliferation and degrades very slowly (the absorption time of PCL 
in vivo can take up to 3 years [6, 1]).  
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In contrast, biological ‘natural’ polymers such as collagen, chitosan, hyaluronic acid, 
and silk fibres possess a range of versatile properties that also make them potential 
candidates for orthopaedic applications. In contrast to PCL, whilst the biological 
polymers listed possess biological cues to some extent that support osteogenic cell 
proliferation, collagen is the only extracellular matrix component involved during 
healing and the main building block of the IM, making it ideal to realise tissue-like 
biomimetic analogues. Alternatives to collagen became popular following concerns 
over immunogenicity and the potential risk of disease transmission depending on its 
source [8], however, since medical grade (atelo)collagen has recently become 
commercially available, its manufacturability at industrial scale is becoming realistic 
for orthopaedic applications [6]. Using a biopolymer such as collagen, which 
resided in the tissue prior to injury, has several relevant biofunctionalities in addition 
to being biomimetic; collagen possesses an innate ability to induce healing through 
initiation of the clotting cascade [9] as well as inducing localised chemotaxis. 
Collagen is the most biocompatible option and its ability to support cell survival and 
proliferation means it is already being used extensively in tissue culture. Compared 
to PCL, collagen is significantly more hydrophilic and allows increased oxygen and 
nutrient permeability [10]. Despite these advantages, its application is largely 
restricted due to its poor mechanical properties and proteolytic stability.   
A material system capable of integrating the functionalities of both PCL and 
collagen could be envisaged in the form of a mechanically-competent, cell-homing 
membrane. In this application, PCL could be used to provide mechanical stability to 
the membrane, whilst collagen will provide the resulting prototype with inherent 
biological cues to induce cell migration and proliferation. 
Various manufacturing methods are available to generate a membrane-like material 
including techniques such as electrospinning (ES), bioprinting, and decellurisation. 
Each technique has its advantages, but the ease of industry scale-up and the ability 
to produce a dense mesh of non-woven fibres in the nano- and micro-scale, with a 
high surface-to-volume ratio, makes ES a promising option aiming to realise 
multifunctional membrane prototypes with defined process-structure-function 
relationships [11].  
The basic principle behind ES involves charging a viscoelastic polymer solution 
through an electrically charged metal needle. The subsequently charged solution is 
attracted to and propelled towards an electrode charged collector plate. The 
electrical field between the needle and collector deforms the polymer solution into a 
jet, as it does so, the solvent evaporates and a matrix of solid fibres is deposited. 
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As described, this method traditionally uses needles to charge the solution and 
contain the solvent – the benefit of this being it prevents excess solvent 
evaporation.  
Although spinning of collagen only [12, 13, 14] leads to matrices with limited 
thickness and mechanical competence [12], the collagen nanofibres were found to 
support MSC viability and provide favourable growth conditions. Some attempts 
have been made to develop a stronger product by spinning collagen-PCL 
composites. These composites have been used in vascular grafts [15], showing 
collagen coated PCL was better than PCL fibres alone with regard to inducing cell 
viability and proliferation; as well as skin grafts [16] which also found enhanced cell 
proliferation in both collagen coated PCL scaffold. Interestingly, the latter study that 
developed PCL-collagen scaffolds for skin grafts also investigated the design of 
coaxial collagen-PCL matrices, where the PCL and collagen were spun together to 
create fibres with a PCL core and collagen shell, and found even greater cell 
proliferation and cell-scaffold interactions. These structure-function relationships 
were thought to be due to better replication of the ECM and the presence of more 
facets for cells to interact with and adhere to than the collagen coated PCL matrix 
[16]. As well as PCL, other researchers successfully electrospun a collagen and 
PLA scaffold demonstrating its use for sustained antibiotic release [17]. Despite their 
preliminary success, all these methods are restricted by their low-throughput (usually 
0.1–1 g/hr/needle[18, 19]) from progressing further towards clinical translation.  
One way to increase the output of electrospun fibres would be to use ‘needle-free’ 
or ‘free-surface’ ES, which until now has not been utilised for creating collagen-
based membranes for orthopaedic reconstruction. Free-surface ES is a technique 
that creates multiple jets from a liquid charged directly onto an electrode - usually a 
rotating wire electrode into a liquid-filled trench or a spike with a concave surface 
that is able to contain small volumes of solution. The increased number of jets, the 
larger volumes of solutions, and the use of a rolling-collector mechanism are 
extensions of traditional syringe-ES that drastically increase the potential output of 
this technique. However, due to the novelty of this method for the application of 
creating a biomaterial, the process parameters need optimising including; humidity, 
solution concentration, solution composition, distance between the electrode and 
the collector, electric potential, flow rate, molecular weight of the polymers and the 
wire spinning rate, among others. To limit the variables as much as possible a spike 
electrode was used in this research. 
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This chapter aims to optimise the free-surface ES method to manufacture a range 
of biomimetic PCL-collagen membranes for guided bone regeneration.  
4.2 Specific methods 
4.2.1 Isolation of type I collagen from rat tail tendons: 
Due to the expense of using commercially-available medical grade collagen, for 
initial prototyping, collagen was extracted in house from rat tail tendons via acid 
treatment [20]. First, frozen rat tails were thawed in 100% ethanol for 20 minutes, 
skinned and then individual tendons were removed from the tendon sheath. The 
tendons were then placed in 17.4 mM acetic acid solution (50mL/rat tail) and stirred 
for 48 hours at 4°C to extract the collagen. After extraction, the mixture was 
centrifuged at 10,000 xg for 40 minutes. The pellet was discarded, and the 
collagen-containing supernatant was neutralised with 0.1 M sodium hydroxide and 
stirred for 12 hours at 4°C, before being centrifuged at 10,000 xg for 45 minutes. 
The supernatant was then replaced with an equal volume of 17.4 M acetic acid to 
re-solubilise the pellet fraction. This solution was then freeze-dried for 48 hours and 
stored in air-tight 50mL falcon tubes at 4°C. 
 
Figure 13: Isolation of rat tail tendons: the skin of the rat tail is ripped off several 
times with a clamp to reveal the collagen-rich tendons (white filaments). 
Image sourced  from Nature Protocols [20] with permission from the Springer 
Nature and Copyright Clearance Centre. 
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4.2.2 Electrospinning solutions: 
To identify the optimal composition of collagen to PCL for manufacturing the GBR 
prototype, a series of solutions were made up. Using freeze-dried in-house 
synthesised collagen and PCL with an average molecular weight of 80 kDa, a 
series of solutions with ratios of 50:50, 60:40, 70:30 and 80:20 were made up in 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP). 20mL of each solution was made up to a 
final concentration of 6% (w/v) and stirred over-night at room temperature to ensure 
the solution was homogenous.   
 
4.2.3 Free-surface electrospinning: 
Using a needle-less electrospinning set-up (Nanospider, figure 14 A) with a spike 
electrode (figure 14 B), single drops of 200 μL of solution were charged with 
increasing voltage up to 60 kV until the drop had been used up  (< 1 minute). The 
spike electrode was cleaned between drops to prevent residue build up. To give the 
solvent enough time to evaporate before reaching the grounded electrode, the 
distance between the electrode and the collector was set to the maximum height of 
19.5 cm. The temperature of the ES environment was 19 ± 5°C and the air humidity 
45 ±  5%. 
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Figure 14: Nanospider needlefree ES apparatus (A) and its accompanying spike 
electrode (B). 
 
4.2.4 Gas liquid displacement porometry using the Porolux: 
To measure the material’s inherent pore size distribution, the Porolux liquid 
displacement porometer was used. The equipment works by expelling the wetting 
fluid from the saturated scaffold by increasing the gas pressure, whereby pores with 
decreased diameter require increased gas pressure to expel the fluid. First 
scaffolds were cut to size to fit the 25mm diameter sample holder before being 
saturated in perfluoroether which acted as the wetting fluid. Perfluoroether is an 
inert liquid with a low surface tension (15.6 mN/m ) and a contact angle of zero.  
The hydrated scaffolds were placed in the sample holder and the chamber was 
sealed before air was introduced into the chamber at increasing pressure until all 
the liquid was expelled. This initial run is referred to as the ‘wet-run’ and is followed 
by a subsequent ‘dry-run’ which is carried out once all the wetting fluid has been 
removed. The flow rates are then compared to measure the first bubble point 
(maximum pore size), mean flow pore size, minimum pore size and average pore 
size distribution. 
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Figure 15: The Porolux 100 device (A) used for porometry analysis of scaffolds, an 
example of the data collected from the device is also shown (B) where the 
scaffold’s smallest, mean, and largest pore can be easily identified from the 
wet curve (blue). 
 
 
4.2.5 Post-manufacture processing (folding and laser cutting): 
10 mL of spinning solutions were electrospun onto the collection fabric and folded 
to the desired thickness (0.5 mm and 1 mm) by briefly warming on a hot-plate set to 
40°C and applying even pressure to bond the layers. Using ApS-Ethos control 
software, three scaffolds with distinct microarchitectures were designed: (1) no 
laser cut pores, (2) pore diameter of 200 μm and distance between pores of 4 mm 
(open area space of 0.01 cm/cm2), and (3) pore diameter of 200 μm and distance 
between pores of 2mm (open area space of 0.04 cm/cm2). The pores were cut into 
the folded scaffolds using a commercial 100-watt CO2 air-cooled laser cutter. Full 
cut-through of the pores was achieved using a single pass at 10% power and a 
velocity of 600mm/s. 
(B) (A) 
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Figure 16: Demonstrates the laser cutter device in operation perforating pores into 
a scaffold which is held in place with weights. 
 
 
Figure 17: The three stages of post-manufacture processing: (A) the initial 
electrospun fibre mesh (white material) directly onto the collector fabric (blue 
material), (B) the elecrospun material after folding and heat-setting on a hot 
plate to bond the layers, (C) the material after laser cutting (this example 
shows 200 μm pores spaced 4 mm apart) 
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𝐼𝑛ℎ𝑒𝑟𝑒𝑛𝑡 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (%) = 1 − (
𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
) × 100 
𝐴𝑝𝑝𝑎𝑟𝑒𝑛𝑡 𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑔. 𝑐𝑚ିଷ) =
𝑚𝑎𝑠𝑠 (𝑔)
(𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (𝑐𝑚) × 𝑎𝑟𝑒𝑎 (𝑚ଶ))
 
Bulk density values for PCL: 1.14, 0.68 for rat tail collagen and 0.82 for 70:30 
collagen:PCL. 
𝑂𝑝𝑒𝑛 𝑎𝑟𝑒𝑎/𝑐𝑚ଶ =  1 − ((𝑎𝑟𝑒𝑎 𝑜𝑓 𝑠𝑖𝑛𝑔𝑙𝑒 𝑝𝑜𝑟𝑒) × 𝑛𝑜. 𝑜𝑓 𝑝𝑜𝑟𝑒𝑠/𝑐𝑚ଶ ) 
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑎 𝑝𝑜𝑟𝑒 = 2𝜋𝑟ℎ + 2𝜋𝑟ଶ 
Equation 2: Formulas used to calculate the inherent porosity of the scaffolds and 
the open areas produced by laser cutting per scaffold. Inherent porosity used 
published bulk density values; 1.14 for PCL [21], 0.68 for rat tail collagen [22], 
and 0.82 for 70:30 collagen:PCL 
 
4.2.6 Scanning electron microscopy (SEM): 
To capture the microarchitecture of the commercial and manufactured scaffolds, 
cell-free dry samples were imaged via SEM. Specimens were individually mounted 
onto sample stubs using adhesive mounting tabs and, to improve image resolution, 
sputter coated with gold using an automatic sputter coater under argon atmosphere 
with a vacuum set to 3x10-2 mbar. Brightness and focus were adjusted, and images 
were captured at a voltage of 20 kV, over 80 seconds, at a pixel rate of 2560 x 1920 
using Hitachi S-3400N image processing software. 
 
4.2.7 SEM microarchitecture analysis: 
To quantify the scaffold’s microarchitecture characteristics such as pore size and 
fibre diameter, SEM analysis was used. For measuring fibre diameter, samples 
were imaged at 10,000 x magnification and the diameter of a minimum of 20 fibres 
were randomly selected and measured. The diameter of the laser cut pores was 
measured at four points across the cross-section of the pore using SEM images of 
a minimum of three pores per sample. 
 
4.2.8 Energy-dispersive X-ray spectroscopy (EDS): 
The EDS function of the SEM was used for surface elemental analysis to identify 
the presence of collagen in the scaffolds by mapping the location of nitrogen and 
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carbon elements. The microscope operated under the following conditions: voltage 
20 kV, current 10 nA, beam diameter 6 µm, and a vacuum pressure of 100 Pa. 
 
4.2.9 Thickness measurement: 
Scaffolds thickness measurements were carried out using a thickness tester with a 
nonwoven pressure foot. With the sample placed on the bottom anvil platform, the 
foot applies 0.5kPa of pressure to each sample and the thickness is measured 
through a digital gauge. Three samples were measured from each group and 
reported as mean ± standard deviation. 
 
Figure 18: The ProGage thickness gauge used to measure the thickness of the 
samples. 
 
4.2.10 Tensile testing:  
The tensile modulus and tensile strength samples were measured using a Titan 5 
Universal strength tester with a 100 N load cell at a rate of 20.00 mm/min. The 
testing was carried out in a controlled environment with a room temperature of 18°C 
and relative humidity of 38% on samples measuring 30 x 20 mm. Samples were 
tested dry and hydrated in PBS which involved saturating the samples in 10 mL of 
PBS for 5 mins before testing. T27 clamp was used as the jaw with a gauge length 
of 20 mm. A minimum of four individual samples were tested from each group and 
measurements were reported as mean ± standard deviation. Tensile strength, 
- 67 - 
 
strain at break and Young's modulus were calculated using the linear, plastic and 
failure regions of the stress-strain curves. 
 
 
 
Figure 19: The Titan 5 Universal strength tester with a 100 N load cell used to 
measure the tensile propertise of the scaffolds. Also shown are the examples 
of the single sheets of scaffolds (not folded), (A) intact with no laser cut pores, 
(B) 200 μm cut pores spaced 4 mm apart, and (C) 200 μm cut pores spaced 2 
mm apart. 
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𝑆𝑡𝑟𝑒𝑠𝑠(𝑀𝑃𝑎) =  ቆ
𝑓𝑜𝑟𝑐𝑒 (𝑁)
𝑎𝑟𝑒𝑎 (𝑚ଶ ቇ
 
 
𝑆𝑡𝑟𝑎𝑖𝑛 (%) =  
𝑙𝑒𝑛𝑔𝑡ℎ (𝑚𝑚)௡௘௪ − 𝑙𝑒𝑛𝑔𝑡ℎ (𝑚𝑚)௢௥௜௚௜௡௔௟
𝑙𝑒𝑛𝑔𝑡ℎ (𝑚𝑚)௢௥௜௚௜௡௔௟
 
Equation 3: Formulas used to calculate the tensile mechanical properties of 
scaffolds. The formulas used to calculate force (N), stress (MPa), and strain 
(%). 
 
 
4.2.11 Scaffold degradation assay:  
1cm2 samples of scaffolds were placed in 5ml PBS with 1% Penicillin/Streptomycin 
in 6 well plates at 37°C for one month and imaged via SEM on day 0 and day 28 to 
compare any changes in their microarchitecture. 
 
4.2.12 Statistics 
Using GraphPad Prism software, statistical analyses were carried out on datasets 
that consisted of at least three independent experiments using a ANOVA with 
multiple comparisons to detect significant differences between the scaffold’s tensile 
properties. All data are expressed as mean ± standard deviation. *P<0.05, 
**P<0.01, ***P<0.001, and ****P<0.0001 defined statistical significance. 
4.3 Results: 
For the creation of an orthopaedic collagen-based membrane prototype, it is 
essential to control the micro- and macroscopic physical morphology to enable 
optimal physiological functioning. This chapter used free surface ES to manufacture 
membranes from a range of PCL and collagen compositions and spinning 
parameters to achieve reliable process-structure relationships. The scaffolds were 
then analysed based on their fibre size (section 4.3.1-4.3.2), pore size (section 
4.3.3) and tensile properties (4.3.4). Ensuring the membranes were biocompatible 
and not cytotoxic was investigated as well as its ability to MSC support proliferation. 
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4.3.1 Optimising electrospinning parameters: 
To achieve the desired mechanical stability, fibre diameter and porosity as well as 
uniform and bead-free fibres, optimization of ES parameters such as electrode-to-
collector distance and applied voltage was done whilst other ES variables such as 
concentration and temperature were set at constant values in all the experimental 
runs. Figure 20 demonstrates the scaffolds produced from 6% PCL at two different 
electrode-to-collector distances (120 and 155 mm) and five different applied 
voltages (20-60 kV). At the lower distance of 120 mm, whilst the lower applied 
voltages were able to produce a matrix on the collector; significant solvent damage 
was also seen at all voltages. The damage can be referred to as solvent ‘spitting’ 
and is caused by not enough time for the solvent to evaporate before reaching the 
collector, it was found to be more prevalent at higher voltages. To conserve 
material, higher voltages past 40 kV were not tested at 120 mm. To reduce the 
effect of solvent spitting, the electrode-to-collector distance was increased to the 
maximum setting of 155 mm. Optimal scaffold production was found at 155 mm and 
40 kV, below this voltage, very little scaffold was produced and at higher voltages 
(50-60 kV) solvent spitting increased. SEM analysis of samples produced at 40 kV 
and 60 kV (both at 155 mm) also demonstrate the effect of solvent spitting. It is 
clear that solvent spitting damages the fibre structure and scaffold as a whole and 
so should be minimised to produce a high-quality biomaterial.  
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Figure 20: Membrane formation via free-surface ES 6% PCL with an electrode-to-
collector distance of either 155 or 120 mm and varied voltage. At 120 mm, 
voltages 20-30 kV, significant spitting was seen, circled in red in column A .At 
155 mm 40-50kV increased fibre deposition and minimal spitting was 
observed (column B). SEM images of membranes electrospun at 155 mm of 
electrode-to-collector distance and both 40 kV and 60 kV were also captured 
to demonstrate the effect of solvent spitting. 
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4.3.2 Optimising spinning blended collagen and PCL solutions 
The spinning parameters were then further optimised using an equal blend of 
collagen and PCL (50:50). It was clear that at all the voltages tested, this solution 
spun more consistently and with fewer defects (spitting and beading) than the pure 
PCL despite the solution concentration being 6% (w/v) for both. This hinted at a 
decreased solution viscosity in the case of the 50:50 collagen:PCL solution 
compared  to the PCL solution control at the same concentration, likely related to 
the hydrogen bonding interactions between PCL’s repeating units and collagen’s 
amino groups. Considering the increased spinnability of the PCL-collagen mixture, 
it was decided that this blend would be spun at 6% (w/v) concentration, whilst pure 
PCL solutions would be spun at reduced polymer concentration, i.e. 3% (w/v), 
aiming to achieve PCL control fibres with comparable homogeneity and fibre 
diameter. The optimised spinning parameters were kept consistent at a voltage of 
40 kV and a spinning distance of 155 mm. 
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Figure 21: Membrane formation via free-surface ES 6% Collagen:PCL (50:50) with 
an electrode-to-collector distance of 155 mm and a range of applied voltages 
(30-60 kV). Column A shows the macroscopic view of the scaffolds spun at 
each voltage, whilst column B shows the microscopic image collected from 
SEM analysis. The average fibre diameter is also shown (C) with error bars 
indicating technical variation between replicates. 
 
 
 
 
- 73 - 
 
Figure 22: Membrane formation via free-surface ES of 6% Collagen:PCL at various 
compositions (50:50-80:20) with an electrode-to-collector distance of 155 mm 
and an applied voltages of 40 kV. Column A shows the macroscopic view of 
the scaffolds spun at each voltage, whilst column B shows the microscopic 
image collected from SEM analysis. Red circles indicate regions of beading. 
The average fibre diameter is also shown (C) with error bars indicating 
technical variation between replicates. 
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Once the spinning parameters were optimised for both the control PCL scaffold and 
the collagen:PCL blended scaffolds, different compositions were spun with the aim 
of ES collagen:PCL mixtures with increased collagen content whilst ensuring the 
formation of membranes with increased mechanical integrity. A range of 
membranes with increasing concentrations of collagen (50-80% w/v) were 
generated (figure 22). Interestingly, SEM analysis of the 50:50 scaffold revealed the 
presence of beads on some of the fibres, possibly due to unequal mixing of the 
solution. Despite distinct differences in the solution’s composition, no clear trend of 
fibre diameter was observed (figure 22 C). Whilst the 80:20 solution was able to 
successfully spin, resulting membrane was brittle and too delicate to handle. 
Therefore, the membrane made with 70:30 collagen:PCL was selected for further 
analysis, alongside the electrospun PCL control. 
 
4.3.3 Pore size analysis: 
Using porometry, the pore size distribution for membranes made of both the PCL 
and 70:30 collagen:PCL was determined (figure 23, A and B respectively) and 
revealed that over 80% of the pores were smaller than 4 μm. The maximum pore 
size of membranes of either PCL or 70:30 collagen:PCL was 36 µm and 44 µm 
respectively, although these larger pores were rare occurrences in the latter case. 
Knowing that cells need a pore size of at least 8 µm to be able to migrate through 
[23] suggests that these scaffolds will likely act as a barrier to cell infiltration, 
angiogenesis, and possibly even nutrient transport.  
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Figure 23: Pore size distribution from the porometry analysis, the top panel shows 
the relative frequency of pores in 6% 70:30 (A), the bottom panel shows the 
relative frequency of pores in 3% PCL (B).  
 
To overcome the inherently-small pore size measured in the electrospun 
membranes, a laser cutter was used to create larger pores. Pores with a diameter 
of 200 µm was chosen as this was found previously to be the average lumen 
diameter of the IM, as well as being linked to osteogenesis in the literature [24], and 
it is the smallest pore the laser cutter can create. Because the pores were too large 
to be measured using the porometer, SEM images were used instead for pore 
diameter analysis (figure 24). Despite using the lowest power settings of the laser 
cutter, the three PCL membranes displayed larger pores (around 500 µm in 
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diameter) compared to the expected value (~200 µm), likely due to the laser-
induced melting of the PCL phase. The presence of collagen in the 70:30 
collagen:PCL membrane resulted in the formation of smaller pores (~280 µm) 
following laser cutting, likely due to the decreased content of the thermoplastic 
polymer in corresponding fibres, ultimately resulting in reduced fibre melting during 
laser cutting. Despite both membranes displayed larger than expected pores, 
insignificant differences in pore size were measured across membrane batches 
(figure 24). 
Figure 24: Results from the SEM analysis of laser cut pores in the 3% PCL scaffold 
(A) and 6% 70:30 scaffold (B). Each bar represents an individual sheet tested 
with a minimum of 4 pores tested from each sheet, error bars show replicate 
variation between pores. 
 
 
4.3.4 Mechanical properties of the laser cut scaffolds 
To investigate the effect of laser cutting on scaffold mechanical properties, tensile 
tests were carried out on membranes prepared with either reduced or increased 
pore frequency and compared against the pristine electrospun control with no laser 
cut pores. Details of the different scaffolds that underwent tensile testing are 
outlined in table 9. As described in equation 2 (section 4.2.5), the open area was 
calculated from the area and number of pores, whilst total porosity was calculated 
as a percentage of the apparent density of the scaffold and bulk density of the 
components. It is of note that even the intact scaffolds are still >90% porous due to 
the electrospun morphology of the scaffolds and high surface area. 
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Table 9: Outline of the open area (area of laser cut pores) and the total porosity 
(inherent porosity plus laser cut pores) for each scaffold type. Three variations 
of each material (PCL and 70:30) were included; intact control (no laser cut 
pores), sparse pores and dense pores. 
  Open area (cm2) Total porosity – (%) 
PC
L 
Intact scaffold 0 94 
Sparse pores 0.1 96 
Dense pores 0.4 97 
70
:3
0 
Intact scaffold 0 93 
Sparse pores 0.1 95 
Dense pores 0.4 96 
 
Representative stress-strain curves of the intact scaffolds are shown in figure 25A 
demonstrating how the data was plotted to extract maximum stress at break 
(ultimate strength), strain at break and the elastic modulus. Both scaffold types 
show similar ultimate strengths of 1.1 ± 0.2 and 1.0 ± 0.2 MPa  for 70:30 and PCL 
respectively (figure 25B). Interestingly, PCL shows a significantly higher strain at 
break point of 0.54 ± 0.05 mm/mm compared to the decreased values measured on 
70:30   scaffolds (strain at break: 0.37 ± 0.07 mm/mm) indicative of brittle properties 
(figure 25C). This finding is confirmed by the decreased elastic modulus measured 
on 70:30 scaffolds in comparison to electrospun PCL controls (figure 25D). 
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Figure 25: Representative stress-strain curves for intact 3% PCL and 6% 70:30 
scaffolds (no laser cut pores) (A), from these curves the breaking stress 
(ultimate strength) (B), breaking strain (C) and the elastic modulus (D) can be 
extracted. The error bars represent the standard errors of the technical 
replicates (n=6), whilst an unpaired t-test was used to measure significance; 
**P < 0.01. 
 
 
 
A) 
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4.3.5 Comparing the properties of 70:30 scaffolds with different 
laser cut pore densities  
Comparison of the different laser cut pore densities and their effect on the 
mechanical properties of the 70:30 scaffolds are shown in figure 26. Interestingly, 
the most unexpected result introducing sparse pores into the membrane was had 
on the maximum break point (figure 26A), whereby a significant increase was 
observed in the ultimate strength of the scaffold compared to the ultimate strength 
of the intact control. Furthermore, the introduction of more pores (dense  pore 
scaffold) resulted in a significant reduction in ultimate strength. Analysis of the 
strain at break (figure 26B) demonstrated how the introduction of both sparse and 
dense pores resulted in a significant reduction in strain at break from the intact 
control. This reduction in strain at break is indicative of an increased brittleness of 
the scaffolds. This is mirrored by the elastic modulus (figure 26C) being significantly 
increased following the introduction of sparse pores compared to the intact control. 
Although not significant, the elastic modulus also appeared higher in the dense 
pore scaffold compared to the intact control. 
 
Figure 26: Results show the maximum breaking stress (ultimate strength) (A), 
breaking strain (B), and the elastic modulus (C) of 6% 70:30 scaffolds. The 
error bars represent the standard errors of the technical replicates (n=6), 
whilst ANOVA was used to measure significance; **P < 0.01, ***P < 0.001. 
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4.3.6 Comparing the properties of PCL scaffolds with different 
laser cut pore densities  
Comparison of the different laser cut pore densities and their effect on the 
mechanical properties of the PCL scaffolds are shown in figure 27. Interestingly, the 
same unexpected increase in maximum break point that was observed following the 
introduction of sparse pores in the 70:30 scaffold was also observed in the PCL 
scaffold (figure 27 A). As well, the introduction of more pores in the dense pore PCL 
scaffold resulted in a significant decrease in maximum break point. Analysis of the 
PCL scaffold’s strain at break (figure 27 B) demonstrated how the introduction of 
dense pores resulted in a reduction in maximum strain at break, indicative of 
increased brittleness, whilst the introduction of sparse pores had no effect. The 
elastic modulus results (figure 27 C) again showed how PCL with sparse pores 
performed similarly to the intact PCL control, but the introduction of dense pores 
unexpectedly showed a significant reduction in elastic modulus indicative of 
reduced stiffness. Overall, whilst some reduction in strain at break and elastic 
modulus, was observed following the introduction of pores, the PCL scaffolds 
appear less brittle and stiff than the 70:30 scaffolds and appear to have a lower 
ultimate strength. 
 
 
Figure 27: Results show the maximum breaking stress (ultimate strength) (A), 
breaking strain (B), and the elastic modulus (C) of 3% PCL scaffolds. The 
error bars represent the standard errors of the technical replicates (n=6), 
whilst ANOVA was used to measure significance; * P < 0.05, **P < 0.01, ***P 
< 0.001.  
 
(A) (B) (C) 
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Once the PCL-Collagen solutions have been spun, it was investigated whether or 
not they could be further tailored by folding and heat treating to increase their final 
thickness. Figure 28 demonstrates how both PCL and 70:30 membranes thickness 
can be increased by 4-fold after folding in half twice . Spinning 20 mL of solution 
resulted in a scaffold thickness of  90±4 µm for 70:30 , which increased to 408±43 
µm after folding; PCL scaffold controls displayed a similar thickness of either 
97±13µm (in the electrospun format) or 408±43µm (after folding and thermal 
bonding). Increasing the number of folds will result in a thicker tissue and this 
demonstrates how post-manufacture scaffold processing can be conveniently 
employed to achieve macroscopic scaffold customisation.   
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Figure 28 scaffold thickness for 70:30 scaffolds (A) and PCL scaffolds (B) in their 
unfolded ‘spun’ form and folded form. The blue lines indicate the average 
original thickness of spun scaffolds and the black lines indicate the average 
thickness of the folded scaffolds. N=3 for 70:30 and n=5 for PCL. 
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The intact folded 70:30 scaffolds were also tested after being hydrated in PBS and 
compared to the dry 70:30 control scaffolds (figure 29). It was shown that hydrating 
the scaffold decreased its ultimate strength, although this trend was mostly found to 
be insignificant (figure 29A). The only significant difference between the dry and 
hydrated samples was seen in the strain at break (figure 29B) whereby the 
hydrated scaffold was found to have a higher breaking strain indicative of a less 
brittle structure compared to the dry scaffold. This finding is further reinforced by the 
lower elastic modulus of the hydrated sample, whilst not a significant difference, is 
also indicative of a less stiff structure.  
 
Figure 29: Results show the maximum breaking stress (ultimate strength) (A), 
breaking strain (B), and the elastic modulus (C) of 6% 70:30 folded scaffolds 
both dry and hydrated with PBS. The error bars represent the standard errors 
of the technical replicates (n=3), whilst an unpaired t-test was used to 
measure significance; * P < 0.05.  
 
4.4 Discussion 
To address the need for a guided bone regeneration device in long bone fracture, a 
novel collagen-PCL prototype scaffold was manufactured, and its microstructure 
and mechanical properties were characterised.  
In the field of tissue engineering, whilst a wide range of manufacturing techniques 
exist, ES is a favoured option due to its ability to produce scaffolds with consistent 
nanofibers, interconnected pores as well as considerable surface to volume ratio. 
However, the ES manufacturing yield is typically restricted by the syringe volume 
with a maximum output of up to 1 g/h of fibre per syringe. These low yields make 
commercialisation and industrial scale up of electrospun scaffold challenging to 
realise. Free surface ES or ‘needle-free’ ES has therefore sparked interest by 
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increasing the yield output and production speed by using baths rather than 
syringes. A bath setup has a much higher volume capacity, and, when a roller 
electrode is used, results in multiple jets along its length which further increase the 
rate of fibre formation. Although synthetic polymers are usually the material of 
choice (such as PCL or PLGA) for ES due to their low cost and structural stability, 
they lack the biological cues necessary for stem cell migration, attachment and 
proliferation. Therefore, when synthetic polymers are used, their surface is often 
conjugated with collagen or other natural polymers [26]. One of the most advanced 
applications of this method has been demonstrated by Ramakrishna et al, who 
used coaxial spinning to create fibres with a PCL core coated in a collagen ‘shell’. 
Although this method proved to be successful for improving cell migration into the 
scaffold, this coating technique comes with the risk of rapid leeching and 
degradation due to the superficial presence of collagen [16][25, 26]. 
Whilst pure collagen scaffolds exist in dentistry, their role is to act as sponges for 
plugging defects. This makes their required structural properties very different to 
what is needed for orthopaedic translation. For guided bone regeneration, the 
scaffold needs structural integrity as a membrane to wrap around the fracture, 
contain the grafted material whilst still be permeable to cell migration and nutrient 
transport. Pure collagen scaffolds for dentistry are often manufactured from 
decellularised porcine and equine tissues (such as Mucograft), which are 
associated with high manufacturing costs, risk of disease transmission, and 
challenging industrially scale up. Access to novel needle-free ES technology and 
using the extraction method for affordable and stable collagen from rat tails resulted 
in a unique opportunity to address the limitations of previous techniques and 
materials. Clinical grade collagen reduces the risk of xenogenic contamination, 
whilst the structural design is tailored with specific functionality in mind, and the 
equipment and materials were chosen based on ease of industrial scale-up. 
Due to the novelty of this approach there was little published research on needle-
free ES collagen scaffolds therefore, one of the aims of this work was to optimise 
the protocol for generating scaffolds from collagen containing solutions. HFIP was 
the solvent chosen due to its sufficient volatility (boiling point of 61°C) to maintain a 
consistent solution concentration in the open bath setup, as well as its ability to 
dissolve both collagen and PCL into a homogenous solution [27]. In the literature, 
the normal working concentrations for solutions is between 2-10% and initial trial 
and error (data not shown) brought the starting polymer solution concentration for 
this work to 6%. Ideally more extensive factorial design of the spinning parameters 
would have been part of the research but were limited due to time constraints. 
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For 6% PCL a spinning distance of 155 mm and a voltage of 40 kv were found to be 
the best spinning parameters both macroscopically and microscopically however 
spinning of 6% 50:50 collagen:PCL appeared to improve the consistency and fibre 
quality at all spinning voltages. It was observed that the 6% 50:50 solution was less 
viscous than the 6% PCL solution likely caused by the difference in the intrinsic 
viscosity of collagen and PCL as well as the different molecular interactions present 
[28]. Collagen’s triple helix molecules are more sensitive to the HFIP solvent which 
results in denaturation of their conformation as well as lower viscosity [29]. Although 
other solvents such as acetic acid and ethanol may better preserve collagen’s triple 
helical structure, they are too volatile for needle-free ES leading to the formation of 
highly variable material. The open bath arrangement of needle-free ES limits the 
number of solvents that can be used; however this has recently been addressed in 
the development of a continuous feed which coats the electrode with spinning 
solution instead of coating by directly rolling in a bath. Considering scaffold 
production was improved following the reduction in solution viscosity, collagen and 
PCL blends were spun at 6% whilst pure PCL blends were spun at 3%. 
After spinning different blends of collagen and PCL, 70:30 was found to have the 
highest collagen content whilst still being structurally sound and easy to handle. 
Above this concentration, the scaffolds were too brittle and fragile and so weren’t 
taken forward for further characterisation. Porometric analysis of the 70:30 and PCL 
scaffolds revealed that the majority of pores in both are smaller than 8 μm and are 
therefore likely to act as a barrier to cell migration and nutrient transport. To 
preserve the structural integrity of the scaffold, whilst improving its ability to allow 
nutrient and cell transport, pores were incorporated using a laser cutter [30]. The 
distribution of 200 μm pores, with either 2 or 4 mm gaps, was chosen as this design 
was simple to control and replicate. Smaller gaps of 1 mm between pores were also 
briefly tested and excluded because of their fragility when handling. Whilst laser 
cutting pores into scaffolds has been successfully used in the development of 
corneal scaffolds, to regulate their strength and transparency [30], its incorporation 
into the post-manufacture processing of an orthopaedic membrane remains novel. 
Before pores were introduced, both the intact 70:30 and PCL scaffolds possess 
similar tensile properties with regards to their breaking points and elastic modulus, 
the only significant difference found was between the two material’s strain at break 
which was lower in the 70:30 blend. Due to the novelty of this device, there is no 
consensus in the literature regarding tensile requirements; therefore, the tensile 
properties of comparable devices and tissues were used instead to inform scaffold 
design. As the device is not envisaged to be weight-bearing or undergo much 
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manipulation once sutured in place, tensile properties were investigated at the 
breaking point. Analysis of 120 rat IM samples by Gaio et al. found their ultimate 
stress ranged from 0.1-0.4 MPa depending on the surface of the cement spacer 
used to induce their formation [31]. Other ES collagen-containing scaffolds, for 
example PLGA-collagen blend using needle-based ES, found their scaffolds to 
have breaking points of 1.1 MPa dry and 0.6 MPa hydrated [32] whilst pure PCL 
scaffolds were found to be stronger at 2 MPa (hydrated) [33]. This was supported 
by other research which found PCL to have a tensile strength of 2 MPa which 
decreased when blended with gelatine to 0.4 MPa [34]. 
Ideally, analysis of human IM sample’s tensile properties would be carried out for 
comparison and would be one of the priorities of future work in this area. Despite 
the lack of specific guidelines, both scaffolds were found to be comparable to other 
scaffolds currently being developed and even exceed the properties of rat IM 10 
fold. Furthermore, handling of the scaffolds for this research found them to be 
resilient and easy to manipulate, meeting the initial qualitative criteria for basic 
handling necessary during surgery. 
The influence of pores and their spacing on tensile strength was clearly 
demonstrated during this research, interestingly, it was seen that the introduction of 
sparse pores increased the ultimate strength of the scaffold compared to the intact 
versions. This finding contradicts work by Li-Ping Lee et al [35] who describe how 
increasing the open area of the structure (either by increasing pore size or number) 
reduces the amount of connective material that supports the scaffold, resulting in 
decreased tensile strength. This negative correlation of decreasing tensile strength 
with increasing pore number was also described by Kong et al who conclude that 
decreasing the number of fibres per unit area that contribute to the force of the 
membrane would in-turn decrease the ultimate strength of the scaffold [23]. The 
discrepancy between the findings in this work and the previously published data is 
likely due to the incorporation of PCL whereby the heat of the laser cutter melted 
the layers of fibre around the pores creating regular anchor points which resulted in 
an overall increase in tensile strength. This interaction is easily offset by the 
presence of too many pores as demonstrated by the tensile strength of the 
scaffolds with dense pores, whereby the open area was too great to be supported 
by the remaining connective material resulting in an overall weaker scaffold. 
As well as laser cutting pores, heating and folding the scaffolds was another 
method used to demonstrate the range of post-manufacture processing techniques 
that can be utilised to tailor the scaffold for specific applications. The aim of this 
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work is to mimic the functionality of the IM and so the scaffold will require thickness 
to enable PRP absorption and mechanical stability (properties which will be tested 
in chapter 6). As expected, both PCL and 70:30 proved to be highly malleable by 
demonstrating how the initial spun scaffolds thickness can be easily increased. 
As these scaffolds are envisaged to be soaked in bone marrow aspirate or PRP, it 
was important to collect pilot data on the scaffolds hydrated state. It was clear that 
the hydrated scaffold appeared weaker than the dry scaffold but no significant 
difference was observed. The only significant difference hydrating the scaffolds 
made was increasing their strain at break. It is also of note that both the folded dry 
and hydrated scaffolds had higher tensile strength following folding and laser 
cutting than the single sheets (4 MPa compared to 1 MPa). This promising finding 
demonstrates how the scaffold’s properties can be tailored depending on the 
specific orthopaedic requirement. 
As well as optimising the collagen and PCL ratios and spinning voltage and 
distance, future work would also involve factorial design of all parameters [36] such 
as concentration, humidity, temperature and viscosity etc. to fully optimise the 
process as is the industry standard [37].  
Next research steps will focus on the material’s ability to absorb and release 
proteins as well as support cell viability and proliferation. 
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5 Biological products  
5.1 Introduction: 
Fracture non-union persists as a prevalent complication, with the incidence in long 
bones reported to range between 5-10% [1, 2]. Its etiopathogenesis remains 
multifactorial with a recent review identifying over 20 factors to be implicated in this 
process [3]. To address impaired fracture healing, Giannoudis PV et al. proposed 
the diamond conceptual framework for bone repair highlighting that, for a 
successful healing response both mechanical stability and biological factors must 
be present [4]. For biological stimulation, while autologous bone graft remains the 
gold standard, recently, other forms have gained popularity including bone marrow 
aspirates (BMA) and/or growth factors [5, 6]. Since their introduction to the clinical 
setting, bone morphogenetic proteins (BMPs) have been extensively used for the 
treatment of non-union fractures [7]. There are numerous publications reporting on 
the clinical results of BMP-2 and BMP-7 [8-10].  However, since the withdrawal of 
BMP-7 from the market and the license limitation of BMP-2 to be used for the 
management of open tibial fractures, other inductive molecules gained popularity 
such as demineralised bone matrix (DBM)[11], teriparatide [12] and platelet rich 
plasma (PRP) [13, 14].  
PRP is a highly enriched source of autologous growth factors and cytokines that 
acts as a biological stimulant [15] and is applied either with the cells intact, or more 
recently, as platelet lysate (PL) where only the growth-factor containing plasma is 
used [16]. Both forms have been found to be highly effective in the treatment of 
orthopaedic trauma [17] and several studies into PRP loaded membranes are 
already proving to be successful at promoting regeneration via the delivery of 
growth factors in cartilage and bone repair [18, 19].When using PRP loaded 
membranes for guided bone regeneration, maximising BM-MSC proliferation and 
migration is key. By ensuring these functions are enhanced, more viable cells are 
available to differentiate, as well as inducing more resident BM-MSC homing to the 
site of injury. Whilst some studies found that the presence of leukocytes in PRP is 
advantageous due to their antimicrobial properties [20] as well as their high 
concentration of cytokines that are involved in bone repair such as VEGF [21, 22], 
there are also concerns related to leukocytes’ role of inducing excessive 
inflammatory and necrotic pathways from the surrounding tissue – providing a 
strong case for their depletion [23, 24]. Therefore it was hypothesised that 
producing PRP using a two-step centrifugation method that could be tailored for 
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theatre application, will be purer in platelets than a clinical standard PRP made 
using a commercial device and will therefore stimulate more BM-MSC proliferation 
and migration.  
This chapter investigates the in vitro effect of platelets and leukocytes on the 
proliferation and migration of BM-MSCs from BMA by studying a range of PRP 
compositions including a clinical-standard PRP. A laboratory-standard PRP made 
using a two-spin centrifugation protocol to enrich platelets but deplete leukocytes 
was also used as control [17, 25]. To investigate the specific importance of 
leukocytes, PRP was processed further by syringe-filtration to remove leukocytes 
and produce a pure filtered PRP (fPRP). These products were then lysed to ensure 
product consistency over the course of in vitro assays; thereafter referred to as 
clinical-standard platelet lysate (C-PL), platelet lysate (PL) and filtered PL (fPL).  
These PLs were then evaluated in vitro utilising primary BM-MSCs, including 
autologous BM-MSC-PL combinations. The aim was to assess if high numbers of 
leukocytes would impede BM-MSC proliferation and migration and whether their 
depletion from clinical PRPs would be desirable for bone regenerative approaches. 
The results will ensure the manufactured collagen-membrane is loaded with 
optimum PRP to stimulate bone repair by maximising autologous BM-MSCs 
migration to the fracture site as well as facilitate BM-MSC proliferation. 
 
5.2 Specific methods: 
5.2.1 Blood collection and generation of PRP: 
Under the regulation of the Leeds East Research Ethics Committee, as outlined in 
section 2.1, healthy donors (n=12, 4 females and 8 males, age range 22-44yrs, 
median =30) were invited to donate 20ml of blood in dipotassium 
ethylenediaminetetraacetic acid (EDTA) and acid-citrate-dextrose (ACD) vacuette 
tubes. These anticoagulants were chosen because of their already widespread use 
in clinics and surgery as well as their existing use in generating C-PRP [26, 27]. 
Prior to processing, each donor’s pooled blood was incubated at RT for 1 hr to 
achieve a clear separation between the layers.  
The blood was centrifuged at 400 xg for 10 minutes at RT (figure 30 B) and then the 
platelet-containing supernatant was collected and further centrifuged at 2700 xg for 
10 minutes (figure 30 C). The pellet was finally resuspended in 1/5 of the 
supernatant (considered the PPP fraction) to produce PRP (figure 30 D). Analysis 
of the sample was carried out using the Hematology-Analyzer as described in 
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section 5.2.5. The time between blood collection and processing was approximately 
2 hours. 
 
Figure 30: Making PRP uses a donor’s blood (A), which is centrifuged into two 
distinct layers (B). The supernatant is collected (C) and centrifuged again at a 
higher speed. The final pellet is resuspended in 1/5th of the supernatant to 
make PRP (D). 
 
5.2.2 Generating commercial PRP (C-PRP): 
Patients undergoing elective orthopaedic surgery with no underlying disease (n=8, 
2 females and 6 males, age range= 22-34yrs, median= 28yrs) had 60ml of their 
blood collected in a syringe containing 6mL ACD-A to get a final concentration of 
10% ACD-A. The blood underwent a 15 minute spin step in a Biomet Biologics 
centrifuge (figure 31 A) to separate the C-PRP from the PPP and red blood cells the 
BioCUE™ Platelet Concentration System (figure 31 B). A 1mL sample of the C-
PRP was collected from each donor in EDTA vacuettes, as well as 1mL of the 
donor-matched whole blood, for analysis using the Hematology-Analyzer (section 
5.2.5).  Three patients also donated 20mL of whole blood for the production of PRP 
as outlined in section 5.2.1 to enable donor matched comparisons between the two 
platelet products.  
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Figure 31: C-PRP was made using an in-theatre centrifuge (A) and the BioCUE™ 
Platelet Concentration System (B) to concentrate the platelets. 
 
5.2.3 Generating filtered PRP (fPRP): 
To remove all leukocytes from PRP (described in section 5.2.1) and generate fPRP, 
samples were filtered using a white blood cell syringe filter. Between 2-5 ml of 
sample in a syringe is allowed to pass through the filter via gravity allowing the 
entrapment of leukocytes whilst the filtered PRP is collected below the syringe 
barrel for further processing. 100 µL of filtered samples were analysed using the 
haematology analyser as described in section 5.2.5. 
 
5.2.4 Leukocyte and platelet stability assay: 
PRP products from three healthy donors were prepared according to section 5.2.1 
in both EDTA and sodium citrate vacuette tubes. Once made, the PRP products 
were incubated at 37°C in sealed falcon tubes for 14 days whilst 100μL aliquots 
were collected on days 1, 4, 7 and 14 for analysis using the haematology analyser. 
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5.2.5 Analysing blood and PRP samples: 
To quantify cell populations in PRP, fPRP and C-PRP 100µL of each sample was 
analysed using the haematology analyser. White blood cells (WBC), red blood cells 
(RBC), platelets (PLT) and leukocyte percentages of lymphocytes (LYM), basophils 
and eosinophils (MXD), and neutrophils (NEUT) were quantified in each sample 
based on each cell type’s electrical impedance. 100μL of donor-matched whole 
blood was also analysed and its cell counts were used as the baseline to calculate 
fold enrichment or depletion in each of the platelet products. 
 
5.2.6 Generating PL and C-PL and fPL: 
To generate the lysed products for in vitro assays, PRP, fPRP and C-PRP were 
processed through three freeze-thaw cycles which involved freezing at -80°C for at 
least one hour followed by defrosting at 37°C for 10 mins [28]. Lysis of the products 
changed their nomenclature from PRP, fPRP and C-PRP, to platelet lysate (PL), 
filtered platelet lysate (fPL) and clinical platelet lysate (PL). The products were then 
centrifuged at 2700 xg to separate the supernatant from intact cells and debris in 
the pellet. The supernatants were then stored at -80°C in aliquots of 1mL to be 
used in BM-MSC proliferation and migration assays (sections 5.2.7 and 5.2.8). 
 
5.2.7 BM-MSC XTT Proliferation assay: 
In order to ensure the optimal platelet product is loaded onto the membrane, the 
efficacy of different products (PL, C-PL and fPL) for supporting BM-MSC 
proliferation was first tested using the in vitro XTT assay. Cultured BM-MSCs up to 
passage four were seeded at a density of 500 cells/well in Stem Macs media in a 
96-well plate and incubated. After 24 hours the wells were rinsed with PBS and 
replaced with 200μL of treatment media. The treatment medias were made up 
using a base media of DMEM, 1% Penicillin/Streptomycin and 2 I.U/mL heparin (to 
prevent clotting of the sample) supplemented with either 10% FCS (positive 
control), 10% mesencult serum (positive control), 5% or 10% platelet product (test 
media), or 10% DMSO (negative control). Cells were cultured in supplemented 
media for five days with a half media change on day three before finally staining 
with XTT reagent according to section 2.9. 
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5.2.8 Migration assays:  
As well as proliferation, the optimum PL product loaded onto the membrane must 
also effectively induce BM-MSC migration. The chemotaxis transwell assay was 
used to test the efficacy of PL, C-PL and fPL’s ability to induce BM-MSC migration. 
First, cultured cells up to passage four were serum-starved for 12 hours before the 
assay. Serum starving involved washing the attached cells in PBS, replacing the 
media with DMEM only (no FCS), and incubating overnight. Following overnight 
serum starving, the cells were trypsinised off the flasks as described in section 2.7 
and suspended in DMEM containing 1% FCS (as opposed to 10% used for 
standard cell culture). The cells were centrifuged at 500 xg for 5 mins before being 
resuspended in DMEM.  
 
Figure 32: BM-MSCs were harvested and seeded into the transwell insert before 
allowing to settle at ambient temperature for 15 mins. Once cells settled, the 
chemoattractant was added to the bottom reservoir chamberand the plate 
placed inside the Incucyte device for imaging. Images adapted from the 
Incucyte chemotaxis cell migration quick guide [29]. 
 
In a 96 transwell plate, 600 cells in 60 µL DMEM media were seeded per well in 
triplicate on the top transwells as illustrated in figure 32. In the bottom wells, 200 µL 
of supplemented media was pipetted including: 10% FCS in DMEM (positive 
control), DMEM with no FCS (negative control) and 10% PL in DMEM (test). All 
medias contained 1% Penicillin/Streptomycin and 2 I.U/mL heparin. The plates 
were incubated for 15 mins to reduce condensation and were then moved into the 
IncuCyte for imaging. Migration was analysed using phase-contrast imaging of the 
bottom of the transwell as cells migrate along the chemotactic gradient. The 
transwell pores measure 8 μm in diameter to allow single cells to move across but 
ensure the concentration gradient is maintained. The bottom of the wells were 
imaged every 30 mins and a mask was generated for each BM-MSC donor to 
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improve accuracy of the cell counting.  The mask was made using up to six 
representative images of the wells on which the processing definition was created – 
this specified the growth threshold, minimum and maximum cell size, as well as the 
minimum and maximum eccentricity of each cell (how defined the cell needs to be 
to be recognised). Figure 33 demonstrates an example mask. 
 
Figure 33: Example of the mask used to quantify cells, cells on top of the well are 
orange, on the bottom of the well are red whilst a black arrow points to an 
uncounted cell in grey. 
 
5.2.9 Statistics 
Statistical analyses were carried out on datasets that consisted of at least three 
independent experiments using a paired student’s t test when comparing two 
groups from the same donor and an unpaired student’s t test when donors weren’t 
matched. One-way ANOVA with Tukey’s multiple comparison test was used when 
comparing more than two groups or two-way ANOVA with Tukey’s multiple 
comparison test for nonparametric results with GraphPad Prism software. All data 
are expressed as mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001, and 
****P<0.0001 defined statistical significance. 
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5.3 Results: 
To test the hypothesis that leukocytes in PRP have a negative effect on BM-MSC 
proliferation and migration, the cellular composition of the PRP were analysed 
(section 5.31) and their platelet and leukocyte stability were assessed (5.32). A 
proliferation experiment was optimised using an XTT assay (5.33) and the platelet 
product’s proliferative capacities were tested (5.34). The IncuCyte migration assay 
was optimised (5.35), and the platelet products migratory capacities were tested 
(5.36). To test the second hypothesis that PRP prepared in-house will induce more 
proliferation and migration than PRP made using a commercial device (C-PRP), the 
differences in cell composition were analysed (5.37), and their effects on 
proliferation (5.38) and migration (5.39) were studied.  
5.3.1 Cellular composition of PRP and fPRP:  
Before the two platelet products (PRP and fPRP) could be tested, they were first 
characterised to ensure that filtration of the leukocytes from fPRP was successful. 
PRP (made in-house) and fPRP (made in-house and syringe filtered) were 
analysed using a haematology analyser (figure 34). Fold change of cells from whole 
blood was calculated as: 
(𝑓𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑎𝑙𝑢𝑒)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
 
For cell types that were completely depleted to zero, the fold change could not be 
defined and so the symbol # was used in place of a value. 
- 98 - 
 
 
Figure 34: Comparing the changing cellular compositions from whole blood to PRP 
and fPRP (n=3) using a haematology analyser. Platelets, red blood cells, 
leukocytes, lymphocytes, basophils and eosinophils and neutrophils were 
counted and their fold changes from whole blood to PRP included. The 
numbers above each product indicate the fold change from whole blood to C-
PRP/PRP, positive values indicate an average fold increase whilst a negative 
value indicates an average fold decrease, # indicates a complete reduction of 
cells to 0. Occasionally fewer than 3 data points are shown due to overlapping 
values forcing some data points to superimpose. 
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It was shown in figure 34 that filtering removes very few platelets causing PRP and 
fPRP to have similar platelet counts: 9.9 ± 3.7 x 103 /µL in PRP and 9.1 ± 4.8 x 103 
/µL in fPRP. Looking at other cell types; red blood cells, lymphocytes, basophils, 
eosinophils and neutrophils, both PRP and fPRP were found to be completely 
depleted of them all. A paired t-test comparing all cell types in PRP and fPRP only 
found a significant difference in their number of leukocytes. PRP was found to 
reduce leukocytes by 1.3 fold from whole blood, leaving an average of 4.8 ± 1.0 x 
103 /µL leukocytes whereas filtration depleted all contaminating leukocytes in fPRP. 
It can be concluded from this data then that the two products are the same except 
for their leukocyte numbers (most likely to be monocytes which the haematology 
analyser cannot quantify). 
 
5.3.2 PRP stability: 
To ensure the PRP products used remained consistent over the course of the 
assays, the stability of key cell populations (leukocytes and platelets) were 
analysed using the haematology analyser. Three PRP preparations made in EDTA 
and sodium citrate were kept at 37°C and tested on days 1, 4, 7 and 14 after 
preparation (figure 35). These anticoagulants were used as lab alternatives to the 
ACD anticoagulant used in theatre to prepare C-PRP. 
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Figure 35: Comparison of the stability of platelets and leukocytes in PRP prepared 
in EDTA and sodium citrate over 14 days.  
 
Although PRP made in sodium citrate resulted in lower platelet counts possibly due 
to their aggregation, compared to PRP made in EDTA, both anticoagulants showed 
a similar trend for platelet preservation. Initially, it appears that platelet numbers 
increase between days one to four but this is likely due to the breaking up of the cell 
aggregates, then, after day four, platelet numbers begin to steadily decrease as 
they become necrotic and lyse. A similar pattern is seen for leukocytes preserved in 
EDTA and sodium citrate although they appear to lyse faster than platelets, with a 
huge loss of intact cells by day seven. By day 14 almost all of the platelets and 
leukocytes in both anticoagulants have lysed.  It is also noteworthy how much more 
varied the initial leukocyte numbers in the sodium citrate samples are compared to 
the EDTA samples, indicative of the impact anticoagulants have on the processing 
of PRP. Overall, this data demonstrates how drastically cell numbers can vary even 
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in the first seven days, supporting previous findings in the literature that they their 
composition changes even after 24 hours at room temperature [30, 31]. Therefore, 
all proliferation and migration assays will use the lysed form of PRP, platelet lysate 
(PL), to ensure consistency of product. 
 
5.3.3 Optimising XTT proliferation assay: 
To optimise the XTT assay, 10% and 5% solutions of different control supplements 
were tested on cultured BM-MSCs for four days to decide the optimal concentration 
to dose the basal media DMEM with. FCS and Mesencult serum were chosen as 
positive controls and DMSO was chosen as the negative control whilst three 
individual BM-MSC cultures were used up to passage four at a seeding density of 
500 cells/well in a 96 well plate. Across all three cultures, it was seen that there was 
a clear distinction between both positive and negative controls at both 
concentrations and the seeding density met the acceptance criteria as the mean 
OD450 of the positive control was greater than 0.2 so no further optimisation was 
necessary. As expected, there was also a clear trend of 10% FCS and 10% 
Mesencult serum inducing more proliferation than their 5% counterparts. As well, it 
was seen that 10% DMSO killed more cells than 5% and so was a more reliable 
negative control. These results support findings in the literature that 10% is 
generally considered the optimum dose [32-34]. 10% will therefore be used as the 
concentration in all media for these assays. 
- 102 - 
 
 
Figure 36: Comparing BM-MSC proliferation after exposure to 10% and 5% doses 
of control supplements; FCS, Mesencult and DMSO on cultured BM-MSCs 
(n=3) whilst standard error bars indicate variance between technical replicates 
in the XTT assay. 
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To assess BM-MSC culture variation, the controls were further tested on five BM-
MSC cultures and it was seen that both FCS and Mesencult consistently induced 
proliferation (figure 37). As all the cultures demonstrated a similar response to the 
supplements, their results were combined as an average and a one way ANOVA 
test with multiple comparisons found that FCS and Mesencult both induced 
significantly more proliferation than the negative control DMSO (P<0.001) 
supporting their use as appropriate controls for this experiment. Due to the similarity 
in response of the BM-MSCs to FCS and Mesencult serum, only FCS was carried 
forward as the positive control. 10% DMSO was also found to be a very reliable 
negative control and so was unnecessary to repeat in future experiments. 
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Figure 37:Testing 10% FCS, 10% Mesencult serum and 10% DMSO as potential 
positive and negative control supplements for doping basal media (BM-MSC 
n=5, *** indicate significance P < 0.001).Error bars for the individual donors 
indicates technical variation between replicates whilst error bars for the 
average graph indicates variation between culture averages. 
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Based on the findings in figure 35, that leukocytes in PRP aren’t stable at 37°C past 
24 hours days, PL will be used instead of PRP for proliferation and migration 
assays. To investigate whether BM-MSCs responded in the same way to PL as to 
PRP was necessary to ensure that the potency of the platelet’s and leukocyte’s 
releasate wasn’t diminished in the freeze-thawing process. To carry out this 
experiment, the PRP from one donor was split into two; one half kept as PRP whilst 
the other half was prepared as PL by freeze-thawing to extract the platelet 
releasate-containing supernatant. Both these products were then tested on three 
BM-MSC cultures (figure 38). This experiment found no significant difference 
between the proliferative response of BM-MSC cultures to PL and PRP. This finding 
further supports the use of PL in place of PRP for these assays. The lack of 
significant difference between both platelet products and FCS in figure 38 is also 
noteworthy, as, despite a slight trend of lower proliferative capacity in the PL 
supplemented media, both PL and PRP are able to support as much BM-MSC 
proliferation as FCS. As all three BM-MSC cultures showed the same response to 
PL and PRP, the results for the three cultures were normalised to FCS and collated 
to allow for statistical analysis which found no significant difference between FCS, 
PL or PRP using an unpaired t-test (figure 38, bottom right).  
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Figure 38: Comparing the proliferative capacity of PL and PRP preparation A on 
individual cultured BM-MSCs and their normalised average (n=3). Error bars 
for culture 1-3 indicate technical variation between replicates whilst error bars 
for the average (bottom right) indicates variation between culture averages 
normalised to FCS. 
 
This effect was further tested on two more platelet preparations (preparation B and 
C) whereby each tested on three BM-MSC cultures as shown in figure 39. Looking 
first at platelet preparation B, despite a slight trend of more proliferation in PRP than 
FCS and PL the differences weren’t found to be significant. Similar results were 
observed in platelet preparation C where, despite BM-MSC culture one showing 
slightly more proliferation when dosed with PRP over PL and FCS, no significant 
difference was found between the supplements. Overall, although there appeared 
to be a minor trend of more proliferation when BM-MSCs were cultured in PRP 
instead of PL, the trend was not found to be significant which validates the use of 
PL as a representative surrogate of PRP. 
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Figure 39: Comparing the proliferative capacity of PL and PRP preparation B and C 
on individual cultured BM-MSCs and their normalised average (n=3). Error 
bars for culture 1-3 indicate technical variation between replicates whilst error 
bars for the average (bottom right) indicates variation between culture 
averages normalised to FCS. 
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Through these optimisation studies, it can be concluded that 10% FCS and DMSO 
are appropriate control supplements for the XTT assay, and that PL can be used as 
a representative surrogate for PRP. As well, these findings indicate that PRP and 
PL are equal to FCS in supporting BM-MSC proliferation. 
 
5.3.4 Comparing PL’s vs fPL’s ability to induce BM-MSC 
proliferation:  
To investigate the effect of leukocytes in PL on BM-MSC proliferation, three BM-
MSC cultures were treated with 10% PL, 10% fPL and 10% PPP (platelet poor 
plasma). To clarify, 10% PL is PRP generated in-house that contained 4. 5 ± 1 x 
103/µL leukocytes and was lysed, 10% fPL is 10% PL that has been filtered to 
remove all leukocytes (whilst maintaining the same platelet number), and 10% PPP 
is the plasma-only by-product which contains no cellular content and is therefore 
used as a negative control for these experiments. Since PPP is simply plasma 
containing proteins and growth factors [35] (including those involved in supporting 
BM-MSC proliferation), the PL products can be considered PPP with added growth 
factors that are released from the lysis of platelets and leukocytes. These three 
products were each generated from two PRP donors (PRP preparations D and E). 
Due to the importance of ensuring that fPRP had no contaminating leukocytes but 
had similar platelet numbers to PRP, as well as ensuring the PPP contained neither 
cell type, their platelet and leukocyte counts were analysed (figure 40) before lysing 
into their PL counterparts. As expected, filtration resulted in only a minor loss of 
platelets from PRP to fPRP, whereas leukocytes are completely depleted in both 
preparations. PPP was also found to contain neither platelets nor leukocytes.  
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Figure 40: Counted using the haematology analyser, individual platelet (PLT) and 
leukocyte (LEUK) counts for PRP preparation D and E were plotted as well as 
their corresponding PPP cell numbers. 
 
The results in figure 40 supports the use of these products in the proliferation assay 
to investigate the effect of leukocytes on BM-MSC proliferation (figure 41). Contrary 
to our initial hypothesis, across three cultures, both PL preparations induced a 
similar proliferation response from the BM-MSCs and in most cases induced equal 
to or greater proliferation than FCS. As expected 10% PPP appeared to induce only 
half the amount of proliferation than its platelet- and leukocyte-containing 
counterparts. This suggests the platelet content plays an important role in 
supporting proliferation that is absent in plasma alone. The consistency in response 
across all cultures meant that the results could be collated and normalised to 10% 
FCS to allow for statistical analysis. A two-way ANOVA analysis of the results found 
that in both PL preparations, PL and fPL were found to induce statistically the same 
level of BM-MSC proliferation. Furthermore, both preparations induce the same 
amount of proliferation as the positive control 10% FCS and, in the case of fPL prep 
E, significantly more proliferation than FCS. These findings suggest that leukocytes 
don’t have a significant negative impact on BM-MSC proliferation and, 
unexpectedly, appear to have a positive role in supporting proliferation. It was also 
demonstrated that whilst PPP was able to induce some proliferation, the presence 
of growth factors from the platelets and leukocytes in PL and fPL significantly 
increased their ability to support proliferation. This supports the hypothesis that the 
cellular contents of platelets and leukocytes play a key role in BM-MSC 
proliferation. 
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Figure 41: Comparing the proliferative capacity of PL, fPL and PPP from two PL 
preparations (D and E) on individual cultured BM-MSCs and their normalised 
average (n=3). Error bars for cultures 7,6 & 3 indicate technical variation 
between replicates whilst error bars for the average (bottom row) indicates 
variation between culture averages normalised to FCS. * P < 0.05, **P < 0.01, 
***P < 0.001. 
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5.3.5 Developing a migration assay towards PL supplemented 
media using the IncuCyte device: 
To investigate BM-MSC migration a few techniques are available, however these 
often require either manipulation of the cells (fluorescent tagging for the 
Ouchterlony-type assay) or an in vivo model (Boyden chamber assay), or they 
cannot precisely differentiate migration from proliferation (scratch wound assay). 
Transwell migration assays are considered an in vitro solution to the Boyden 
chamber and involve cells migrating along a chemotactic gradient toward the 
stimulant of interest through a porous transwell where they can be counted. Despite 
their efficacy, transwell assays are limited by the lack of live cell imaging [36, 37] 
and their short duration (usually 4 hours) [38]. A recent advancement of the 
transwell assay incorporates time-lapse phase contrast imaging of the transwell 
throughout the assay and a processing software to quantify cells. The 8μm 
diameter of the transwell pores ensures only actively migrating cells are quantified 
as well as maintaining a stable chemotactic gradient for 48 hours [39]. This method 
is also thought to be more accurate as regular imaging of individual wells 
throughout the experiment reduces the risk of technical error. For these reasons the 
Incucyte was chosen as the assay to quantify BM-MSC migration towards different 
PL preparations, specifically investigating the effect leukocytes play on BM-MSC 
migration.  
Measuring PL’s impact on BM-MSCs using the Incucyte is a novel technique that 
has not yet been published in the literature, and so required thorough optimisation 
including; overnight cell starving, cell seeding density, dose of media supplement 
and assay duration. Overnight cell starving is necessary in some migration assays 
to increase the cellular response and reduce the effect any residual serum from the 
growth media may have. Optimisation of seeding density was needed to ensure 
there are as many cells as possible available to migrate but not so many that they 
prevent the software from accurately identifying individual cells. The dose of PL 
needed optimising to maximise migration as well as ensure high quality images 
were captured as there was a risk that the density of the solution would 
compromise image quality at higher concentrations. And finally, whilst the Incucyte 
transwells are able to maintain a stable gradient for 48 hours (however due to 
limited access, assays were conducted up to 36 hours) the assay duration still 
needed optimising to ensure BM-MSCs would stay viable and migrate in that time. 
For these experiments, PL was again used as a surrogate for PRP not only due to 
platelet and leukocyte instability, but also to improve imaging of the transwells as it 
was found that the presence of intact cells in PRP prevented clear image capture of 
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the cells. In these experiments, as outlined in methods section 5.2.8, cells were 
seeded on top of the transwell in serum-free media and allowed to migrate towards 
a serum- or PL-supplemented media in the bottom chamber for up to 36 hours. 
Over the course of the experiment, a camera captured multiple phase-contrast 
images of the top and bottom of the transwell and a ‘mask’ is created that quantifies 
the BM-MSCs as they migrate along the chemotactic gradient. The main data 
output from this assay is the total area of the bottom of the transwell that is covered 
by BM-MSCs (object area µm2/well).  
Initially, to optimise seeding density and the effect of overnight starving; starved and 
unstarved BM-MSCs from three cultures were seeded at densities of 250, 500 and 
1000 cells/well in triplicate in a 96 well with 10% FCS (positive control) and 0.5% 
FCS (negative control) supplemented media in the bottom wells.  
As shown in figure 42, row A, 1000 cells/well was too confluent for making an 
accurate mask to quantify cell migration so were excluded from the analysis. 
Analysis of the controls first shows that, at both 250 and 500 cells/well seeding 
densities, starved and unstarved, 10% FCS induced an increase in the object area 
of the bottom of the well (indicative of migration) more than 0.5% FCS which 
produced a minimal migratory response. The clear distinction in response to the 
positive and negative controls supports their suitability for these migration 
experiments. Furthermore, whilst the top panel in column B shows that unstarved 
cells seeded at 250 cells/well and 500 cells/well exhibit the same total migration, a 
more distinct difference was seen in the starved cells (bottom panel, column B). 
More of the starved cells migrated, they did so at a faster rate towards 10% FCS, 
and as expected, more migration was induced from 500 cells/well than from 250 
cells/well. In the top panel of column C, whilst starving the cells made no obvious 
difference to the rate or amount of migration at 250 cells/well, starving 500 cells/well 
(bottom panel, column C) increased the rate and total amount of migration. Based 
on these findings, starved cells, seeded at 500 cells/well were chosen for future 
experiments alongside 10% and 0.5% FCS as the positive and negative controls.  
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Figure 42: Example of seeded wells at 1000, 500 and 250 cells/well in the top panel 
A. Results from the IncuCyte migration assay comparing unstarved seeding 
densities (top of column B) and starved seeding densities (bottom of column 
B) as well as the effect of starving cells overnight at 250 cells/well (top of 
column C) and 500 cells/well (bottom of column C).  
 
Following optimisation of the seeding density, the concentration of PL then had to 
be optimised to maximise migration and ensure image clarity. 20%,10% and 5% PL 
concentration in base media was tested on three BM-MSC cultures (figure 43). 
Data for 20% PL was excluded as the high concentration of lysate made the media 
too cloudy for accurate image capture and analysis. Across all three cultures it was 
shown that, up to 12 hours the both 10% and 5% PL induce a similar response from 
the cells as 10% FCS. However, after 12 hours, both PL concentrations appear to 
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induce more migration than 10% FCS. As well, 10% PL appeared to induce the 
most total migration in all three cultures and, in two of the three cultures, 10% PL 
also had the steepest curve indicative of a faster migratory response. It is also 
noteworthy to mention that, although 10% FCS does not appear to induce any more 
migration than the 0.5% FCS in figure 43, a closer look at the data in figure 43 
demonstrates how its migratory effect is made negligible in comparison to the 
substantial response both 10% and 5% PL bring about. 
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Figure 43: Compares the effect of 10% PL and 5% PL on cultured BM-MSCs (n=3) 
using the IncuCyte migration assay.  
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To enable statistical analysis of the supplement’s effects on BM-MSC migration, 
three time-points were chosen; 12, 24 and 36 hours and the results of which are 
shown in figure 44. Occasionally statistics comparing 0.5% FCS to the other 
conditions could not be carried out because the mean migration for 0.5% FCS was 
not greater than zero. It was observed that after just 12 hours, in all three cultures, 
10% PL had already induced significantly more migration than 10% and 0.5% FCS. 
As well, in two of the three cultures, 10% PL induced significantly more migration 
than 5% PL. At 24 hours the same trend continued with 10% PL still inducing 
significantly more migration than 5% PL as well as 10% and 0.5% FCS in all three 
cultures. Although cells weren’t as responsive to 5% PL as they were to 10% PL, 
5% PL was still found to induce significantly more migration than the positive FCS 
control. At 36 hours, BM-MSCs were found migrating towards 0.5% FCS in two of 
the three cultures which could be indicative of the assay reaching its limit of 
accuracy. Despite this, 10% PL was still found to induce significantly more 
migration than both 5% PL and 10% FCS, with 5% PL again inducing more 
migration than either of the FCS controls. Overall, 10% PL was found to 
consistently induce the most migration across all three time points and all three BM-
MSC cultures, and that, despite being the positive control, 10% FCS was 
consistently outperformed by both PL concentrations demonstrating PL’s strong 
chemotactic properties. 
To optimise this experiment, it would have been preferential to test PL from more 
than one donors but due to the precious nature of the samples, the limited volume 
harvested and the clarity of the results, only one donor was tested. This assay also 
demonstrated culture variability as BM-MSC culture 4 appeared much more 
migratory than the other cultures. These cells might possess an inherently more 
migratory phenotype which could include; higher expression of the GTPases Rac 
and Cdc42 which control actin assembly and cell protrusions such as pseudopodia 
and enable motility, possessing more GF receptors on their membranes such as 
CXCR4 which binds SDF-1 and FGFR which binds FGF [40]which makes them 
more responsive to the growth factors in the media, or they could have weaker cell-
cell adhesions which could also contribute to faster migration [41, 42]. This 
demonstrates how varied the BM-MSCs responses can be to the same PL 
preparation and indicates that BM-MSC variability is almost as significant as PL 
variability. In highly migratory cells it appears that the addition of PL, whilst it still 
has a positive effect the strength of the effect is not as significant as seen in less 
migratory cells. 
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Figure 44: Migration towards 10% PL, 5% PL using the IncuCyte assay which 
measures total cell area on the underside of the well against time at time-
points: 12. 24 and 36 hours. One PL prep was used (n=1) on cultured BM-
MSCs (n=3). The error bars represent the standard errors of the technical 
replicates, * P < 0.05, **P < 0.01, ***P < 0.001. 
 
In regards to time-points, figure 44 shows how, across the three BM-MSC cultures, 
cells steadily migrate towards the chemoattractant up to 36 hours and that 12, 24 
and 36 hour time-points are appropriate to demonstrate the overall migration 
patterns.  
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Figure 45: BM-MSC (n=3) migration towards 10% PL at the three time points; 12, 
24 and 36 hours to demonstrate steady migration over the course of the 
assay. The error bars represent the standard errors of the technical replicates, 
* P < 0.05, **P < 0.01 ***P < 0.001, ****P < 0.0001. 
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From this data it can be concluded that 10% PL will be used alongside 10% FCS 
and 0.5% FCS in future experiments on 500 starved cells/well, over the course of a 
36 hour-long assay. 
 
5.3.6 Comparing PL’s and fPL’s ability to induce migration in BM-
MSCs: 
Once the Incucyte migration assay was optimised, the effect of leukocytes on BM-
MSC migration was tested using three PL preparations (preparation D, F and G) 
that were generated from three female donors aged between 24-34 years. Each PL 
preparation was divided into two and one half was kept as PL whilst the other half 
was filtered to remove all leukocytes to produce fPL. Both PL and fPL preparations 
were tested on BM-MSC cultures from three healthy donors. Figure 46 shows the 
individual migratory responses of three BM-MSC cultures as well as their averaged 
trend of migration towards the different PL preparations.  Looking at PL preparation 
D (left hand column, figure 46), except for BM-MSC donor 6, there appeared to be 
little difference between either 10% PL, 10% fPL or 10% FCS. Removal of 
leukocytes from PL preparation D was not found to have a consistently positive 
effect. PL preparation F (middle column, figure 46) showed that the complete 
removal of leukocytes did appear to reduce BM-MSC’s migratory response in all 
three BM-MSC cultures. Finally, with regards to PL preparation G (right column, 
figure 46) both PL and fPL induced similar migratory responses from BM-MSCs 
except for culture 9 which showed a trend of increased migration towards the 
leukocyte-and platelet-containing PL over fPL. Overall, looking at the average 
response of the three BM-MSC cultures to the individual PL preparations (bottom 
row, figure 46) it can be seen that both 10% PL and fPL are consistently as good 
as, if not better than, 10% FCS at inducing BM-MSC migration, consistent with the 
optimisation data shown in figure 45. 
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Figure 46: A representative real-time trace of total cell area on the underside of the 
well against time comparing 10% PL with 10% fPL’s ability to induce migration 
using the IncuCyte migration assay using PL preparations (D,F and G, n=3) 
cultured BM-MSCs. Error bars indicate the variation between BM-MSC 
cultures for each PL preparation.  
 
To better compare the different platelet preparations, three time-points at 12, 24 
and 36 hours were chosen for statistical analysis of each PL preparation’s average 
(BM-MSC n=3) as shown in figure 47.  It was seen that, after 12 hours, despite a 
trend of PL and fPL inducing more migration than FCS, the difference was only 
found to be significant in PL preparation F between 10% PL and 10% FCS. Again at 
24 hours, despite a trend of PL and fPL inducing more migration than 10% FCS in 
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all three cultures only in PL preparation F were PL and fPL found to be significant. 
The trend continued up to 36 hours with no significant difference found in PL 
preparations D and G, but in PL preparation F both PL and fPL were found to 
significantly outperform 10% FCS. Towards the end of the assay cells were also 
found to start migrating towards 0.5% FCS in PL preparations D and F. The 
combined results from figure 46 and 47 indicate that removal of leukocytes does not 
significantly improve migration and indeed their presence, in the case of PL 
preparation F, may even be beneficial. 
 
 
 
Figure 47: Migration towards10% PL, 10% fPL, 10% FCs and 0.5% FCS using the IncuCyte assay 
which measures total cell area on the underside of the well against time at time-points: 12. 24 
and 36 hours. PL preparations D,F and G were used (n=3) on cultured BM-MSCs (n=3). The 
error bars represent the standard errors of the technical replicates, * P < 0.05, **P < 0.01, ***P 
< 0.001. 
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To explain the variability between BM-MSC cultures, the total cell seeding density 
at time point zero was checked to ensure equal cell loading (figure 48). Cell seeding 
densities between cultures were found to be consistent therefore ruling out unequal 
seeding as a potential explanation for the difference in migratory response. Despite 
what appears to be a strong chemotactic gradient for some BM-MSC cultures was 
found to have much lower migratory effect on others, demonstrating the impact BM-
MSC variability has on the success of PL to induce migration. Due to the distinct 
difference between BM-MSC culture’s total migration, the y-axis for object area 
(µm2/well) can be considered a representative unit and was not normalised 
between cultures.  
 
Because the units for this assay are only representative, it is difficult to compare 
different BM-MSC cultures and PL preparations, however, looking at all three PL 
preparations averages, PL preparation F appears to induce the most consistent 
migratory response from cells. Looking at the preparation’s cell numbers (table 10) 
might explain the differences observed. PL preparation D had the biggest difference 
in platelet numbers between PL and fPL (100x103/μL fewer platelets in fPL) as well 
as 3x103/μL fewer leukocytes, and whilst PL appeared to induce more migration 
than fPL, the trend wasn’t found to be significant. Both the PL and fPL products of 
preparation F were found to have the most platelets and least leukocytes of the 
three preparations and the dramatic difference between PL and fPL is considered to 
be due to the loss of either 50x103/μL platelets or 2.3x103/μL leukocytes from PL to 
fPL. Because of its cell composition, fPL of preparation F is likely to reflect the role 
of leukocytes. Preparation G’s PL and fPL had to lowest platelet numbers and 
highest leukocytes numbers and yet the difference between PL and fPL is maybe 
the least distinct of the three preparations.  
 
 
Figure 48: Representative phase-contrast images of the top of the wells seeded with 500cells/well. 
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Table 10: Platelet and Leukocyte numbers of PL and fPL preparations D, F & G as 
analysed on the haematology analyser. 
 PL preparation fPL preparation 
Sample: Platelets 
(x103/μL) 
Leukocytes 
(x103/μL) 
Platelets 
(x103/μL) 
Leukocytes 
(x103/μL) 
 
D 752 3 652 0 
F 843 2.3 793 0 
G 555 5 500 1 
 
Overall it appears that, like in the proliferation assays in section 5.34, leukocytes in 
PL have no significant detrimental effect on BM-MSC migration and, based on the 
results of PL preparation F (figures 46 and 47), could even play a positive role. As 
well, the consistency of effect from each PL preparation over time suggests their 
stimulatory effects have longevity in vitro. 
 
5.3.7 In-house and commercial PRP cell compositions: 
Following on from the initial hypothesis; that leukocytes would be detrimental to 
BM-MSC proliferation and migration, despite no significantly detrimental effect of 
leukocytes was found it was also hypothesised that the purer PRP prepared in-
house (PRP) will induce more proliferation and migration than PRP made using a 
commercial device (C-PRP). To test this, the two products were analysed using the 
haematology analyser to identify the differences in their cellular compositions 
(figure 49). PRP had significantly higher numbers of platelets (15.9 ± 5.6 x 105 
PLT/μL) in comparison to C-PRP (6.4 ± 3.4 x 105 PLT/μL) as well as significantly 
lower leukocyte numbers (1.5 ± 1.4 x 103 LEUK/μL) compared to C-PRP (20.6 ± 8.5 
x 103 LEUK/μL). Furthermore, whilst both preparations depleted red blood cells, 
PRP was found to have significantly fewer than C-PRP. Basophils and eosinophils 
were analysed together based on their similar cell size and again, C-PRP enriched 
both cell types, with the exception of one donor, whilst PRP significantly reduced 
them. C-PRP’s neutrophil numbers showed the least consistency, but on average 
C-PRP had a 1.8 fold enrichment of neutrophils whereas PRP completely depleted 
them. Significant variation in starting numbers between the products were also 
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observed for red blood cells, leukocytes and neutrophils. This is likely due to the 
different anticoagulants used and differences in their ability to preserve cells for 
accurate cell counting, however the final differences between the PRP and C-PRP 
are so significant that these initial variations are made negligible. Based on these 
findings, PRP made in-house can be classified using the PAW classification system 
[43] as P4-B-β which describes it’s platelet count as ‘super’ with a greater than six 
fold increase  of platelets from baseline (using whole blood counts as the baseline 
value) and more than 1,250,000 platelets/μL (P4), as well, its white blood cells 
count is below the baseline (B) as is its neutrophil count (β). C-PRP made using the 
commercial device can be categorised as P2-A-α based on its moderate platelet 
count (defined as being greater than baseline up to 750,000 platelets/μL) and a fold 
increase of platelets between 1-4 times above baseline (P2). C-PRP also has a 
greater than baseline white blood cell count (A) and greater than baseline 
neutrophil count (α). Overall, the data shows a clear trend of PRP’s ability to reduce 
leukocytes and enrich platelets significantly more so than C-PRP, whilst C-PRP 
non-specifically enriched all cell types except for red blood cells. It is also of note 
that whilst the commercial device that makes C-PRP refers to the final product as 
‘PRP’, it actually enriches leukocytes and lymphocytes as much as it does platelets, 
and in some cases, even more so. 
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Figure 49:Compares the changing cell compositions from whole blood to C-PRP 
and PRP (n=11 each). The numbers above each product indicate the fold 
change from whole blood to C-PRP/PRP, positive values indicate an average 
fold increase whilst a negative value indicates an average fold decrease, # 
was used to indicate a complete reduction of cells to 0. An unpaired t-test was 
used to compare C-PRP and PRP whilst a paired t-test was used to compare 
each product after platelet concentration:*= P < 0.05, **=P < 0.01, ***=P < 
0.001, ****=P < 0.0001. 
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The observed differences in figure 49 indicate that the final differences in cell 
populations between C-PRP and PRP could be due to the different anticoagulants 
used, as well as the different centrifugation protocols. Therefore, to test the role of 
anticoagulants, the protocol used to generate PRP was carried out with two 
different anticoagulants: ACD-A (used to make C-PRP in theatre) and EDTA (used 
to make PRP in-house) and the cells of the subsequent PRPs were quantified using 
the haematology analyser (figure 50).  
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Figure 50: Compares the role ACD-A and EDTA have on enriching and depleting 
the key cell populations from whole blood to PRP (n=5 for ACD-A and n=11 
for EDTA). The numbers above each product indicate the fold change from 
whole blood to C-PRP/PRP, positive values indicate an average fold increase 
whilst a negative value indicates an average fold decrease. A paired t-test 
was used to compare each product after platelet concentration:*= P < 0.05, 
**=P < 0.01, ***=P < 0.001, ****=P < 0.0001. 
 
Generating PRP is process that can damage the cells whilst the repeated pelleting 
and re-suspending requires a strong anticoagulant that prevents the cells from 
aggregating. Looking first at platelets the results show that; when using the same 
protocol, both anticoagulants are able to preserve and enrich platelets to a similar 
extent. Despite ACD-A enriching on average slightly more platelets (7 fold increase 
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compared to 6.9 fold increase in EDTA) EDTA seems to produce a more consistent 
product, however the larger sample size for EDTA than ACD-A could have partially 
contributed to the differences observed. Both anticoagulants were found to equally 
deplete red blood cells to zero. The biggest difference between the two 
anticoagulants however is seen in the effect they have on leukocytes. Using ACD-A 
and the in-house PRP producing method, it was found that leukocytes were 
depleted only 4.9 fold whilst using EDTA decreased leukocytes 11.1 fold. It is of 
note that EDTA’s average fold depletion of leukocytes observed in figure 50 is 
much greater than the average seen in figure 49 likely due to donor variability and 
more of the PRP samples in figure 50 having their leukocyte numbers depleted to 
less than 1.The differences these anticoagulants have on different cell populations 
is likely due to the difference in strength of anticoagulation, whilst both involve the 
chelation of circulating calcium cations, EDTA has a stronger bond to the calcium 
ions whereas ACD-A’s attachment is weaker and reversible. Therefore, whilst ACD-
A may suitable for the commercial PRP protocol, it may not be strong enough 
anticoagulant to withstand the extensive manipulation of the in-house method 
resulting in less distinction between buffy coat layers and higher contamination of 
leukocytes. This data suggests that the type of anticoagulant contributes to the 
difference in leukocyte numbers between C-PRP and PRP and that the different 
processing protocols contributes to the difference in platelet and red blood cell 
numbers, however, as it wasn’t possible to test blood collected in EDTA in the 
commercial device it cannot be confirmed which, the anticoagulant or the 
processing protocol, makes the most significant difference. 
 
5.3.8 Comparing PL’s and C-PL’s ability to induce BM-MSC 
proliferation: 
Analysis of PL and C-PL confirmed that they are significantly different in terms of 
platelet and leukocyte numbers and so it was hypothesised that they would have 
significantly different effects on BM-MSC proliferation. To test this hypothesis the 
optimised XTT assay (section 5.33) was used to test 10% C-PL (n=5) and 10% PL 
(n=5) with 10% PPP and 10% FCS (as controls) on cultured BM-MSC cultures 
(figure 51). To account for BM-MSC variation, each data point was normalised to its 
BM-MSC’s average response to 10% FCS. One PL preparation (PL: J) was also 
tested on donor matched BM-MSCs. It was seen that in four out of the five PL 
preparations, 10% PL was found to induce significantly more BM-MSC proliferation 
than its leukocyte-rich counterpart C-PL. Furthermore, in three of the PL donors, C-
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PL was found to induce significantly less proliferation than 10% FCS. Surprisingly, 
PPP was found to induce as much proliferation as FCS and C-PL, and, despite a 
consistent trend of PL inducing more proliferation than PPP, the difference was not 
found to be significant. This indicates that the growth factors found in PPP (as 
opposed to those that have been lysed from the leukocytes and platelets in PL and 
C-PL) are able to support some proliferation. Lysing the mostly-platelets in PL was 
found to significantly increase BM-MSC’s proliferative capacity, at least to the level 
of FCS, whereas lysing the platelets combined with leukocytes in C-PL doesn’t 
improve the base-line proliferation provided by PPP and in some cases, hinders 
proliferation. This suggests that the growth factors responsible for supporting 
proliferation are found in the plasma and platelets, which C-PL has fewer of than 
PL. Importantly, these trends were seen in PL preparation J that was donor 
matched, which indicates that the trends observed are likely to occur in the clinical 
setting using autologous PL. 
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Figure 51 compare the effect of leukocytes on BM-BMSC proliferation using the 
XTT assay to test 10% PL and 10% C-PL (n=5) against 10% FCS and 10% 
PPP. All PL preparations were tested on n=4 BM-MSCs except for PL J which 
was tested on n=1 autologous matched BM-MSCs. Error bars indicate 
variation between BM-MSC donors (PL A, B, H, & I), error bars for PL J 
indicate technical error between replicates. One-way ANOVA with Tukey’s 
multiple comparison test was used to identify significance * P < 0.05, **P < 
0.01 **, ***P < 0.001, **** P < 0.0001. 
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5.3.9 Comparing PL and C-PL’s ability to induce BM-MSC 
migration: 
PL and C-PL were also tested on BM-MSC migration, with the same IncuCyte 
migration assay that was optimised in section 5.35, using two PL preparations (H 
and I) each tested on three BM-MSC cultures (figure 52). It is of note that, due to 
condensation forming on the plate at 28 hours, data after that point could not be 
analysed. Looking first at PL preparation H, BM-MSC cultures 6 and 5 responded 
similarly to PL and C-PL; both induced an increase in the total phase object area on 
the underside of the well indicative of more total migration than the positive control. 
Both PL and C-PL show similar trends of migration, with PL appearing to bring 
about a faster initial migratory response. BM-MSC culture 3 responds differently to 
the platelet products; despite being the most static of the cultures, it initially begins 
to migrate towards PL but its’ response plateaus off and by 28 hours its response is 
equal to C-PL and FCS. BM-MSC culture 3’s response is more inconsistent than 
the other cultures but this is likely because its total migration is so low that any 
variation in the mask between scans appear more exaggerated than in other 
cultures that migrated more. The average of all three cultures’ response to the PL H 
platelet products shows that, despite a faster initial response to PL, after 28 hours 
there is no difference between PL and C-PL’s total migration and both are far more 
inductive of migration than FCS. Looking next at PL preparation I, BM-MSCs from 
culture 6 and 5, after 16 hours, begin to migrate rapidly towards PL and C-PL 
making the migration towards FCS appear negligible by comparison. The BM-
MSCs continue to migrate towards PL and C-PL at a consistent rate up to 28 hours. 
Interestingly, PL induces a strong consistent migratory response from BM-MSCs in 
culture 3 whereas C-PL induces a much weaker response which plateaus after 24 
hours and is only marginally better than FCS. Despite some variation in the 
responses of the three BM-MSC cultures to PL preparation I, both PL and C-PL 
induce a strong migratory response at least equal to, if not greater than, FCS. 
Considering the significantly higher numbers of leukocytes in C-PL, these findings 
indicate that the presence of leukocyte-derived proteins is not a detriment to BM-
MSC migration and potentially contribute towards improved migration. To find out 
whether these trends are significant or not, statistics were carried out at three time 
points (figure 53). 
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Figure 52 compares the ability of PL and C-PL (n=2) to stimulate migration in BM-
MSC cultures (n=3) using the IncuCyte migration assay. Error bars indicate 
the variation between BM-MSC cultures for each PL preparation.  
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In figure 53, it can be seen that after just 12 hours, both PL and C-PL show much 
more migration than 0.5% FCS and despite a slight trend of PL inducing more 
migration than 10% FCS, they are not significantly different. By 24 hours, PL has 
induced significantly more migration than the controls in both preparations as does 
C-PL in one preparation (PL preparation I). Across both time points there was a 
clear trend of both PL and C-PL inducing as much migration as FCS, and often, 
more. This supports the finding in figure 52 that both platelet products are effective 
options for inducing migration and that leukocytes do not have a significantly 
inhibitory effect.  
Figure 53 shows the amount of BM-BMSC migration towards 10% PL, 10% C-PL, 
10% FCS and 0.5% FCS using the IncuCyte assay at time-points: 12 and 24 
hours. All PL preparations (n=2) were tested on n=3 BM-MSCs. The error 
bars represent the standard errors of the means, * P < 0.05, **P < 0.01, ***P < 
0.001. 
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5.4 Discussion:  
In order to attract and amplify BM-MSCs to the site of injury, a collagen membrane 
loaded with PRP will be used. However, whilst the clinical effectiveness of PRP is 
generally accepted, due to the lack of quality control, the variation in manufacturing, 
processing, delivery and its different applications (e.g. rotator cuff repair [44] and 
osteoarthritis [45, 46]), the ‘optimal’ composition of PRP is still hotly debated.  
The main issue with lack of standardisation is exemplified by one study which found 
that PRP had no significant effect on bone healing [47], however, a closer look at 
the platelet numbers used in the study found that some of the PRP tested had over 
16-fold more platelets than other PRP. Despite the vast differences in platelet 
numbers and omitted leukocyte numbers, these products were all classified under 
the same umbrella term ‘PRP’. This is commonplace across the literature, whereby, 
the absence of standardised nomenclature, quality control, as well as thorough 
analysis of cellular contents, makes it difficult to draw clear conclusions. According 
to Delong et al.’s [43] platelet number, activation  method and white blood cell 
number (PAW) classification system, C-PRP is classified as P2-A-α (which 
identifies the increase of platelets as ‘moderate’ and the leukocytes as ‘enriched 
above baseline’) whilst PRP is classified as P4-B-β (which identifies the platelet 
concentration as ‘highly enriched’ above baseline and leukocytes depleted below 
baseline). Platelet activation of PRP is most commonly used to initiate the formation 
of a gel for confined delivery of growth factors [48] as well as to ensure platelet 
lysis. Exogenous activators such as thrombin and calcium chloride weren’t used in 
this research as they are not used as standard in current orthopaedic applications 
of PRP, and it has been well described that exposure to collagen at the site of injury 
induces similar activation and release of growth factors as thrombin [43, 48, 49]. As 
well as variation in platelet concentrations, the lack of regulation also instils concern 
in the scientific community over the use of highly concentrated leukocytes, their 
associated pro-inflammatory cytokines (specifically TNF-α and IL-1β), and the risk 
that they could counteract the platelet’s beneficial effects and impede bone 
regeneration [24]. TNF-α and IL-1β are known to induce inflammation causing a 
biphasic physiological response; whilst inflammation is necessary for healing [50], 
in excess it is thought to activate the NFκB pathway [24] inhibiting osteogenesis 
and promoting osteoclastogenesis [51]. However, more recently, these 
proinflammatory cytokines have been linked to increased osteogenesis [52], BM-
MSC migration [53] and proliferation [38] indicative of the lack of consensus in the 
field.  
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This study addressed these concerns by better defining platelets and leukocyte’s 
roles in the two key physiological processes of bone regeneration: BM-MSC 
proliferation and BM-MSC migration. With regards to proliferation, once the assay 
was optimised, it was first found that both PRP and PL induce as much proliferation 
as FCS, supporting their use as in vitro xeno-free media supplements providing an 
alternative to FCS and contributing to the development of autologous cell expansion 
for tissue engineering purposes [16]. Removing leukocytes from PL to make fPL did 
not further improve their ability to induce proliferation whilst direct comparison of PL 
and C-PL found C-PL to be suboptimal at supporting BM-MSC proliferation. This 
response from the BM-MSCs was also observed using donor-matched platelet 
products, proving that the response from the cells was not due to the allogeneic 
nature of the platelet products. Collectively this data points to C-PL’s poor 
performance compared to PL and fPL is likely due to its lower number of platelets 
rather than its higher number of leukocytes as originally thought– both of which are 
theories that have been reported to reduce proliferation in the literature [24, 43, 54, 
55]. This suggests that, in our experimental conditions, the cytokines released from 
leukocytes neither enhanced nor inhibited BM-MSC proliferation and that platelets 
are most likely responsible for releasing the predominant growth factors involved in 
supporting BM-MSC proliferation. Due to the limited volume of samples collected, 
these results are limited by the lack of a direct comparison between fPL and filtered 
C-PL. Due to the bigger difference in leukocyte number between the two products, 
if no significant difference was observed this would have supported the theory that it 
is platelets, rather than leukocytes, that determine major outcomes in BM-MSC 
proliferation. Future work in this area should also include ‘spiking’ experiments 
whereby fPL is dosed with increasing numbers of leukocytes to measure any dose-
dependent response from the cells. 
With regards to BM-MSC migration, all three platelet products; PL, C-PL and fPL 
induced significantly more migration than FCS. This result supports two previous 
studies that used BM-MSCs seeded onto transwells [24, 56] and another that used 
BM-MSCs seeded in a Boyden chamber [57] which all found 10% PRP to 
outperform FCS. PRP and PL’s significant chemotactic effects are thought to be a 
result of their greater concentration of cytokines and chemokines, such as VEGF 
and SDF-1, that are released from platelet’s α-granules [58, 59]. As was seen in the 
proliferation experiments, removing leukocytes from PL did not further enhance its 
effect on BM-MSC migration, but even seemed to reduce it. Whilst there is no 
precedent for the use of platelet products in BM-MSC migration studies, the current 
data supports previous literature of platelet products outperforming FCS [24, 56]. 
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The methods used are also unique in that, not only is the total migration shown, but 
also the increased rate of cell migration towards the platelet products. Furthermore, 
these findings suggest that whilst platelet and leukocyte numbers contribute 
towards BM-MSC migration, it is likely that most of the cytokines that induce 
migration are present in the plasma component of PRP (i.e. PPP) – and so any 
additional platelet or leukocytes make no significant difference. Unfortunately PPP 
wasn’t tested in migration experiments due to the limited number of wells the 
IncuCyte device could capture at each time point. 
Interestingly, the two platelet products (H and I) bring about notably different 
responses from BM-MSC culture 3. Whilst BM-MSC culture 3 appears to be the 
most static culture tested, the platelet products of preparation H induce as much 
migration as FCS whilst the platelet products of preparation I induce considerably 
more migration. This indicates there is donor variation platelet product donors as 
well as between BM-MSC donors. Although both products have seemingly similar 
platelet and leukocyte numbers, PL preparation I’s success could be due to the 
slightly higher platelet count (1,162 x 103 PLTs/μL for PL I compared to 1,000 x 103 
PLTs/μL for PL H). Another possible cause for the difference could be PL 
preparation I’s plasma (PPP) simply contains higher concentrations of chemokines. 
Whilst the impact of donor age on PRP functionality has not yet been investigated 
specifically, research by Evanson et al. found a negative correlation with age and 
growth factor concentrations in PRP preparations [60] which could also explain 
variability between donors aside from platelet and leukocyte numbers.  
Based on these findings it could be proposed that, with regards to migration, the 
compositions of both PL and C-PL can be characterised as ‘high quality’ based on 
their ability to induce BM-MSC migration, whilst for proliferation, PL is a suitable 
product whereas C-PL is suboptimal. This suggests that to generate a high quality 
product for both BM-MSC proliferation and migration should simply focus on 
enriching platelets without regard for leukocytes – this could be easily achieved by 
decreasing the final volume to yield a more concentrated platelet product. However 
the excessive enrichment of platelets faces the risk paradoxically inhibiting cell 
proliferation, viability and migration [43]. A therapeutically effective ‘window’ of 
platelet concentration is likely to be the case rather than a specific pure 
concentration. This therapeutically optimum platelet concentration could be 
identified by testing the functionality of PPP (plasma only) that has been treated 
with a range of platelet concentrations to identify the therapeutic concentration 
range. 
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Whilst BM-MSC donor variation was expected [61, 62], measuring the surface 
expression of specific growth factor receptors such as CD140a and CD140b for 
PDGF [63] on BM-MSCs could indicate how responsive donor’s BM-MSCs will be 
to PRP treatment . Variation in PRP donors is an overlooked issue in the literature 
and acts as a bottleneck for its therapeutic standardisation – therefore, developing 
the best PRP protocol is key as well as assaying PRP and BM-MSC quality before 
use will equally contribute towards successful treatment outcomes. 
This study also supports the notion that the specific clinical application and desired 
outcome should be considered for defining best formulations of platelet products for 
bone regeneration.  If cell proliferation is thought to be limiting regeneration, for 
example in elderly patients that have low numbers of autologous BM-MSCs [64], 
then C-PL will be sub-optimal and PRP with higher concentrations of platelets 
should be used. If however, the surgeon’s priority is to induce BM-MSC migration to 
the site of injury, for example to attract BM-MSCs towards an unpopulated bone 
scaffold, then the current clinical standard C-PL may be sufficient.  Although the 
work presented here gives insight into the role of platelets and leukocytes, it does 
not address which specific growth factors and cytokines are involved. Future work 
should be directed at defining the growth factor profile of ‘high quality’ PRP samples 
based on their ability to induce BM-MSC proliferation and migration as a means of 
quality control. As well, what affect these products have on inducing 
chondrogenesis and osteogenesis would provide a better insight into their long-term 
clinical use. 
In conclusion, this study found that both PL and fPL induce as much BM-MSC 
proliferation as FCS and that low platelet number, rather than high leukocyte 
number, hinders C-PL’s performance with regard to proliferation. Promisingly, with 
regards to migration, all platelet products induced significant, sustained responses 
from BM-MSCs up to 24 hours, regardless of their cell composition. This data 
demonstrates that PL is an effective product to load membranes with to maximise 
BM-MSC proliferation and migration at the site of injury. To confirm this, 
membranes loaded with PL (and C-PL as the clinical control product), will be tested 
in chapter 6. 
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6 Functionality testing of scaffolds 
6.1 Introduction: 
Following the design and fabrication of a novel collagen-PCL membrane, the next 
step in development is to elucidate its viability as an effective GBR device by 
characterising specific functions. As well as mechanical strength (which has already 
been tested in chapter 4), these desired functions include; the ability to absorb and 
release platelet products at the site of injury, to be biocompatible and support BM-
MSC proliferation, a degradation time that is long enough to achieve bone building 
before membrane disintegration and finally; once loaded with PL, to support rare 
BM-MSC colony formation. Since the healing of bone is dependent on the influx 
and proliferation of BM-MSCs, this chapter focuses on ensuring the membrane 
developed can support these rare cells for maximum reossification.  
As of yet, collagen membranes have not been used in orthopaedics due to the 
absence of a stable and mechanically sound enough product [1, 2]. This research 
aims to incorporate novel ES techniques to manufacture stable, biocompatible 
collagen scaffolds to retain grafted material at the site of injury in long bone defects. 
It is hypothesised that this approach will optimise current fracture repair treatments 
based on two key factors; 1) the success of the guided bone regeneration approach 
in the masquelet technique, whereby the presence of a protective biological 
membrane enhances bone healing [3, 4], and 2) the successful application of 
collagen membranes in oral biology, whereby the scaffold is used as a flap to 
segregate the defect and protect it from soft tissue ingrowth that would impair 
healing [5-7]. Despite anatomical differences, the use of collagen membranes in 
dentistry provides a useful insight into their potential success if translated into long 
bone fracture. 
Promisingly, commercial scaffolds such as Bio-Gide used in dentistry have also 
been found to induce ossification in rabbits and humans undergoing bilateral root 
resection and even demonstrated better bone healing compared to the collagen 
solution only control (no membrane) [8]. Another commercial product used in 
dentistry is Mucograft, which is used for oral soft tissue regeneration, however, it 
has also recently been associated with bone healing in rat calvarial defects [9]. 
Despite these scaffold’s successful use in small bone defects, their direct 
translation into orthopaedics, and non-union fractures specifically, is impeded by 
their rapid degradation. The minimum time needed for complete bone healing is 
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thought to be around 12 weeks [10, 11] depending on fracture location, however 
Mucograft has been described to completely degrade after 7 days  [2] and Bio-Gide 
was found to degrade by 80% after 9 weeks [1]. This rapid degradation time means 
that the scaffold is not able to provide structural support or biomechanical stability 
until the new bone is fully formed. As well as their short degradation profiles, an 
optimal scaffold for bone repair must be able to absorb and release growth factors, 
stable enough to be handled and retain the grafted material, as well as be pliable 
enough to mould around the defect. These desired properties have been collated 
from over two decades of GBR research and development [6, 12] as well as from 
demand from the clinical orthopaedic community [4], for an alternative solution to 
the existing methods such as bone grafts, bone substitutes, bone marrow aspirate, 
and the already described two-stage masquelet technique. 
Delivering PRP to the site of injury is a common step in the treatment of most bone 
fractures, however it is often administered through the soaking synthetic bone chips 
and bone grafts [13]. Despite PRP being a key contributor to bone healing [14], the 
volumes supplied to the site of injury are limited by the delivery method and it was 
hypothesised that this volume can be increased by using the absorbent collagen 
membrane as another means of delivery to maximise bone generation. Whilst some 
success has been attributed to alternative methods of PRP delivery, such as 
injections which was found to increase bone formation around hydroxyapatite 
dental implants in dogs [15], generally this is an inaccurate method that does not 
ensure confinement of the PRP to the site of injury or consistent distribution around 
the defect [13]. 
Developing a novel membrane poses a challenge to effectively test its functionality 
due to the lack of pre-existing standard protocols. To address this, assays had to be 
adapted; including the incorporation of a PRP loaded membrane into the CFU-F 
assay for BM-MSC colony formation, the development of a protein release assay to 
quantify its release kinetics, alongside standard protocols for measuring in vitro 
cytotoxicity and proliferation(ISO 10993-5:2009), and absorption capacity (BS EN 
13726-1:2002). 
This chapter focuses on testing the key functions of the prototype electrospun 70:30 
collagen:PCL scaffold compared against the PCL only control scaffold. 
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6.2 Specific Methods: 
Unless specified, all scaffolds were dried for 12 hrs at 40°C before use to ensure all 
solvent had fully evaporated before testing. 
 
6.2.1 Scaffold eluate XTT cytotoxicity assay:  
Scaffold eluates were prepared from PCL and 70:30 scaffolds (n=2 from each 
scaffold type) according to the ISO standard: ISO 10993-12:2007 part 12. Sample 
preparation and reference materials were prepared by macerating 600 mg of the 
scaffold sample into 6 ml of basal DMEM media (not containing FCS) in a sterile 
bijou which was incubated at 37°C for 72 hours. The solution was centrifuged at 
180 xg to remove the scaffold sections and the extract media was frozen at -4°C. 
Once the eluate was prepared, cytotoxicity was evaluated according to ISO: 10993-
5:2009(E) part 5: Tests for in vitro cytotoxicity. Cells from three BM-MSC cultures 
(n=3) were each seeded in triplicate in 200 µL basal media at densities of 10,000 
cells/well in a 96 well plate for 24 hrs. After 24 hrs incubation, the basal media was 
removed and replaced with 200 µl of the thawed treatment media containing either 
the scaffold eluate, the negative control (basal media with 10% DMSO), or the 
positive control (basal media). Cells were then incubated in treatment media for 
another 24 hrs before adding the XTT reagents. 
 
6.2.2 Scaffold eluate proliferation assay: 
To assess the impact scaffold eluates would have on BM-MSC proliferation, an 
extended adaptation of the XTT assay outlined in section 5.2.7 was used. First, 
scaffold eluates were prepared in the same way as in section 6.2.1, followed by 
seeding cells at a density of 500 cells/well in a 96 well plate for 24 hrs in basal 
media (not containing FCS). After 24 hrs, the basal media was removed and 
replaced with 200 µl of treatment medium containing either the scaffold eluate, the 
negative control (basal media with 10% DMSO), or the positive control (basal 
media). Cells were cultured for five days, during which, the media was replenished 
at the start of day three. After five days, the XTT assay was carried out and 
analysed as described in section 2.8 to quantify cell proliferation compared to the 
positive control. 
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6.2.3 Scaffold absorbance of PL: 
Folded scaffolds roughly 1 cm2 in size were measured using a thickness gauge 
(and dried at 40°C for 12 hrs before weighing them (weightdry). Once weighed, each 
scaffold was placed in 1 ml of 100°%°human PL from Cook Regentec. Because of 
the large volumes needed, commercially sourced PL was used in this assay for 
consistency. Scaffolds were soaked in PL at room temperature for 15 mins to mimic 
the clinical setting [16, 17]. After soaking, the scaffolds were removed and the 
excess CRPL was allowed to drip-off for 30 seconds.  Finally, the PL-soaked 
scaffolds were weighed again (weightsoaked) to calculate their percent weight 
increase, as an indicator of absorption capacity using equation 4. Whilst the percent 
weight increase of each scaffold was then normalised to the initial area of the 
sample using equation 5. 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 (%) = (
𝑊𝑒𝑖𝑔ℎ𝑡 ௦௢௔௞௘ௗ(g) −  𝑊𝑒𝑖𝑔ℎ𝑡ௗ௥௬(𝑔)
𝑊𝑒𝑖𝑔ℎ𝑡ௗ௥௬ (𝑔)
 ) × 100 
Equation 4: Formula used to calculate the percent increase in weight of the PL 
soaked scaffolds 
𝐴𝑟𝑒𝑎(𝑐𝑚ଶ) = 2 (𝑙𝑤 + 𝑤ℎ + ℎ𝑙) 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (𝑔/𝑐𝑚ଶ) =  
𝑊𝑒𝑖𝑔ℎ𝑡 ௦௢௔௞௘ௗ(g) −  𝑊𝑒𝑖𝑔ℎ𝑡ௗ௥௬ (𝑔)
𝐴𝑟𝑒𝑎 (𝑐𝑚ଶ)
  
Equation 5: Formula used to first calculate the surface area of each scaffold where l 
equals length, w equals width and h equals height of each sample. Using the 
area, the weight increase of the soaked scaffolds can then be normalised. 
 
The volume absorbed was also calculated to ensure the weight increase was 
accurately representative of the volume absorbed using equation 6. Because of the 
different shapes and sizes of the scaffolds, this volume was normalised to each 
scaffold’s area.  
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝜇𝐿/𝑐𝑚ଶ)  =
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒(𝜇𝐿)  − 𝑈𝑛𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝜇𝐿)
𝐴𝑟𝑒𝑎 (𝑐𝑚ଶ)
 
Equation 6: Formula used to calculate the volume absorbed by the scaffolds 
normalised to their area 
 
6.2.4 Scaffold release of PL:  
To measure the rate at which the scaffolds release the growth factors in PL this 
assay was designed which mimics the in vivo setting in vitro. It employs three main 
- 144 - 
 
steps which will be outlined below: 
1) Sample collection 
2) BCA assay 
3) Analysis 
 
6.2.5 Scaffold release of PL – sample collection 
Following absorbance measurements (section 6.2.3), the PL soaked scaffolds were 
incubated in 3mL of simulated body fluid (SBF) at 37°C. Two samples were used 
for each scaffold type group, as well as an unloaded control group (not soaked in 
PL). Fluid samples were collected sacrificially at regular time points whereby 
60µL/time point was extracted and replaced with an equal volume of SBF (appendix 
1). The time points were collected every five minutes for the first two hours, then 
hourly for the following 10 hours, then every 12 hours for up to 64 hours. After 64 
hours, the scaffolds were removed and suspended to remove excess solution 
before being moved into fresh SBF for one hour before 60 µL was extracted again. 
The aim of this final extraction was to quantify any protein that remained bound to 
the scaffold by creating a maximum diffusion gradient (to ensure protein released 
into the SBF hadn’t reached equilibrium). The 60µL aliquots were stored in sealed 
eppendorf tubes at 4°C until all time points were collected and ready for the BCA 
assay.  
 
6.2.6 Scaffold release of PL – Bicinchoninic acid (BCA) assay: 
The BCA assay is a colorimetric assay which enables quantification of protein in a 
sample using a bovine serum albumin (BSA) standard curve. First, the BSA 
standard was established with a final working range of 0-2000 μg/mL made up 
using 2 mg/mL BSA diluted in SBF following a dilution series outlined in table 11. 
SBF composition is outlined in appendix 1 [18]. 25 μL of each standard and test 
samples was pipetted in duplicate in a 96-well plate followed by 200 μL of the BCA 
working reagent. The plate was covered and agitated on a microplate shaker for 30 
seconds before incubation at 37°C for 30 mins. The absorbance was subsequently 
measured at 570 nm using a microplate reader. The average blank (SBF) 
absorbance was subtracted and the protein concentration (μg/mL) of the unknown 
samples was measured by comparing with a standard curve (R2 = 0.9936) obtained 
from the BSA standards (figure 54). 
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Table 11: The dilution series used to make the range of BSA concentrations for the 
standard curve 
 
 
Figure 54: The standard curve produced from the albumin standards outlined in 
table 11 and their corresponding optical density (OD). Error bars indicate 
variation between technical replicates. 
 
6.2.7 Scaffold release of PL – Analysis 
To quantify the amount of proteins released from the scaffolds, the average blank 
(SBF only) OD reading was subtracted from each time point’s OD reading. Due to 
the sacrificial nature of the release assay, each blank-corrected OD reading was 
divided by the dilution factor which was calculated for each sample using equation 
7. 
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𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 =  
𝐹𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)
𝑆𝑜𝑙𝑢𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)
 
Equation 7: Formula used to calculate the dilution factor for each time point of the 
release assay where the final volume is the final volume of the well and the 
solute volume is the volume left in the well after each sample has been 
collected and before it is replenished with fresh SBF. 
 
The protein concentration was then quantified by dividing each blank-corrected, 
dilution-corrected OD value by the linear regression of the BSA standards 
(y=0.0005958+0) as outlined in equation 8. 
 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔/𝑚𝐿) = ൬
𝑂𝐷
𝑙𝑖𝑛𝑒𝑎𝑟 𝑟𝑒𝑔𝑟𝑒𝑎𝑠𝑠𝑖𝑜𝑛
൰ ÷  𝑣𝑜𝑙𝑢𝑚𝑒  𝑜𝑓 𝑆𝐵𝐹 (𝑚𝐿) 
Equation 8: Formula used to calculate the protein concentration based on the 
optical density (OD), linear regression of the standard curve and the volume 
of simulated body fluid (SBF) in each well. 
 
The percent of protein concentration released for each time point was calculated as 
a fraction of the total amount of protein initially absorbed as described in equation 9. 
 
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 ቀ
𝜇𝑔
𝑚𝐿
ቁ = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 (𝜇𝐿) × ൬
𝑂𝐷 𝑜𝑓 1𝜇𝐿 𝑝𝑢𝑟𝑒 𝑃𝐿
𝑙𝑖𝑛𝑒𝑎𝑟 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛
൰ 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 (%) =  
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 (𝜇𝑔/𝑚𝐿)
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 (𝜇𝑔/𝑚𝐿) 
 × 100 
Equation 9: Formulas used to calculate the percent of protein released from the 
scaffolds based on the total amount that was absorbed [19]. 
 
6.2.8 Protein quantification in 10% PL: 
To test whether the PL loaded scaffold released as much protein as is found in 10% 
PL (which had been previously optimised for cell proliferation in section 5.33) the 
protein quantities in 10% PL were analysed. C-PL products from 4 donors were 
diluted 1:10 in SBF alongside the BSA standards. The BCA assay was carried out 
on each PL product in triplicates using the microplate reader. As well, the average 
blank OD reading was subtracted from each OD reading. The same equations as 
outlined in section 6.2.7  were used to quantify the protein concentrations in the PL 
products. 
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6.2.9 Degradability: 
To monitor scaffold degradation, roughly 1 cm2 sections of single, unfolded sheets 
of 70:30 were cut up in triplicate and placed into 2 ml PBS in a 6 well plate. The 
plates were photographed, incubated at 37°C for up to 4 weeks, before analysing 
under SEM and photographed again. 
 
6.2.10  PRP loaded scaffold CFU-F proliferation assay: 
An adaptation of the CFU-F assay  was used to quantify how C-PL-loaded 
membranes (70:30 and PCL) affected the proliferation and migration capacity of 
uncultured BM-MSCs. As in previous assays (section 5.2.7 and 5.2.8), PL was used 
in place of PRP to ensure consistency of product. First, fresh BMA from three 
donors underwent red blood cell lysis after which a total of 5 x 105 cells were plated 
in 15mL expansion media to adhere over 24 hrs. After initial attachment and a PBS 
wash, the media was replaced with either 15 mL expansion media containing 2 
I.U/mL sodium heparin solution (control) or 15 mL DMEM media (no serum) 
containing 2 I.U/mL sodium heparin solution (test). 1 cm2 square sections, 400 μm 
thick, of UV-sterilised 70:30 and PCL scaffolds were soaked in 2 mL of C-PL from 
one donor for 15 mins until saturated before being placed in the centre of the test 
dishes (figure 55). The dishes were incubated for a further 19 days with a half-
media change in the second week. After 21 days, the dishes were washed in PBS, 
fixed in 10% (v/v) formalin and stained in 1% (w/v) methylene blue. All colonies 
were imaged using a plate scanner at 1200 dpi. Colony area, integrated density and 
number per dish was quantified using ImageJ whereby scanned images were 
converted to 8-bit greyscale and a threshold mask was applied before colonies 
were analysed and measured. 
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Figure 55: An example CFUF dish with a PL loaded 70:30 membrane. 
 
6.2.11 Statistics 
Statistical analyses were carried out on datasets that consisted of at least three 
independent experiments using a paired student’s t test when comparing two 
groups from the same donor and an unpaired student’s t test when donors weren’t 
matched. One-way ANOVA with Tukey’s multiple comparison test was used when 
comparing more than two groups or two-way ANOVA with Tukey’s multiple 
comparison test for nonparametric results with GraphPad Prism software. All data 
are expressed as mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001, and 
****P<0.0001 defined statistical significance. 
6.3 Results: 
Creating a novel scaffold requires testing its specific functions depending on the 
desired application, testing its functionality in these early phases of development 
ensures the ideal scaffold is fabricated by identifying potential weaknesses and 
strengths. This chapter used the XTT assay to assess the scaffold’s effect on BM-
MSC cytotoxicity and proliferation, as well as an adapted BCA assay to quantify 
protein absorption and release. Degradability was also assessed qualitatively and 
the CFU-F assay was used to test whether the loaded scaffold could support in vitro 
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BM-MSC proliferation. 70:30 was the scaffold chosen for this work as optimised in 
chapter 4, PCL only scaffold is used here as a control scaffold. 
 
6.3.1 Cytotoxicity: 
As outlined in ISO 10993-5:2009 (tests for in vitro cytotoxicity), 1 x 104 BM-
MSCs/well were seeded in a 96 well plate in triplicate and exposed to either basal 
media (positive control), basal media containing 70:30 scaffold extract (test), or 
basal media containing 10% DMSO (negative control) for 24 hrs to identify the 
scaffold extract’s effect on BM-MSC viability. Three individual BM-MSC cultures 
were used up to passage four and their average absorbance is shown in figure 56. 
The test at 1 x 104 BM-MSCs/well met the acceptance criteria as the mean OD450 of 
blanks was greater than 0.2 [20] so no further optimisation was necessary. As 
expected, there was a significant difference found between both the negative and 
positive controls (P < 0.05), and the negative and test media (P < 0.05). The 
scaffold extract containing media was found to be statistically similar to the basal 
media indicating no cytotoxic effect of the scaffold extract on BM-MSCs. 
 
Figure 56: Average cytotoxicity results of three BM-MSC cultures exposed to basal 
media (BM), basal media containing 70:30 scaffold extract (BM+70:30), and 
basal media containing 10% DMSO (BM+DMSO). Standard error bars 
indicate variation between cultures (n=3).  
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6.3.2 Effect of the scaffold on BM-MSC proliferation: 
Whilst the short 24 hr assay outlined in section 6.3.1 is useful to assess the effects 
of 70:30 scaffold’s extract on BM-MSC survival a longer assay of 5 days exposure 
to the extract containing media is useful to assess its effect on BM-MSC 
proliferation. BM-MSCs were exposed to either basal media (positive control), basal 
media containing scaffold extract (test) or basal media containing 10% DMSO 
(negative control). Although no significant difference was found between the 
negative control and either the positive or test media, a clear trend of increased 
proliferation was observed in the basal media and extract containing media. The 
scaffold extract was found to have no significant negative effect on BM-MSC 
proliferation. 
 
 
Figure 57: Average proliferation results of three BM-MSC cultures exposed to basal 
media (BM), basal media containing 70:30 scaffold extract (BM+70:30), and 
basal media containing 10% DMSO (BM+DMSO). Error bars indicate variation 
between cultures (n=3). 
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6.3.3 Measuring the scaffold’s ability to absorb PRP: 
To quantify 70:30 scaffold’s ability to absorb PRP, the absorption capacity (weight 
increase normalised to area) and absorbed volume (normalised to area) were 
quantified for 70:30 scaffolds, control PCL scaffolds, and the current commercial 
control scaffold Mucograft (Geistlich). Due to limited samples available of the 
Mucograft scaffold only one sample was tested, whereas three scaffolds of 70:30 
and PCL were tested, this discrepancy in numbers prevented statistical analysis. 
Despite the absence of statistics, it is apparent that both the in-house manufactured 
scaffolds (PCL and 70:30) appeared to have a much higher absorption capacity 
than Mucograft. The normalised volume absorbed suggests the scaffolds are more 
similar to one another than the absorption capacity data alone would indicate. This 
promising finding has demonstrated how the 70:30 scaffold performs at least as 
well as the commercial equivalent, if not better, as it appears to outperform 
Mucograft despite being made up of less than half its size.  
Figure 58: The results of the scaffold’s average absorption capacity (A) and volume 
absorbed (B) both normalised to the scaffold’s area. Standard error bars show 
variation between repeats (PCL and 70:30 n=3, Mucograft n=1). 
 
6.3.4 Release: 
To first validate the BSA assay for this application and investigate whether the 
albumin standard could be used as a representative surrogate for quantifying 
protein in PL its standard curve was compared to different concentrations of PL 
diluted in simulated body fluid (SBF); 1:1, 1:5 and 1:10. It can be seen in figure 59 
that the standard curve of PL 1:10 provides the most reliable linear coefficient 
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correlation and almost directly overlays the albumin standard. This validates the 
albumin standard as an effective way to calculate protein concentrations in PL and 
demonstrates that the protein concentrations in PL can be reliably calculated using 
this method. 
  
 
Figure 59: Optimisation of serial dilutions of PL diluted in  simulated body fluid 
(SBF) with starting concentrations of 1:1 (PL:SBF), 1:5, and 1:10, alongside 
the BSA albumin standard concentrations. Error bars indicate variation 
between technical replicates. OD is read at 570nm. 
 
Following protein absorbance, it was important to understand how the scaffold 
would release the absorbed proteins; whether the proteins would be released 
gradually, or rapidly as a ‘burst’ release. The cumulative release of PL loaded 
scaffolds over 60 hours is shown in figure 60 A and shows how most of the release 
occurs in the first 2 hrs before plateauing. As the first 2 hrs appears to be the most 
critical in the release kinetics, the data is shown separately in more detail (figure 60 
B). It can be seen that whilst the PCL scaffolds show the most variation, they also 
appear to initially release most of the protein indicative of lower absorption of the PL 
into the scaffold and suggestive of a more superficial coating compared to 70:30 
and Mucograft. The 70:30 scaffolds appear to release PRP more consistently than 
PCL as their data points overlay each other, the release profile compared to PCL 
also appears to be more gradual indicative of more absorption into the scaffold. 
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Although only one Mucograft scaffold was tested, it showed the most gradual 
release of PRP which was expected due to its sponge-like structure.  
  
 
Figure 60: The cumulative protein released from the scaffolds as a percentage of 
the initial amount absorbed shown over 60 hours (A) and the first 2 hours (B). 
Each scaffold tested is shown separately; PCL n=2, 70:30 n=2, Mucograft 
n=1.  
 
To ensure the loaded scaffolds could absorb and release enough protein to support 
BM-MSC proliferation, the cumulative amount released from each scaffold in the 
first hour was compared against the amount of protein in 10% PL (as has previously 
found to induce sufficient BM-MSC proliferation in the literature [21, 22] and section 
5.33), the results are shown in figure 61. The amount of protein released in 10% PL 
(dotted line in figure 61) was found to equal 1552.5±325.1 μg/ml and all three 
scaffold types were found to surpass this amount with the 70:30 scaffolds releasing 
2709.1±21.3 μg/ml in the first hour. The unloaded 70:30 scaffold was also included 
to confirm that negligible protein was released from the scaffold itself (85.3μg/ml). 
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Figure 61: The results of the average cumulative amount of protein released in the 
first hour from PCL (n=2), 70:30 (n=2), Mucograft (n=1) and an unloaded 
70:30 control scaffold (n=1).  
 
 
6.3.5 Assessment of the scaffold’s degradation profile: 
For the initial assessment of the scaffold’s degradation profile, macroscopic 
analysis of the membranes after 30 days hydrated in PBS was carried out (figure 
62). After 30 days, no observable change to their structure or composition was 
found.  
SEM analysis of the scaffolds showed that after 30 days, morphological changes in 
the fibres were prevalent (figure 63). Fibres appeared swollen and were less distinct 
after soaking in SBF for 30 days.  Despite this expected change in the membranes’ 
microarchitecture, the scaffolds were still found to be very much intact and resilient. 
This qualitative preliminary finding supports the use of the scaffolds in the modified 
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CFU-F assays where the scaffolds need to stay intact for over 2 weeks at 37°C in 
media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 0 
Day 30 
Figure 62: Degradation assay in SBF. Image shows 70:30 scaffold samples 
soaked in SBF at day 0 and day 30 (n=3). 
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Figure 63: Degradation SEM images.SEM analysis of the 70:30 scaffolds hydrated 
in SBF at 37°C after 1 day and 30 days. Representative images at x200 and 
x2000 magnification are shown. Scale bars show 100 μm at x200 and 10μm 
at x2000. 
 
6.3.6 Loaded scaffold ability to support colony formation: 
Once it was confirmed that the loaded scaffolds could absorb and release similar 
amounts of protein as was found in 10% PL (figure 61), and the scaffolds would 
stay intact over the course of the assay (figure 62 and 63), their ability to support 
BM-MSC colony formation was then investigated using the modified CFU-F assay. 
To mimic the clinical application, uncultured BM-MSCs from BM aspirates were 
used in these experiments. BM-MSCs were cultured in dishes containing either 
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standard Stem Macs expansion media (control) or basal serum-free media with the 
addition of a clinically approved PL (C-PL)-loaded membrane (test). Both PCL and 
70:30 loaded scaffolds were tested and colony formation was observed in all test 
dishes. The colonies observed all had similar morphologies as shown in figure 64, 
and using ImageJ analysis, the colonies’ area, density and number were quantified. 
Whilst analysis of the PCL loaded scaffolds appeared to induce fewer colonies than 
the control expansion media, this difference was not found to be significant and 
whilst fewer colonies were counted, the PCL-loaded membrane appeared to result 
in larger and denser colonies. A similar trend was observed in the 70:30 loaded 
scaffolds whereby, although no significance was found, the fewer colonies that 
grew were often larger and denser than the colonies in the control expansion 
media. These findings demonstrate how C-PL loaded membranes (both PCL and 
70:30) can support the formation of rare BM-MSC colonies from BMA at least as 
well as expansion media, if not better. 
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Figure 64 Modified CFU-F assay to incorporate loaded scaffolds. A) representative 
dishes of colonies grown in expansion media (EM), C-PL loaded PCL 
membrane (PCL), and a C-PL loaded 70:30 membrane (70:30). B) shows the 
characterisation of colonies exposed to PCL loaded membranes (n=3) whilst 
C) shows the characterisation of colonies cultured with 70:30 loaded scaffolds 
(n=3). Error bars indicate the standard error between cultures. 
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6.4  Discussion: 
In order to test the key functions of the prototype electrospun 70:30 collagen:PCL 
scaffold, this exploratory pilot study investigated its cytotoxic and proliferative 
characteristics, as well as its ability to absorb and release proteins, its degradation 
profile, and its ability to support colony formation.  
Promisingly, this study found the scaffold induced no cytotoxic effects on BM-MSCs 
nor did it inhibit BM-MSC proliferation. These characteristics are fundamental in the 
development of a biomaterial so were tested according to industry standard 
protocols. Further investigation would have included direct contact cytotoxicity, 
however it is accepted that eluate cytotoxicity is a reliable indicator of a material’s 
cytotoxic effects [23, 24]. 
Whilst the normalised absorption capacity and volume showed some discrepancy 
(likely due to lack of accuracy in detecting such small changes in weight and 
volume), both indicate that 70:30 is as least as good as Mucograft, with regard to its 
ability to absorb PL, if not better, despite being less than half the size. The success 
of both scaffolds suggest that their structures provide sufficient mechanisms for 
protein uptake[25]. Furthermore, as both 70:30 and PCL scaffold have similar 
absorption capacities, this unexpectedly indicates that the presence of collagen 
doesn’t significantly increase its absorption despite its hydrophilicity [26, 27]. Again, 
this is likely because, at this scale, it is the highly porous structure of the scaffolds 
that contributes to its absorption capacity, rather than its composition. It is predicted 
that the hydrophilic effect of collagen in 70:30 scaffolds would show significantly 
higher absorptive capacity than PCL only scaffold if larger samples were tested. 
Although no significant difference was found between 70:30 and PCL with regards 
to their ability to absorb PL, their release profiles show slightly different trends. PCL 
has a faster release profile suggestive of a superficial coating of PL which sits in the 
pores rather than true absorption into the fibres of scaffold. 70:30’s slower release 
correlates to its hydrophilic collagen content enabling absorption into the fibres and 
a more gradual release. Collectively, this absorbance and release data support 
70:30’s structure and composition as the optimum delivery material for this scaffold. 
With regards to scaffold degradation, this initial qualitative assessment found that, 
despite some morphological changes of the fibres as was expected, overall the 
scaffolds were found to remain intact over the course of the assay. Further 
quantitative characterisation work is needed on the rate of scaffold degradation 
long-term and ensuring that it is able to survive the 12-week minimum regeneration 
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period required for bone healing. The risk of incorporating collagen into a 
biomaterial is that it will degrade too quickly for thorough in vitro characterisation 
and even more concerning, that it will degrade before it has induced sufficient 
tissue regeneration [26, 28]. Collagen’s poor mechanical properties have restricted 
its use in commercial bone scaffolds where mechanical stability is required [29] 
however, here it has been shown that when manufactured as a composite material 
with PCL the scaffold has sufficient stability for in vitro testing and characterisation. 
Further analysis of how much collagen remains at the end of this degradation assay 
is needed and if the data suggests that a significant proportion of the collagen is 
lost and does degrade other post-manufacture processing techniques can be 
incorporated to enhance its longevity such as cross-linking [30]. As mentioned 
previously, more in-depth analysis of the scaffolds degradation profile will include 
measuring changes in weight over longer incubation periods as well as using EDX 
analysis and Sirius red staining [31] to monitor changes in composition. 
Incorporating cells and collagenase into future degradation assays will also result in 
a more accurate representation of the in vivo setting and the interaction of cells and 
enzymes on the scaffold as has been demonstrated by Gaspar et al [32]. 
Most promising of this study was the data collected from the CFUF assay which not 
only further validated the cytocompatibility and proliferation results, as well as 
demonstrated sufficient absorption and release of functional PL to support BM-MSC 
growth, but also confirmed practically how the loaded scaffolds could support rare 
BM-MSC colony formation. Both the loaded 70:30 and PCL scaffolds were found to 
perform at least as well as the expansion media (EM) controls and even appeared 
to induce larger and denser colonies which is widely believed to indicate faster 
proliferation [33, 34]. Because of BM-MSCs key role in bone regeneration, inducing 
their faster proliferation, as was observed in this study, is a valuable characteristic 
for a scaffold’s clinical application. Despite some concerns in the literature over 
HFIP’s toxic effects [35], this study shows how they can be overcome, alleviating 
any risk of cytotoxicity by allowing complete solvent evaporation. 
It is of note that due to the novelty of this work, Mucograft was the only commercial 
scaffold that was comparable for use as a control. And due to its high cost, only a 
limited amount was sourced for experiments. Ideally more control scaffolds would 
be tested as controls alongside the prototype membranes to get a better 
understanding of their novelty and the role their structure and composition have on 
the functioning of the prototypes. Limited sample volumes were also an issue when 
loading the scaffolds with PL as they exceeded the volume of clinical samples 
available. As a solution, human PL was sourced commercially from Cook Regentec. 
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However as this product comes already lysed, its platelet, leukocyte and growth 
factor content cannot be determined and direct comparisons to the PL products 
tested in chapter 5 are restricted. Future development of this work would include 
characterisation of scaffolds loaded with ‘in-house’ PL and ‘in-theatre’ C-PL for a 
more accurate replication of the clinical setting. 
Importantly, this chapter investigates the success of a novel ES prototype collagen-
containing scaffold compared to a PCL-only control. It was found that, as both 
scaffolds performed well with regards to absorbance and release of PL and their 
ability to support colony formation, there is no distinct advantage to incorporating 
collagen. However, despite no significant difference observed from these assays, it 
is believed that the advantage of collagen’s presence is still vital to scaffold 
properties that were not possible to investigate in this pilot study. Time constraints 
prevented; 1) cell attachment analysis which a study by Sousa et al. showed is 
significantly enhanced in the presence of collagen [36], 2) a more in-depth study of 
the scaffold’s degradation profile since a PCL-only scaffold is more likely to need 
removal in a second surgery, whereas collagen is fully biodegradable [37],3) and 
enhanced vascularity [38]. The incorporation of chlorioallantoic membrane (CAM) 
assays and subcutaneous implantation into animal in vivo models [39] are the next 
stages to demonstrate the need for collagen for optimal integration and 
biocompatibility. 
Whilst more in-depth functional characterisation work is needed on the prototypes, 
this pilot study has demonstrated the potential application of this scaffold and 
fulfilled the initial criteria set out for a successful guided bone regeneration device. 
The work contributes towards optimised bone healing and the development of 
future scaffolds. 
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7 Conclusions 
As outlined at the start, the aim of this project was to design and develop a 
biomimetic collagen-based membrane, modelled on the IM, to act as a guided bone 
regeneration device for long bone fracture repair. The key properties of the pilot 
membrane were for it to be biocompatible, have appropriate mechanical strength, to 
absorb and release PRP, and to support BM-MSC proliferation. 
To begin the design process, the IM tissue that was to be mimicked had to be 
characterised. Using histological techniques, the IM was found to be thicker than 
periosteum, to have less distinct layers than expected and to drastically vary in 
blood vessel size and overall thickness between donors. These differences are 
thought to be due to differences in age, anatomical location and fracture severity 
between donors. Despite a small sample size of 7 donors these findings were 
translated into the design process by widening the acceptance criteria of the 
scaffold’s thickness, porosity and fibre diameter. As well, due to the rarity of human 
IM samples, this analysis contributed to the relatively small amount of existing 
literature on the human IM’s structure and microarchitecture. Analysis of the IM’s 
birefringence was particularly novel and revealing of the collagen fibrils 
organisation. If further defined in a larger study with a wider donor pool, this 
information could enhance our understanding of optimal fibre orientation of 
manufactured scaffolds. 
Based on the samples that were harvested and characterised, it was decided that 
the biomimetic scaffold would be made of a blend of collagen and PCL to meet the 
criteria of biocompatibility and mechanical properties. Needleless electrospinning 
was also chosen with clinical translation in mind as well as its ability to manufacture 
highly porous scaffolds. This technique was found to successfully produce 
consistent scaffolds composed of up to 70% collagen with sub-micron fibre 
diameters. The small fibre diameter contributed to a dense construct with over 80% 
of pores being smaller than 4 µm. As has been outlined, PCL was chosen as the 
polymer of choice because of its prevalent use in existing biomedical devices 
however, future development of this project would incorporate a larger polymer 
library. Co-polymers also pose an interesting avenue to pursue, for example PLGA 
which is made from a blend of poly lactic acid and glycolic acid, the ratios of which 
can be adjusted to tailor the final scaffold’s degradation and hydrophilicity [1]. Other 
more novel scaffolds could be investigated such as polyurethane which has, elastic 
properties that could be interesting to incorporate [2] and composites such as poly 
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lactic acid blended with hydroxyapatite particles which have already shown 
promising results [3]. 
Although some manufacturing problems were encountered, for example; the thinner 
than designed membranes and the small inherent pore size, the multidisciplinary 
aspect of the project resulted in innovative solutions such as heat-treating, folding 
and laser cutting. As well, despite these problems being not initially expected they 
were not entirely negative results. For example, the sub-micron pore sizes of the 
scaffold could be useful in drug-delivery applications or wound healing where 
barrier membranes with high surface area are desirable [4, 5]. Furthermore, laser 
cutting the pores into the scaffolds proved to further improve their strength by acting 
as anchoring points between the layers and annealing the construct overall. 
In order to attract and amplify BM-MSCs to the site of injury, chemoattractants and 
growth factors from platelet lysate (PL) were analysed. It was decided that, as BM-
MSC proliferation and migration were fundamental in ensuring optimal bone 
healing, these two functions would be the focus of analysing PL’s success. 
Promisingly, PL was found to induce as much BM-MSC proliferation as FCS (the 
standard culture medium supplement) as well as out-perform FCS at inducing BM-
MSC migration regardless of its cell composition. The main conclusion that can be 
drawn from this body of work is that low platelet numbers, rather than high 
leukocyte numbers, are responsible for limiting PL’s proliferative and migratory 
effects. These findings contribute towards the development of xeno-free cell culture 
techniques specifically useful for tissue engineering applications. Whilst leukocytes 
were not found to have any observable negative effects, a future study could 
include ‘doping’ filtered pure plasma with known numbers of leukocytes and 
platelets to be truly certain of their roles.  
 
To bring all the research together, the manufactured collagen membrane was 
functionally tested with clinical translation in mind using industry standard protocols 
where possible. The scaffold was found to have no harmful cytotoxic effects nor 
limit BM-MSCs proliferation capacities compared to standard culture media. As 
well, the scaffolds were found to sufficiently absorb and release proteins sourced 
from PL, withstand initial degradation assays as well as support colony formation. 
Although this pilot data is in vitro based, it still provides a promising indication into 
the scaffold’s ability to endure future in vivo testing. Most exciting was the 70:30 
scaffolds absorption capacity that was found to be similar to a commercial scaffold 
despite being less than half its size. Collectively, this absorbance and release data 
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support the structure and composition of the 70:30 scaffold as the optimum delivery 
material. 
Previously, collagen’s poor mechanical properties have restricted its use in 
commercial scaffolds where mechanical stability is required however, here it has 
been shown that when manufactured as a composite material with PCL the scaffold 
has sufficient stability to withstand in vitro testing. Further characterisation work is 
needed on the rate of scaffold degradation long-term and ensuring that it is able to 
survive the 12-week minimum regeneration period required for bone healing [6, 7]. 
How much collagen is retained over the course of a degradation assay could also 
be carried out using a picro Sirius red assay in parallel to the degradation assay 
using sacrificial samples at time points throughout the experiment. If the data 
suggests that a significant proportion of the collagen is lost and does degrade other 
post-manufacture processing techniques can be incorporated to enhance its 
longevity (such as cross-linking) [8, 9].  
The final experiment of this research brought together all the aspects studied 
throughout using CFU-F assay with a PL-loaded scaffold. This data not only 
validated the absence of any cytotoxic effects of the scaffold, but also demonstrated 
the ability to absorb and release sufficient PL to support rare BM-MSC colony 
formation. Both the loaded 70:30 and PCL scaffolds were found to perform at least 
as well as the standard culture media and even appeared to induce faster 
proliferation (indicated by larger, denser colonies). However, interestingly, no 
significant difference was observed between the 70:30 and PCL scaffolds in their 
ability to induce colony formation. This lack of difference between the scaffolds 
could result from the assay not being a direct contact assay, where the cells are 
cultured directly onto the scaffold. Cell attachment and proliferation on the scaffold 
would be a useful indicator for how the cells interact with, and are supported by the 
scaffold, and would be a priority experiment in the next stage of this work. Because 
of BM-MSCs key role in bone regeneration, inducing their faster proliferation, as 
was observed in this study, is a valuable characteristic for a scaffold’s clinical 
application. Despite concerns over HFIP’s toxic effects, this study found no 
cytotoxic effect caused by the scaffolds, indicative of complete solvent evaporation, 
however residual HFIP would be a priority to test and quantify before any clinical 
translation. To fully test the abilities of this scaffold, importantly its cell attachment 
and in vivo vascularisation, intergration and degradation profile chlorioallantoic 
membrane (CAM) assays [10, 11] and subcutaneous implantation into animal in 
vivo models [11, 12] are the next stages of research. Further study into the effect of 
different pore sizes and densities on the scaffolds mechanical properties would also 
- 167 - 
 
be carried out as well as incorporation of post-processing techniques, such as 
plasma treating the surface of the scaffold, to enhance hydrophilicity and cell 
attachment. 
Collectively, this work has advanced the field of tissue engineering by developing 
and applying a novel technique and a novel material to successfully create a 
biomimetic scaffold with quantities of collagen that was initially not thought possible 
at the start of this project. The continuation of this work, and its translation into 
clinical manufacturing would result in the streamlining of a two-stage surgical 
procedure into a single-stage procedure resulting in significant savings to the NHS, 
faster healing times for patients, shorter hospital stays, and time saved for 
surgeons. The interactions between cells, growth factors and scaffolds are also now 
better understood which would have a wider impact on the field of tissue 
engineering as a whole, outside of orthopaedics, and the ability to manufacture 
scaffolds in this way could result in the production of dermal patches, cartilage 
implants, corneal scaffolds to name a few. 
This study has demonstrated the potential application of a biomimetic collagen-PCL 
scaffold and fulfilled the initial criteria set out to create a guided bone regeneration 
device. The work contributes towards optimised bone healing and the development 
of future scaffolds. 
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8 Appendix 1 
8.1 Standard solutions: 
Cell freezing media 
90% FCS, 10% DMSO 
Formaldehyde 
4% formalin solution (v/v) in PBS 
Methylene blue solution 
1% (w/v) methylene blue dissolved in 10mM disodium tetraborate (pH 8) 
Basal media 
DMEM, 1% Penicillin/Streptomycin (v/v) 
Expansion media 
Stem Macs media, 1% Penicillin/Streptomycin (v/v) 
Simulated body fluid 
dH2O 1000ml, Sodium chloride (NaCl) 8.04g, Sodium bicarbonate (NaHCO3) 0.36g, 
Potassium chloride (KCl) 0.23g, Potassium Hydrogen Phosphate Trihydrate 
(K2HPO4 3H2O) 0.23g, Magnesium Chloride (MgCl2 6H2O) 0.31g, 1.0M Hydrochloric 
acid (HCL) 39ml, Calcium chloride (CaCl2) 0.29g, Sodium sulphate (Na2SO4) 0.07g, 
Tris(hydroxymethyl)aminomethane 6.12g, adjust to pH 7.4 with 1.0M-HCL. 
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9 Appendix 2: 
9.1 Consumables: 
Consumables Manufacturer 
Acrodisc white blood cell strainer Pall Life sciences 
Cell Strainer (70 mm) BD Falcon 
CFU-F dish (15mm) Corning 
Cryovials (1.8 mL) Nunc 
Eppendorf tubes Eppendorf 
Falcon Tubes (15 mL, 50 mL) Corning 
Flat bottom well plates – (6, 12, 24, 48, 96 well) Corning 
Histology Slide Covers Thermo Scientific 
Mr Frosty Freezing Container Thermo Scientific 
Mucograft scaffold Geistlich 
Non Tissue Culture Treated Plates (6, 12 well) Cellstar 
Pipette Tips (10 mL, 1000 mL) Anachem 
Scalpel Swann Morton 
SEM Specimen Stubs and Mounts Agar Scientific 
Strippete (5 mL, 10 mL, 25 mL) Corning 
SuperFrost Plus Histology Slides Thermo Scientific 
Syringe (10 mL) BD Biosciences 
Tissue Culture Flasks (25 cm3) Corning 
Tissue Culture Round Dishes (100 mm or 60 
mm diameter) 
Corning 
Vacuette blood tubes (EDTA and ACD-A) Greiner Bio-one 
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9.2 Equipment: 
Equipment Manufacturer 
Auto Sputter Coater Agar Scientific 
AL54 Scales Mettler Toledo 
Attune 2 Laser System Flow Cytometer Applied Biosystems 
Attune software Applied Biosystems 
Bevel Tipped Trocar Stryker 
Centrifuge 5415D Eppendorf   
Centrifuge 5810R Eppendorf  
CKX41/BX45Microscope  Olympus 
Class II Laminar Flow Biological Safety 
Cabinet 
Nuaire 
CO2 Incubator InCuStage Sanyo 
Epsom 3590 Photo Scanner Epsom 
Freezer (-80 C) New Brunswick Scientific 
Gilson Pipette Gilson 
GX Microscope  GX Microscope 
Haematology analyser Sysmex 
Haemocytometer  Hawksley 
Hitachi 5-3400N SEM  Hitachi 
Hitachi 5-3400N SEM Software Hitachi 
Hot Plate  Stuart Scientific  
ImageJ Software ImageJ 
IncuCyte Essen 
Infinity 1 Camera Lumenera 
Infinity Image Acquisition software Lumenera 
Laser cutter FB700 FB series 
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Mucograft Geistlich 
NanoSpider NS Lab Elmarco 
Porolux 100FM Porometer 
ProGage Thickness Tester Thwing-Albert Instrument Company 
Tissue Processor – ASP200 Leica  
Tensile Testing Machine James Heal 
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9.3 Solutions: 
Solution Supplier 
1.0M Hydrochloric acid (HCL)  Sigma Aldrich 
2-Propranol Sigma-Aldrich 
Acetic acid  Sigma Aldrich 
Albumin standard 2mg/mL Thermo Scientific 
Alcian blue Sigma-Aldrich 
Ammonium Chloride Solution Stemcell Technologies 
BCA Thermo Scientific 
Calcium chloride (CaCl2)  Thermo Scientific 
Dimethyl sulfoxide Hybri-Max Sigma-Aldrich 
DNAse Sigma life science 
DPX mountant  Dako 
Dulbecco's modified eagles medium 
(DMEM) 
Sigma-Aldrich 
Eosin VWR international 
Ethanol Fisher Scientific 
Faetal calf serum Bio Sera 
Formaldehyde (37%) Fisher Scientific 
Haematoxylin VWR international 
Haematoxylin Weigerts (solution A) Atom Scientific 
Haematoxylin Weigerts (solution B) Atom Scientific 
Heparin Sodium 1000 IU/ml Fannin 
HFIP (purity > 99.0%) Sigma 
Human platetlate lysate Cook Regentec 
Magnesium Chloride (MgCl2 6H2O)  Sigma Aldrich 
Magnesium Sulphate Sigma 
Mesencult serum  Stemcell Technologies 
Methyl Blue 2% in 2.5% Acetic Acid Atom Scientific 
Paraffin Wax Cell Path 
PCL (Mn: 80 000 g mol-1) Sigma 
Penicillin/Streptomycin Thermo Fisher 
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Perfluoroether Galpore 
Phosphate buffered saline (PBS) Sigma-Aldrich 
Phosphotungstic Acid (1%) Atom Scientific 
Ponceau Fuchsin (Masson) Atom Scientific 
Potassium chloride (KCl)  Thermo Scientific 
Potassium Hydrogen Phosphate 
Trihydrate (K2HPO4 3H2O)  
Sigma Aldrich 
Scott's Tap Water Sigma-Aldirch 
Sirius Red Powder Atom Scientific 
Sodium Bicarbonate Sigma 
Sodium bicarbonate (NaHCO3) Sigma Aldrich 
Sodium chloride (NaCl) Sigma Aldrich 
Sodium hydroxide  Sigma Aldrich 
Sodium sulphate (Na2SO4)  Sigma Aldrich 
Stem Macs Miltenyi Biotec 
Tris(hydroxymethyl)aminomethane Thermo Scientific 
Trypan Blue Solution (0.4%) Sigma-Aldrich 
Trypsin Gibco  
XTT Cell Viability Assay Thermo Scientific 
Xylene Atom Scientific 
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10 Appendix 3 
10.1 Patient Consent form 
 
